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ABSTRACT 
Diabetes and periodontal disease exhibit a bidirectional relationship centered on an enhanced 
inflammatory response manifested both locally and systemically. The observation that 
hyperglycemia by itself, in the absence of additional inflammatory signals, promotes a pro-
inflammatory environment indicates that diabetes is an independent risk factor for periodontal 
disease. Leukocyte pre-activation or priming in diabetes has been demonstrated. Excessive ROS 
release by leukocytes, upregulation of pro-inflammatory mediators and adhesion molecules are 
characteristic to T2DM-associated low-grade inflammation. However, the mechanisms by which 
chronic hyperglycemia leads to leukocyte activation are not fully understood. Furthermore, the 
vm 
impact of TlDM on innate immunity is controversial. In order to control the level of 
inflammation in diabetes and promote resolution, we need to identify the molecular mechanisms 
that trigger the inflammatory response. RvEl is an endogenously synthesized lipid mediator of 
inflammation derived from the Q-3 fatty acid EPA with potent anti-inflammatory and pro-
resolution properties. RvEl has reduced PMN infiltration during acute inflammation in several 
disease models and has promoted molecular circuits characteristic to the resolution phase of 
inflammation. Akita is a Tl DM mouse model that carries a spontaneous mutation in the INS2 
resulting in chronic hyperglycemia that is non-lethal in the absence of INS. Akita mice were used 
in the present study to investigate: 1. The impact of chronic hyperglycemia on leukocyte 
recruitment; 2. The impact of chronic hyperglycemia on leukocyte-EC interactions; 3. The 
impact of chronic hyperglycemia on phagocytosis and bacterial killing by PMN; 4. RvEl actions 
on leukocyte recruitment and 5. RvEl actions on leukocyte surface adhesion molecules PSGL-1 
and CD 11 a in vivo. The methods used included the dorsal subcutaneous air pouch model used to 
investigate leukocyte recruitment, gingival intravital microscopy used to investigate leukocyte-
EC interactions, ex vivo phagocytosis and bacterial killing assays, and F ACS to investigate 
leukocyte surface antigens and phagocytosis by PMN. It was found that PMN recruitment and 
bacterial killing were impaired in Akita. Furthermore, leukocytes had increased rolling rate along 
gingival endothelium in Akita without exogenous stimulation comparable to low-dose TNFa-
induced gingivitis in WT mice. Leukocytes of Akita had a 20% increase in surface PSGL-1 and 
mononuclear cells had 1 7% increase in surface CD 11 a in the absence of exogenous 
inflammatory stimuli. RvEl reduced PSGL-1 on circulating PMN in Akita. Furthermore, RvEl 
reduced PMN infiltration in the air pouches and reduced PMN PSGL-1 levels in acute 
inflammation in WT mice. These findings suggest that in TlDM leukocytes undergo phenotypic 
changes toward a systemic low-grade inflammatory state. This homeostatic shift favors enhanced 
IX 
leukocyte-EC interactions that may lead to local activation and microvascular damage mediated 
by PMN-derived factors contributing to progressive angiopathy that underlies all diabetic 
complications. RvEl was able to reduce surface PSGL-1 over-expression suggesting a possible 
preventive measure for diabetic angiopathy. Furthermore, RvEl showed anti-inflammatory 
actions during acute inflammation by reducing recruitment and PSGL-1 expression by WT 
PMN. RvEl had no action on leukocytes of diabetic mice during episodes of acute inflammation. 
Taken together the present study brings evidence that in Tl DM the adhesive, migratory and 
pathogen-clearing functions of immune cells are altered. These changes may be reversed with 
new therapies that can act to promote the resolution of low-grade inflammation characteristic to 
chronic conditions such as DM, Alzheimer's and coronary heart disease. 
X 
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PART A 
Introduction 
Introduction 
1. Diabetes Mellitus 
1.1. Epidemiologic Considerations 
Diabetes 1s a multifactorial life-threatening chronic disease characterized by 
dysregulation of endocrine and metabolic pathways involved in control of blood glucose (BG) 
levels resulting in hyperglycemia. Uncontrolled diabetes gradually impacts many of the body's 
systems particularly the nervous and the circulatory resulting in irreversible long-term 
complications. According the Centers for Disease Control and Prevention (CDC) there were 
approximately 15 million people diagnosed with diabetes in the US in 2005. The prevalence 
increased to nearly 24 million by 2008 impacting almost 8% of the US population. Furthermore, 
57 million people were estimated to have pre-diabetes with high risk of developing diabetes 
without preventive measures and therapy. The World Health Organization (WHO) reports more 
than 220 million people diagnosed with diabetes and an estimated increase by 50% in the next 10 
years without urgent action. Nearly 3 million deaths per year are attributed to diabetes 
accounting for 5% of deaths globally. They are expected to double between 2005 and 2030. 
The estimated lifetime risk of developing diabetes for individuals born in the US has a 
heterogeneous distribution among races and between sexes in favor of male individuals. On 
average males have 1 in 3 risk and females 2 in 5. Hispanic females have the highest risk 
estimated at 1 in 2 followed by non-Hispanic black women, Hispanic males, non-Hispanic white 
females and non-Hispanic white males, the latter having 1 in 4 risk [265]. 
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1.2. Definition, Etiology and Classification 
Chronic hyperglycemia is a hallmark of diabetes mellitus (DM) regardless of its 
pathophysiological mechanism. There are two main types of DM based on the primary cause of 
hyperglycemia, type 1 diabetes (TlDM), formerly known as insulin-dependent or childhood-
onset or juvenile and type II diabetes (T2DM), formerly known as non-insulin-dependent or 
adult-onset. 
TlDM accounts for less than 10% of diabetes cases and type II for more than 90% of the 
total. Approximately 10% of T2DM cases are monogenic forms of DM including mitochondrial 
diabetes (MIDD 1 ), maturity-onset diabetes of the young (MODY) with 6 different subtypes all of 
which involve some genetic defect of ~-cell function and diabetes caused by genetic defects in 
insulin (INS) action, and neonatal/infancy onset DM. Nonetheless, less frequently DM can result 
from diseases of exocrine pancreas, endocrinopathies, drug- or chemical-induced diabetes, 
gestational diabetes and genetic syndromes associated with DM [385, 457, 325] (table 1). 
BG levels are primarily maintained through a tightly regulated balance between glucose 
output by liver physiologically stimulated by glucagon and suppressed by INS, and glucose 
uptake by muscle physiologically stimulated by INS. The secretion of INS is increased when BG 
levels exceeds 5.5 mmol/1 and is reduced when they fall bellow 4.5 mmol/1 [84]. 
1 Maternally inherited diabetes and deafness (see table 1) 
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Diabi:tcs Type Mccha111s111 ol < )11sc t 
I (<10% of all forms): 
(A) (90%) 
(B) (10%) 
II (90% of all forms): 
(A) Non-obese 
(B) Obese 
Genetic defects of pancreatic ~-cell function: 
MODYl 
MODY2 
MODY3 
MODY4 
MODY5 
MODY6 
Maternally inherited diabetes and deafness (MIDD) 
Neonatal diabetes 
Insulin gene mutations - permanent infancy DM 
Genetic defects in insulin action: 
Type A insulin resistance 
Type B insulin resistance 
Leprechaunism (Donohue syndrome) 
Rabson-Mendenhall syndrome 
Lipoatrophic diabetes 
Exocrine pancreas pathology: Chronic pancreatitis , 
Cystic fibrosis , Fibrocalculous pancreatopathy , 
Hemochromatosis , Pancreatic cancer , Pancreatectomy 
Endocrinopathies: Acromegaly, Cushing syndrome , 
Glucoganoma , Hyperthyroidism , Pheochromocytoma 
Gestational DM 
Drug- or chemical-induced diabetes: Adrenergic 
agonists , Diazoxide , Dilantin , IFN a , Glucocorticoids , 
Nicotinic acid , Pentamidine , Thiazides , T3/T4, Vacor 
Syndromes associated with diabetes : Down ' s, 
Friedreich ' s ataxia , Huntington ' s chorea , Klinefelter ' s, 
Laurence-Moon-Biedl , Myotonic dystrophy , Porphyria , 
Prader-Willi , Turner ' s, Wolfram 's 
Primary destruction of pancreatic ~-cells 
Immune-mediated - ICA , IAA, GAD65A, IA-2 
Idiopathic 
Predominantly INS resistance 
Relative INS deficiency 
Predominantly INS secretory defect 
Mutations in transcription factor s, INS, Kir6. 2: 
HNF-4a 
Glucokinase (2nd most frequent MODY) 
HNF-la (2/3 of all MODY) 
IPF-1 (PDXl) 
HNF-1~ 
NeuroDl 
A3243G mutation in tRNA for Leu (UUR) 
Mutations in K;r6, 2 
INS mutations: R65C, CA6Y , L8 6P, L8 11P, y A19X 
Mutations with impact on IR: 
Absent or dysfunctional IR 
Autoantibodies to the IR 
Mutations in 19p13.2 within INSR gene 
Mutations in INSR gene 
Mutations in IRSl , IRS3 and others 
Destruction of pancreatic islets 
Carbohydrate and lipid metabolism 
dysregulation 
Placental hormones and adipokines , IRS 1 
Reduced INS secre tion 
~-cells destruction 
(vacor , pentamidine) 
Impaired INS action 
(nicotinic acid, 
glucocorticoids) 
Predominantly insulin resistance 
Table 1 Classification of diabetes 
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In adipose tissue INS stimulates the uptake and storage of fatty acids as triglycerides 
(TG) and inhibits the lipolysis of stored TG. Circulating INS has a half-live of 3-5 minutes. After 
being secreted into the portal circulation 60% of INS is cleared by the liver through its the first-
pass metabolism and 35-40% by the kidney [183]. The brain has its own regulatory mechanisms 
of ensuring adequate glucose levels at all times (Fig. A. I. I.). The two main gluconeogenetic 
organs, kidney and liver maintain adequate BG levels in prolonged fasting periods and during 
high-intensity exercise [430, 254]. Furthermore, catecholamines, glucocorticoids, thyroid and 
growth hormones (GH) also increase BG levels mainly through stimulation of glycogenolysis 
and gluconeogenesis ( catecholamines, glucocorticoids, GH), transcriptional regulation of genes 
involved in glucose homeostasis (glucocorticoids, T /) and inhibition of INS secretion (GH) and 
action (glucocorticoids) [29, 248, 14, 302, 65]. 
In TlDM there is a primary deficiency in insulin production due to pancreatic ~-cell 
destruction leading to hypoinsulinemia and ultimately hyperglycemia. In 90% of T 1 DM cases 
reduction in islet mass is immune-mediated, patients having circulating antibodies to islet cells 
(ICA), insulin (IAA), glutamic acid decarboxylase (GAD65) or tyrosine phosphatases (IA-2 and 
IA-2~) at the time of diagnosis and in 10% of the cases is idiopathic (type lB) with no evidence 
2 T3, triiodothyronine is the major active form of thyroid hormone (TH); T4 , thyroxine (major circulating form of 
TH) is converted to T 3 inside cells by 5 '-deiodinase 
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of autoimmunity leading to death of f3-cells [97]. The autoimmune response seen in TIDM 
results from a failure of self-tolerance in T-cells. 
T2DM is characterized by a peripheral insulin resistance (IR), which leads to 
hyperinsulinemia and eventually to pancreatic f3-cell exhaustion and apoptotic death. Impaired 
glucose tolerance (IGT) and impaired fasting plasma glucose (IFG) refer to intermediate 
metabolic stages between euglycemia and T2DM. Patients with IGT have normal BG levels most 
of the time but become hyperglycemic after large glucose loads. On the other hand, patients with 
IFG have increased fasting BG levels but are usually euglycemic after food intake. The 
pathophysiology of both IGT and IFG is related to some degree of primary IR. IGT and IFG are 
not clinical entities on their own but rather represent risk factors for development of T2DM [ 11]. 
The exact mechanisms leading to development of IR are not fully understood. Activation 
of inflammatory pathways systemically or in adipose and other peripheral tissues has been 
correlated with IR [367, 184, 101]. There is increasing evidence that endoplasmic reticulum (ER) 
functions expand beyond post-translational protein processing into metabolic regulatory actions 
being considered a central nutrient sensor. Metabolic imbalances eventually induce ER stress 
that results in both inhibition of INS signaling and activation of pro-inflammatory pathways 
[153, 264]. 
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1 GLUTI , high capacity & high affinity (Km 1-2 mM) ; 2 GLUT2 , high capacity & low affinity (Km 15-20 mM) ; 3 
GLUT4 , insulin regulated (Km 5 mM) ; 4 GLUT3 , high affinity (Km 1 mM) & high capacity ; GLUT , glucose 
transporter. 
Figure A.1.1. 
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Figure A.1.1. Blood Glucose Regulation 
The liver physiologically maintains BG levels through glycogenolysis (main) and 
gluconeogenesis (secondary) in the first phase of fasting ( 4-16 h postprandial) with an average 
glucose release of 10 g/h (left, blue). When exogenous carbohydrates become available the liver 
stops releasing stored and de nova synthesized glucose and delivers the newly absorbed glucose 
from intestine at a rate of 50 g/h. This massive glucose output results in increased BG levels that 
stimulate f3-cells to release INS while glucagon secretion is inhibited. INS action on peripheral 
tissues ensures an exit of glucose from circulation at a rate of 44 g/h (middle , pink). During 
exercise the liver releases 46 g/h glucose to deliver 40 g/h to muscle cells mainly under glucagon 
regulation (60%). High-intensity physical work during fasting or dysregulated glucose release 
from liver may result in transient hypoglycemia that leads to increased glucagon and 
catecholamine secretion, and inhibition of INS. When fasting is prolonged glucose metabolism is 
maintained primarily through gluconeogenesis in liver and kidney[254, 430] 
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1.3. Clinical Context 
Tl DM has the highest incidence in northern European countries and US states populated 
with persons of Scandinavian descent such as Minnesota. In Scandinavia the incidence in 
children aged 14 years or younger is 3 7 per 100. 000/year. The US overall annual incidence is 15 
per 100.000/year. Global incidence of TlDM is increasing. Interestingly, ethnic genetic 
heterogeneity seems to play a key role in development of TlDM [86, 171]. 
About two-thirds of TlDM susceptibility is due to genetic factors mainly related to HLA 
genes located on chromosome 6p21. More than 95% of people with TlDM possess HLA-DR3 or 
HLA-DR4 haplotype and individuals having any of the two concurrently with HLA-DQBl *0302 
(DQ8 haplotype) have the highest chance of inheriting TlDM. Furthermore, several non-HLA 
genes confer susceptibility to TlDM, specifically INS gene (INS) located on chromosome 11 
with variable number of tandem repeats (VNTRs) in the promoter region and polymorphisms in 
CTLA4 and PTPN22. Polymorphisms in the immunoregulatory cytotoxic T-lymphocyte antigen 
(CTLA)-4 gene were also associated with increased susceptibility for TlDM [413, 176]. 
Furthermore, several single nucleotide polymorphisms (SNPs) in the interleukin (IL) 4 gene with 
at least 7 SNPs impacting the function of the protein were associated with TlDM [382]. 
Similarly, polymorphisms in IL-4R and Il-13 genes were also correlated with TlDM suggesting 
a possible loss ofIL-4 regulatory pathway in the pathogenesis ofTlDM [194]. 
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Nonetheless, administration of IL-4 and IL-10 to diabetic mice has suppressed cytokine 
production by T helper (Th) 1 lymphocytes in pancreatic islets [317] and splenocytes form non-
obese diabetic mice (NOD) overexpressing IL-4 failed to transfer diabetes to severely combined 
immune deficient (SCID)-NOD recipients [ 445]. Another important association was found 
between polymorphisms in the IL-1 gene cluster and increased risk of developing TlDM [35, 
195]. Although the role of IL-1 in the pathogenesis of T 1 DM had been previously established 
studies on association of genetic polymorphisms with Tl DM are relatively recent [226]. One 
study showed that IL-IR deficient NOD mice have a slower progression of pancreatic islet 
destruction compared to WT controls supporting the active involvement of IL-1 in pathogenesis 
of TlDM [403]. These observations led to the concept of developing anti-IL-1 therapies for 
TlDM that are currently under investigation [305] 
One-third of TlDM susceptibility is due to environmental factors such as childhood 
infections that may dysregulate the immune system to develop autoimmunity, cow milk 
consumption, rubella and Coxackie B4 viruses. Viral contribution- to pathogenesis of TlDM is 
controversial. Three main hypotheses suggest possible mechanisms leading to ~-cell destruction: 
1) injury and inflammation to ~-cells with consequent release of their sequestered antigens, 2) 
viral proteins that mimic ~-cells antigens and 3) latent persistence of a "predisposing" virus 
acquired early in life followed by re-infection later in life with a related "precipitating" virus that 
shares antigenic epitopes with the pre-existing one. 
10 
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TIDM onset 1s immune-mediated m 90% of the cases and leads to destruction of 
pancreatic islet cells resulting in primary hypoinsulinemia and hyperglycemia. In less than 10% 
of TIDM cases there is no evidence of autoimmunity against ~-cells to explain hypoinsulinemia 
and thus fall into the idiopathic TlDM, or type lB category. A mutation in PAX-4 gene 
(Argl33Trp) involved in development of pancreatic islets was associated with some idiopathic 
ketone-prone diabetic cases. In most cases of TlDM a T-cell/macrophage-mediated insulitis 
leads to ~-cell depletion and islet atrophy with subsequent hypoinsulinemia. 
TlDM patients present with classical signs and symptoms of DM: polyuria (excessive 
urination), polydipsia (excessive thirst) and polyphagia (excessive hunger). While most TlDM 
patients have these three symptoms at the time of diagnosis some may also experience 
unexpected weight loss, fatigue and weakness, changes in visual acuity, irritability, and 
xerostomia ( dry mouth). Most diabetic symptoms result from some degree of hyperosmolar state 
induced by high BG levels and sensory or autonomous neuropathy [2~6]. 
There are three most common acute complications of TIDM including hypoglycemic 
coma, ketoacidosis and hyperosmolar coma. Hypoglycemic coma is usually mild and can be 
reversed by eating or drinking carbohydrates. It is usually the result of lower than usual food 
intake, excessive fluid intake or excessive exercise. Ketoacidosis is diagnosed from BG levels 
>250 mg/dl, an arterial pH<7.3 and moderate ketonemia. Ketosis occurs by changing the energy 
metabolism to generate ketone bodies acetoacetate and ~-hydroxybutyrate from fatty acids in 
11 
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context of low INS and high gucagon levels. Accumulation of ketone bodies results in metabolic 
acidosis that is initially compensated by the physiological bicarbonate buffering system. This 
mechanism is readily exhausted leading to hyperventilation and eventually to a Kussmaul 
respiratory pattern. Furthermore, glucose levels are increased by glycogen breakdown in liver 
that is normally suppressed by INS and through gluconeogenesis from other metabolic sources. 
Some of the circulating glucose in excess escapes into urine and pulls sodium (Na+) and 
potassium (K+) ions generating osmotic diuresis accompanied by dehydration. The resulting 
symptoms of vomiting, dehydration, deep gasping breathing, confusion and occasionally coma 
complete the ketoacidotic context frequently seen in T 1 DM patients with uncontrolled glycemia. 
Non-ketonic hyperosmolar coma is more often associated with T2DM. It results from high serum 
osmolarity due to very high levels of glucose (>600 mg/dl) and leads to polyuria, volume 
depletion and hemoconcentration with risk of thrombosis and neurological signs (Fig.A.1.2-3.). 
More than 90% of the persons diagnosed with DM worldwide have T2DM. Genetic and 
environmental factors contribute to IR and loss of ~-cell. IR results in decreased skeletal muscle 
glucose release, increased hepatic glucose production and increased free fatty acids release from 
adipose tissue. Liver is the main contributor to the high levels of BG in T2DM by increased 
glycogenolysis in the absence of INS' s inhibitory action and through gluconeogenesis. Increased 
gluconeogenesis in liver occurs as a result of hypothalamic IR manifested as a failure of INS-
dependent K+ ATP channels to .open. Thus vagal inhibition of gluconeogenesis is abolished [309]. 
12 
Introduction 
T2DM is one of the most heritable multigenic diseases having genetic predisposing 
variations in specific genes contributing its onset. These genetic polymorphisms are currently 
being characterized. Although there is no HLA linkage in T2DM increasing evidence suggests 
that SNPs in several candidate diabetogenic and obesity-related genes play a more important role 
in susceptibility to T2DM than was previously thought. Several genome wide association studies 
(GWAS) have identified at least 19 genes with SNPs associated with T2DM and the list is 
growing. Interestingly most of these genes are not involved in pathways of glucose metabolism 
and need further studies to unveil the biological processes behind these associations [281]. A 
recent study has investigated the impact of 19 SNPs associated with T2DM on physiology of 
INS processing, secretion and sensitivity in over 29.000 subjects and has shown that they 
influence glycemic regulation by several pathways [163] (table 2). 
Regardless of the IR onset mechanisms hyperplasia of ~-cells occurs early in 
development of T2DM and chronic deposition of amyloid in pancreatic islets at later stages 
progressively reduces endocrine function. Obesity is associated with diabetes in 60-70% of the 
T2DM cases in North America, Europe and Africa and in less than 30% of cases in Asia. 
Multiple obesity-associated factors including circulating non-esterified fatty acids, inflammatory 
mediators, adipokines are linked to pathogenesis of IR. 
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Figure A.1.2. Blood Glucose Regulation in T2DM 
Excess nutrients, particularly carbohydrates and lipids, lead to sustained high BG levels resulting 
in increased INS release into the circulation. Repeated BG levels just above normal limit (FPG 
levels of 110-126 mg/dl), diagnosed as prediabetes, maintain a hypersecretory state in ~-cells 
and generally precede IR (left, blue). Development ofIR in peripheral tissues prevents adequate 
uptake and use/storage of circulating glucose resulting in high BG levels and compensatory 
hyperinsulinemia, the first phase of T2DM (middle, orange). Continuous supra-solicitation of~-
cells is accompanied by their apoptotic death mostly due to ER stress hypoinsulinemia 
characterizing the second phase of T2DM. Deregulation of lipid, carbohydrate and protein 
metabolisms and IR in peripheral organs, liver and the hypothalamus perturb hepatic BG 
regulation resulting in massive release of glucose from both glycogenolysis and gluconeogenesis 
(right, pink). 
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Figure A.1.3. Pathophysiology of Blood Glucose Variation 
INS is constantly secreted in low quantities (~20 µU/ml) in response to minor variations in BG 
levels. A major increase in INS secretion occurs when BG exceeds 5.5 mmol/l and is 
accompanied by reduction in glucagon serum levels. BG levels below 4. 6 mmol/l inhibit INS 
release and increase circulating glucagon levels. Hypoglycemia as defined by BG below 4.6 
mmol/1 results in clinical signs and symptoms that progress to brain damage and ultimately death 
when BG is less than 1.1 mmol/1. 
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I 'lli\l \,,nl ·1,1l1l1t1 ( il.'111.' \ " ariation l\,kchanism of As soc1 :1l1011 
MADD SNP AIT j Fasting proinsulin 
Abnormal insulin processing 
SNP GIA j Fasting proinsulin VPS13C 
TCF7L2 SNP TIC 
SLC30A8 SNP CIT j Fasting proinsulin 
GIPR SNP AIT ! Insulinogenic index 
C2CD4B SNP AIG 
EIF2AK3 M j B-cell death 
WFSl M j ER stress 
Decreased insulin secretion INS M j ER stress 
CEL M j B-cell death 
GCK SNP AIG 
FADSl SNP TIC 
DGKB SNP TIG j Fasting glucose 
PROXl SNP CIT ! Insulinogenic index 
G6PC2 SNP CIT 
MTNRlB SNP GIC 
ABCC8 M Mutated SURl 
KCNJll M Mutated K+ channel in ~-cell 
CDKALl SNP Unknown 
CDKN2A/B SNP Unknown 
HHEX SNP Unknown 
MTNRlB SNP Unknown 
IGF2BP2 SNP Unknown 
GCKR SNP CIT j C-peptide; ! INS sensitivity 
IGFl SNP GIA ! INS sensitivity 
AGPAT2 M Adipocyte TG synthesis defect 
PPARG M 
Abnormal insulin sensing Defects in adipocyte development 
BSCL2 M 
CAVl M Unknown 
LMNA M Unknown 
INSR M Defects in INS action 
Abbreviations: SNP, single nucleotide polymorphism ; M, mutation ; TG, triglyceride. 
Table 2 Genetic correlations in T2DM 
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Some patients with T2DM have polyuria, polydipsia and polyphagia while other 
individuals are asymptomatic and are being diagnosed only after glycosuria and hyperglycemia 
are detected. This latter insidious onset of T2DM is particularly seen in obese patients and is 
often associated with neurologic or cardiovascular (CV) complication at the time of diagnosis. 
Fat distribution may vary but is often associated with upper body predominance including 
abdomen , chest, neck, face and a waist-to-hip ratio greater than 0.9 in men and 0.8 in women 
correlates with increased risk of diabetes. 
The diagnostic tools for DM include measurements of hemoglobin AlC (HbAic), fasting 
and/or random (casual) plasma glucose and glucose tolerance . According to the 2010 guidelines 
of the American Diabetes Association and the International Expert Committee3 report of 2009 
the criteria for diagnosis of T2DM include: 1) HbA 1c >6.5 % on more than two occasions4 
(normal values 4-6%), 2) a casual plasma glucose of >200 mg/dl (11.1 mmol/1) confirmed on a 
subsequent day by either a fasting plasma glucose5 (FPG) of> 126 mg/dl (7 mmol/1), a 2h oral 
glucose tolerance test6 (OGTT) value >200 mg/dl (11.1 mmol/1) or a casual plasma glucose >200 
mg/dl (11.1 mmol/1) with T2DM symptoms including polyuria, polydipsia, weight loss and 
3 Members appointed by the American Diabetes Association , the European Association for the Study of Diabetes 
and the International Diabetes Federation 
4 Diagnostic test should be performed using a method that is certified by National Glycohemoglobin Standardization 
Program (NGSP) and standardized to the DCCT assay. 
5 Fasting is defined as no food intake for at least 8h. 
6 Using a glucose load containing the equivalent of 75 g anhydrous glucose dissolved in water. 
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fatigue. There is an intermediate diagnostic category of individuals with FPG levels of 110-126 
mg/dl (6.1-7 mmol/1) or 2h OGTT values of 140-200 mg/dl (7.8-11.1 mmol/1) considered to have 
pre-diabetes. HbA1c is also a reliable monitoring test for 'long-term' control of BG over 2-3 
months and it should be measured every 3-4 months in patients with either TlDM or T2DM. A 
HbA1c value <7% indicates well controlled DM [11, 298, 185]. 
The Insulin Resistance Syndrome (IRS), also called metabolic syndrome or syndrome X, 
is a separate entity that groups several clinical parameters namely obesity ( especially abdominal 
or visceral obesity), elevated plasma TG, low levels of high-density lipoproteins (HDLs) and 
high blood pressure that associate with IR and compensatory hyperinsulinemia in an individual 
[97]. The 'diabetic dyslipidemia' is characteristic for IRS. It includes high serum triglyceride 
levels (300-400 mg/dl), low HDL ( <30 mg/dl) and qualitative changes in low-density 
lipoproteins (LDL) with smaller particles that carry excess amounts of free cholesterol. 
High levels of LDL, hyperuricemia, abdominal obesity, pro-thrombotic and pro-
inflammatory state have been recently included in these syndromic associations and altogether 
significantly increase the risk of atherosclerotic disease and myocardial ischemia. IR at levels 
comparable to those seen in T2DM occurs in 25% of the general nonobese nondiabetic 
population and these individuals are at much higher risk of developing DM [236, 325]. 
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In both TlDM and T2DM microvascular and macrovascular changes result in long-term 
complications including diabetic nephropathy, retinopathy, neuropathy, CV diseases (CVD), 
peripheral vascular diseases and periodontal disease. Acute diabetic complications resulting from 
metabolic and vascular changes include hypoglycemic coma, ketoacidotic coma, hyperosmolar 
non-ketonic coma, myocardial infarction (MI) and stroke. Microangiopathy manifests as small 
blood vessel wall changes due to endothelial cell (EC) dysfunction and basement membrane 
thickening, rheological changes and neovascularization. Macrovascular changes include 
atheromatosis of medium and large arteries due to EC injury, monocyte-govemed inflammation 
and accumulation of oxidized LDL (oxLDL) in arterial intima, and arterial or venous thrombosis 
due to hypercoagulability and decreased fibrinolysis (Fig. A.1.4.). 
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Figure A.1.4. Diabetes - The Big Picture 
Elevated BG levels characterize both types of DM. TIDM results from primary pancreatic 
endocrine insufficiency due to islet destruction accompanied by hypoinsulinemia (top yellow). In 
more than 90% of cases autoimmunity causes islet damage. T2DM (90% of all DM) results from 
resistance of peripheral tissues to insulin action and is accompanied in early stages by 
compensatory hyperinsulinemia (bottom yellow). Uncontrolled T2DM leads to pancreatic 
insufficiency and ultimately to hypoinsulinemia. Chronic hyperglycemia is the hallmark of DM 
and the primary cause for long-term complications (orange). Vascular changes due to sustained 
high BG levels are central to development of chronic (red) and acute life threatening 
complications (purple). Circulating leukocytes undergo phenotypic changes due to direct in 
indirect actions of excess glucose. The impact of these changes on innate and acquired immunity 
is not fully understood. 
* syndrome X, metabolic syndrome ** microangiopathy _,.. retinopathy, nephropathy, 
neuropathy (sensory and autonomous); macroangiopathy _,.. atherosclerosis; impaired wound 
healing 
*** ketoacidosis, hypoglycemia, non-ketonic hyperosmolar coma, myocardial infarction, stroke 
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1.4. Animal Models for Diabetes Research 
Most animal models used in DM research are rodents although other species are also used 
for studying DM pathogenesis and new therapies. TlDM, T2DM and related phenotypes such as 
obesity and IR benefit from use of specific mouse models for the in vivo and ex vivo study of 
pathophysiological and pharmacological processes related to DM. The two main methods of 
obtaining a diabetic phenotype in a mouse are toxin induced, usually by administration of 
streptozocin or alloxan, and selective in-house breeding of strains that carry spontaneous 
mutations producing the relevant phenotype. Total or partial pancreatectomy is another less 
frequently used method of inducing DM in rodents and larger animals. Furthermore, several 
specific genetically engineered mutations have generated knock-in, knockout and tissue specific 
knockout mice. Subcutaneous administration of phlorizin, a natural flavonoid, to mice induces 
glycosuria and polyuria with near-normal glycemia by blocking the reabsorption of glucose in 
the proximal renal tubule upon binding to the Na+/glucose transporter. Thus, it is a good model 
for studying the tissue-specific impact of hyperglycemia early in development ofDM [321]. 
The most popular TlDM animal models include streptozocin (STZ)-induced DM m 
rodents and spontaneously developed DM mainly the non-obese diabetic mice (NOD) and the 
bio-breeding diabetes-prone rats (BB). STZ is isolated from Streptomyces achromogenes . It is a 
nitrosurea derivative with broad-spectrum antibiotic and anti-neoplastic activities. A single dose 
of STZ can induce DM in mice most likely due to its toxic effect as potent alkylating agent that 
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can generate multiple DNA strand breaks. The NOD mouse was derived through selective 
breeding from a mouse strain used in the study of cataract development. NOD mice develop 
lymphocyte-mediated insulitis, IAA and subclinical ~-cell destruction with subsequent 
hypoinsulinemia as early as 4-5 weeks of age. Unlike human TlDM the NOD mice are not INS-
dependent until later in life, they have a more heterogeneous sex distribution in favor of males 
and develop a milder ketoacidosis. These mice are characterized by multiple complex polygenic 
susceptibility loci with the major histocompatibility complex (MHC) region having a strong 
genetic influence in the pathogenesis of DM. Specifically NOD mouse has unique haplotype 
with H2g7 allele at the I-A locus and a null allele at I-Ea homologous to human HLA-DQB and 
DRa respectively [31 O]. For this reason the NOD mouse is considered highly analogous to 
human TlDM and makes it suitable for the study of genetic linkage in DM. The BB rats develop 
DM by similar mechanisms to the NOD mouse including T-, B-cell and NK cell pancreatic 
infiltrates but suffer from more severe ketoacidosis and have a specific profound T-cell 
lymphopenia. Both models have been used to study possible preventive therapy for TlDM using 
oral INS or nicotinamide and showed positive results especially in NOD mice but human trials 
with these agents had disappointing results [ 426]. 
Several knockout and transgenic mice have been developed to suppress expression of 
antigens like proinusulin and GAD or over-express T-cell receptors (TCR) or artificially-induced 
~-cell antigens such as viral lymphocytic choriomeningitis virus, hemagglutinin and ovalbumin 
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to mediate pancreatic islet destruction [213]. All of these models have been used to study the 
contribution of specific genes and their products to the development of T 1 D M. Rodent models of 
monogenic diabetes and obesity are used in T2DM research specifically the db/db mouse (leptin 
resistant) , Ob/Ob mouse (leptin resistant) , KK mouse (Azgpl glycoprotein gene) , the fa/fa rat 
(leptin resistant), Goto Kakizaki (GK) rat and others. 
The Akita mouse is another monogenic mouse model of DM that mostly resembles 
human TlDM and other MODY types of DM in pathogenesis and phenotype. Akita mouse is a 
heterozygous carrier of a missense point mutation in INS2 gene 7 (Akita WTIC96Y) with early onset 
hyperglycemia and progressive development of diabetic complications (Fig. A. I. 5-7) [28, 68, 
328]. Akita mutation prevents the formation of one essential disulfide bond between chains A 
and B of INS leading to formation of a misfolded mature INS that induces proteotoxicity and ER 
stress resulting in apoptosis of pancreatic f3-cells and hypoinsulinemia [167, 328]. Although 
Akita is widely accepted as a model of Tl DM having primary insulin deficiency and normal to 
low body weight and plasma lipid levels the Akita mouse seems to develop IR associated with 
reduced expression of GLUT4 and increased expression protein kinase C (PKC) in skeletal 
muscle [149] 
7 INS 2, responsible for the production of 80% of total mouse INS ; INS] physiologically produces 20% of total INS 
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Figure A.1.5. Post-translational Protein Modifications - Insulin (INS) Processing 
Under physiologic conditions pancreatic ~-cells continuously transcribe and translate the INS 
gene (INS) is into preproinsulin peptides (from exons 2 and 3) comprising of pre-peptide (light 
grey), B chain (green), C chain (dark grey), A chain (blue) and two short links (2 basic amino 
acids) at B-C and C-A connections (yellow) (left). ER recognizes and uptakes the pro-peptide via 
SRP/SRP-R interactions then removes the SRP generating the nascent protein that will further 
undergo processing to achieve its final tertiary structure mainly maintained by two inter-chain 
disulfide bonds between C residues in positions 31, 43 (B chain) and 96, 109 (A chain) 
respectively. Inside Golgi folded insulin undergoes proteolytic cleavage of C chain (C peptide) 
generating the metabolically active mature insulin that is packed into secretory vesicles to be 
released into the blood circulation (right). Primary structure of insulin prepropetide showing 
amino acid sequence and position of the essential C residues mentioned (bottom). 
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Figure A.1.6. Akita Mutation and Insulin Misfolding 
A. Cartoon representing the secondary structure of human insulin (INS) showing its central 
skeleton composed of peptide bonds (grey, C atoms; blue, N atoms) and the two C residues of 
chain A (left) in positions 96 and 109 (green) that form the two inter-chain disulfide bonds with 
C of chain B in positions 31 and 43 respectively. The two bonds are essential for the stability of 
secondary structure of mature INS. A third disulfide bond of mature INS is formed between C95 
and Cl00 of chain A (not shown). Focus on C96 residue of chain A in folded INS (right). 
B. Ball and stick 3D representation of folded INS showing atomic structure of all residues (grey, 
C; blue, N; red, O; white, H) and inter-residue bonds with focus on C96 residue (green) of chain 
A that forms a disulfide bond (yellow) with C31 in chain B (tertiary structure). 
C. Computational 3D simulation of tertiary INS structure with representation of van der Waals 
interactions in molecular mechanics force fields. Arrow indicates C96 (green) bound to C31 
(yellow) and the van der Waals fields of the two residues (transparent green and yellow). 
D. Akita missense point mutation (TGC ~TAC, nucleotide 1907, exon 3) in INS2 of mice leads 
to replacement of C96 residue with Y. Schematic representation of tertiary structure in INS2 
(high homology to human INS) as a result of Akita mutation. Heterozygous Akita mice 
(Akitawr ic96 r) become hyperglycemic as early as 4 weeks of age and develop classical diabetic 
symptoms within the first 2 months of life. Homozygous Akita mice (Akitac 96 r1c96r) do not 
survive past 1-2 weeks from birth. 
31 
Introduction 
C57BL/6-JNS2 Akita+ /-
Decrease in ~-cell density 
Birth Lw 6w 7-8 w 12w Death Age 
I I :Ill (>lOm) 
BG (mg/dl) 325 645 
BW(g) 24 vs. 26 normal gain decreased 
Polyuria + ++ ++ ++ 
Polydipsia + + + 
Polyphagia + + + 
Nephropathy + ++ 
Retinopathy + ++ 
Neuropathy + ++ ++ 
Figure A.1.7. 
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Figure A.1.7. Akita Phenotype 
Reduction in ~-cell mass as a result of apoptotic death induced by Akita mutation occurs within 
the first month of life. Homozygous mice (1Ns2-1-) do not survive past 2 weeks and heterozygous 
Akita (1Ns2-1+) show the first signs of a diabetic phenotype between 4-6 weeks when BG levels 
increase progressively and polyuria is apparent. By 12 weeks BG levels exceed 500 mg/dl and all 
diabetic signs and symptoms can bee seen and past 10 months Akita develop severe forms of 
diabetic complications. 
Note: early onset of polyuria demonstrates the rapid impact of uncontrolled hyperglycemia on 
kidneys 
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1.5. Therapeutic Options for Diabetes 
Control of BG and Blood Pressure 
Control of BG levels is the primary aim of diabetes management. The current therapeutic 
options for control of BG are restricted diet, administration of insulin, oral antidiabetic drugs 
grouped into INS secretagogues (sulfonylureas, meglitinides, d-phenylalanine derivatives), 
biguanidines, thiazolidinediones and a-glucosidase inhibitors. 
A diet with low glycemic index improves glycemic control and reduces the risk of 
hypoglycemic events [ 402]. Additionally, exercise combined with controlled diet reduces the 
incidence of DM in high risk individuals (IGT and IRS) and improves systolic and diastolic 
blood pressure (BP) levels [291]. Continuous subcutaneous INS infusion is better at controlling 
BG levels and preventing severe hypoglycemia compared to multiple INS injections [245]. Long 
acting INS has similar benefits on overall glycemic control as intermediate acting INS but offers 
better control of nocturnal BG levels. A presumed mitogenic action of long acting INS warrants 
caution in prescription until further evidence against this possibility is available [ 421]. 
From all oral anti diabetic drugs sulfonylureas, mainly second generation (glyburide, 
glipizide, glimepiride) and biguanidines including metformin are the treatment of choice for 
T2DM in addition to controlled diet. INS secretagogues act by binding to ~-cells sulfonylurea 
receptors (SUR) associated with the inward rectifier ATP-sensitive K+ channel inhibiting the 
efflux of K+ ions. This results in membrane depolarization and opening of voltage-gated calcium 
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(Ca2+) channels, influx of Ca2+ and subsequent release of preformed INS. Long-term 
administration of sulfonylureas also reduces plasma levels of glucagon by an unclear 
mechanism. Biguanidines act independent of f3-cell function by reducing hepatic and renal 
gluconeogenesis, slowing glucose absorption from gastrointestinal tract, directly stimulating 
glycolysis in tissues and reducing the plasma glucagon levels. Thiazolidinediones decrease IR 
mainly by regulating genes involved in glucose and lipid metabolism and adipocyte 
differentiation being ligands of peroxisome proliferator-activated receptor-gamma (PPAR-y), 
part of the steroid and thyroid superfamily of nuclear receptors. Alpha-glucosidase inhibitors are 
competitive inhibitors of a-glucosidases in the small intestine reducing the postprandial 
digestion and absorption of starch and di saccharides [ 183]. 
Several clinical trials have been conducted with patients having either TlDM or T2DM 
to assess the benefits of glycemic control in DM. The Diabetes Control and Complications Trial 
(DCCT) was a randomized long-term prospective study involving 1441 patients with TlDM 
aged 13-39 years observed for 6.5 years between 1983 and 1989. Patients were divided into 
conventional therapy as defined by one or two daily INS injections with self-monitoring of urine 
and BG without adjustment of INS dosage and intensive therapy as defined by three or more INS 
administrations daily with self-monitoring and adjustment of INS dosage accordingly. At the end 
of the study it was concluded that intensive INS therapy effectively controls BG, delays the onset 
and slows the progression of retinopathy, nephropathy and neuropathy in patients with TlDM. 
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Based on these observations the DCCT research group introduced the concept of glycemic 
memory that includes the long-term benefits of significant periods of glycemic control [75, 183]. 
Multiple clinical trials were similarly conducted for T2DM. The United Kingdom 
Prospective Diabetes Study (UKPDS) was a very large randomized prospective study including 
3867 newly diagnosed T2DM patients aged 25-65 years observed over 10 years between 1977 
and 1987. The average initial HbA1c levels was 9.1%. A significant proportion of the patients 
were overweight and hypertensive. The aim of the study was to assess the impact of intensive 
glycemic control and of blood pressure (BP) control on risk of developing microvascular and 
macrovascular complications in T2DM. Treatment groups included control group on 
conventional therapy with controlled diet alone and separate groups on intensive therapy with 
either insulin or sulfonylureas (chlorpropamide, glyburide, or glipizide) alone. Metformin was 
added as a randomization option for patients responding unsatisfactorily to other therapies. A 
separate group included patients under tight control of BP with stepwise antihypertensive therapy 
including either an angiotensin-converting enzyme (ACE) inhibitor ( captopril) or a ~-blocker 
(atenolol). More drugs were added in the following stepwise sequence: a diuretic, slow-release 
nifedipine, methydopa, and prazosin to achieve tight BP control. At the end of the study the 
following were concluded: intensive therapy to reduce BG reduces the risk of microvascular 
complications overall compared to conventional therapy; metformin alone significantly reduces 
the risk of macrovascular disease (myocardial infarction, stroke); tight BP control significantly 
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reduced the risk of both microvascular and macrovascular complications with higher efficiency 
than reducing HbA1c levels to 7% [410, 411]. 
A more recent double-blind randomized prospective clinical trial with a 2-by-2 factorial 
design called Nateglinide (meglitinide class of antidiabetics) and Valsartan (angiotensin II 
receptor antagonist) in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) 
including 9306 patients from 40 countries ( average age 64 years) with impaired glucose 
tolerance and established CVD or CV risk has assessed the impact of Nateglinide and Valsartan 
treatments in addition to lifestyle modification on DM incidence, DM related clinical parameters 
and CV events over 5 years. At the end of the study it was concluded that Nateglinide treatment 
three times daily with up to 60 mg/dose does not prevent CV events or DM onset while 
Valsartan treatment as single dose of up to 160 mg/day reduced the incidence of DM by 14% 
without significant impact on the rate of CV events [269, 270]. 
Other smaller studies including the Kumamoto study (110 patients, 6 years follow-up), 
the Steno-2 study (160 patients, 7.8 years follow-up) and the STOP-NIDDM (1429 patients, 3 
years follow-up) have shown similar results to the DCCT and UKPDS studies indicating that 
control of BG levels reduces the risk of developing and slows the progression of diabetic 
complications [183, 236]. 
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Low-dose Aspirin 
The prevention of primary MI in patients with DM with daily aspirin 8 was first addressed 
in a randomized, double blind, placebo-controlled trial by the Physicians' Health Study Research 
Group including 22,071 participants with an average of 5 years follow-up completed in 1989. 
The study had found a 44% reduction in MI risk but a slightly increased risk of hemorrhagic 
stroke. Reduction in MI risk was apparent only in patients over 50 years of age [304]. Based on 
these observations and a few supporting studies that followed the American Diabetes Association 
strongly recommended long term daily aspirin for primary prevention of MI in DM. The 
efficiency of daily aspirin (75-325 mg/dose/day) and other anticoagulants alone or in 
combination with statins9 (HMG-CoA 10 reductase inhibitors) on prevention of CV events and 
stroke in patients with DM has since been tested in large trials [56, 76]. Despite the initial results 
supporting the CV preventive action of aspirin in DM a meta-analysis of randomized trials of 
antiplatelet therapy for prevention of life-threatening events in high-risk patients has found a 
modest overall 7% reduction in CV events in the subpopulation of patients with DM. On the 
other hand it was concluded that daily low doses of aspirin (LDA) (75-150 mg/day) are as 
efficient as higher doses in preventing stable angina, intermittent claudication and atrial 
8 Aspirin, from "spirsaure" , old German name for acetylsalicylic acid; first prepared by French chemist Charles 
Frederic Gerhardt in 1853 
9 Drugs used to lower plasma cholesterol levels 
10 HMG-CoA , 3-hydroxy-3-methyl-glutaryl-coenzyme A; essential intermediate in cholesterol synthesis in humans 
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fibrillation in patients with high risk [ 16]. A couple important negative trials that followed, 
namely the POPADAD (Prevention of Progression Of Arterial Disease and Diabetes) and the 
JPAD (Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes) have 
questioned the highly efficient preventive action of aspirin in DM although these latter trials 
were criticized to be underpowered. Indeed both trials have used soft end points including the 
development of peripheral arterial disease and stable angina as primary events rather than harder 
end points like MI and CV death [33, 284, 98]. Altogether, to date, there is insufficient evidence 
to support aspirin's action to prevent CV events in patients with DM more efficiently than in 
individuals without. In line with these observations the 2010 position statement of the American 
Diabetes Association recommends daily LDA (75-162 mg/day) for prevention of primary CV 
events in patients with DM and no previous history of vascular disease who are at increased risk 
(10 year risk of CVD events over 10%) and who are not at increased risk for bleeding. Adults 
with increased CVD risk are most men over age 50 years and women over age 60 years 
diagnosed with DM who have one or more additional major risk factors including smoking, 
hypertension, dyslipidemia, family history of premature CVD, and albuminuria. Patients with 
intermediate risk are younger patients with one or more risk factors and older patients with no 
risk factors. They may be prescribed LDA for prevention of primary CV events until further 
evidence is available. Aspirin should not be recommended for CV prevention for patients with 
DM at low risk including those who do not fall into high or intermediate risk categories [306]. 
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Regeneration of ~-cell 
The decreased (3-cell mass and function in both TlDM and T2DM has been the target of 
research in DM therapy for years aiming at rehabilitation of pancreatic endocrine function. 
Transplantation of pancreatic islets was partially successful as allografts fail in a few years and 
xenografts are even more readily rejected offering no long-term solution for DM. Semipermeable 
membranes to protect the graft from the host immune cells have been designed but showed 
questionable biocompatibility and selective permeability for cytokines [ 69, 91]. Regeneration 
and transdifferentiation are promising and are under investigation. It is controversial whether 
adult pancreas has progenitor cells but we know that adult pancreas and liver contain cells with 
epigenetic memory of their common embryonic origin [ 454]. In situ and in vitro (3-cell expansion 
and reprogramming of liver cells, pancreatic acinar cells or a-cells [ 455] into (3-cells using 
adenoviruses expressing just three transcription factors (pancreatic duodenal homebox-1, 
musculoaponeurotic fibrosarcoma oncogene homolog A and neurogenin-3) show promising 
results. The embryonic stem cells (ESc) differentiation into (3-cells is also promising but far from 
convincing results. While ESc-derived '(3-cell' has been obtained a few years ago the transition 
of intermediate derived cells through endoderm has been achieved only recently. Furthermore, 
we have little knowledge on the final differentiation phase of (3-cells in humans specifically 
whether they undergo replacement or expansion. Nonetheless, the exact mechanism of (3-cell 
adaptation to secretory demand and its correlation to INS sensitivity are yet unknown [133]. 
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2. Diabetes Mechanisms and Inflammation 
2.1. Mechanisms of Diabetic Complications 
In both types of DM hyperglycemia is directly related to pancreatic dysfunction and 
ultimately leads to macro- and microvascular complications including atherosclerosis, ischemic 
heart disease, nephropathy, retinopathy, neuropathy and periodontal disease. Uncontrolled 
hyperglycemia is central to development of angiopathy through several biochemical and 
molecular mechanisms manifested in both intra- and extracellular compartments. The four major 
pathways through which hyperglycemia alters cellular physiology and extracellular matrix 
structure are the polyol pathway, the hexosamine pathway, activation of PKC, and advanced 
glycation end product (AGE) formation. The first three pathways generally alter cellular function 
by acting directly on intracellular pathways while AGE directly impact the extracellular matrix 
(ECM) quality and indirectly the normal cell function through specific receptors for AGE 
(RAGE). Increasing evidence suggests that excessive production of reactive oxygen species 
(ROS) by the mitochondrial electron transport chain in chronic hyperglycemia is the trigger point 
of glucose-induced metabolic alterations by inhibition of glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) [51, 42,181,275]. 
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2.1.1. Reactive Oxygen Species (ROS) 
Overproduction of ROS by the mitochondrial electron transport chain was proposed as a 
unifying mechanism for diabetic microvascular complications as it relates to all metabolic 
changes that occur in DM [51, 52, 275, 274]. The breakdown of glucose through glycolysis 
generates nicotinamide adenine dinucleotide (NADH) and flavin adenine dinucleotide (F ADH2) 
to provide the energy necessary for producing adenosine triposphate (ATP) through oxidative 
phosphorylation by the mitochondrial electron transport chain. The latter uses the difference in 
electric potential at the inner mitochondrial membrane to generate high-energy bonds in ATP. 
High mitochondrial membrane potential due to intracellular excess of glucose leads to 
overproduction of ROS by increased half-life of the superoxide (02 )-producing electron 
transport systems. High levels of 0 2- and consumption of NAD+ inhibit GAPDH resulting in 
accumulation of upstream intermediates in glycolysis that will be processed through pathways of 
glucose overutilization such as polyol, hexozamine, de novo synthesis of diacylglycerol (DAG), 
a cofactor of PKC, and formation of AGEs from accumulating trioses (Fig. A.2.1). Furthermore, 
ROS increase local production of TGF~ 1, fibronectin and plasminogen activator inhibitor (PAI) 
1 in renal cells playing a critical role in excessive ECM deposition [162, 131, 130, 204]. 
Nonetheless, a recent study showed that hyperglycemia-induced ROS overproduction increases 
the expression of RAGE and its endogenous pro-inflammatory ligands calgranulins, and DNA 
binding protein amphoterin in human aortic endothelial cells and STZ diabetic mice [ 449]. 
42 
AGE 
+ Protein -N H, 
Glyoxal 
RCO 
--------... 
Methylglyoxal · 
-----HEXOZAMINE 
Retroaldol 
condensation 
Introduction 
■utoxidation 
PARP 
© 
Figure A.2.1. 
43 
Introduction 
Figure A.2.1. Biochemical Mechanisms Underlying Diabetic Complications 
Degradation of glucose through glycolysis occurs in the cytoplasm and mitochondria of most 
eukaryotic cells. Pyruvate, the end product of glycolysis, enters the citric acid cycle (Krebs) that 
is coupled with the mitochondrial electron transport chain to produce high-energy bonds in ATP 
for use in cellular activities (green). Dysregulation of glycolysis by excess intracellular glucose 
mainly resulting in overproduction of ROS leads to inhibition of GAPDH involved in a rate-
limiting step. Subsequent accumulation of metabolites upstream of glyceraldehyde-3-phosphate 
leads to activation of polyol (pink), hexozamine (purple), AGE (orange) and PKC (red) 
pathways ultimately inducing a pro-inflammatory phenotype. 
Abbreviations: AGE, advanced glycation end product; SDH, Sorbitol dehydrogenase; RCO, 
reactive carbonyl compounds; GSSG, oxidized glutathione; GSH, reduced glutathione; P, 
phosphate; PPP, pyrophosphate; SOD, superoxide dismutase; GFAT, Glutamine fructose-6-
phosphate amidotransferase; SOD, superoxide dismutase; 02-, superoxide anion; UDPGlcNAc, 
UDP-N-acetylglucosamine; OGT, 0-linked GlcNAc transferase; PKC, protein kinase C; PARP, 
poly(ADP-ribose) polymerase; NF-kB, nuclear factor kappa B; TGF-B, transforming growth 
factor B; ROS, reactive oxygen species; C, cysteine; 2SC, S-(2succinyl)cysteine (2SC) 
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2.1.2. Polyol Pathway 
The polyol pathway overutilizes the NADPH/H + -dependent enzyme aldose reductase 
(AR) in the presence of high intracellular glucose to produce sorbitol that will further be 
oxidized to fructose producing NADH, and thus depletes NADPH stores and increases 
NADH/NAD + ratio. Aldose reductase has low affinity for glucose under physiologic conditions 
(high Km) and thus little glucose undergoes this pathway of metabolization. Flux through this 
pathway in human erythrocytes can use up to 11 % and rabbit lens up to 33% of glucose during 
hyperglycemia indicating species and tissue specificity [ 51]. 
Several mechanisms have been proposed to explain the impact of hyperglycemia through 
polyol pathway. One of them is the sorbitol-induced osmotic stress resulting from its reduced 
diffusion across cell membranes although , except for the lens, the concentration of sorbitol in 
blood vessels and nerves is too low to generate an osmotic effect. Another proposed mechanism 
is decrease in Na+/K+ ATPase activity by reduction of phosphatidylinositol synthesis although 
activation of PKC is a stronger inhibitor of this ATPase through arachidonic acid (AA) and 
prostaglandin E2 (PGE2). The third and most important mechanism proposed is the increase in 
NADH/NAD + ratio that ultimately inhibits GAPDH and increases levels of triose phosphates that 
enter other pathways such as DAG-PKC and AGE . Although hyperglycemia does induce 
reduction in NAD+ availability its massive depletion is primarily a result of poly-(ADP-ribose) 
polymerase (PARP) activation through ROS. PARP depletes NAD+ stores by cleavage to 
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nicotinamide, removes ADP-ribose residues from nuclear proteins, increase ROS concentration 
and shunts glycolytic intermediates to pathways that activate PKC [102]. Since NADPH is 
needed for generation of NO and glutathione the polyol pathway also favors vasoconstriction and 
reduces antioxidant capability of endothelial cells (EC) by inhibiting the generation of reduced 
glutathione (GSH). Studies on knockout and transgenic mice for AR suggest that this latter 
mechanism is the primary means by which polyol pathway impacts nerves and blood vessels 
[147, 423]. Similarly, inhibition of AR in rats improved microvascular permeability although in 
higher mammals and humans it showed inconsistent results probably due significant variability 
in AR activity across species [ 404, 166]. 
2.1.3. Hexozamine Pathway 
The hexozamine pathway uses fructose-6-phosphate excess to generate glucosamine-6-
phosphate, a substrate for proteoglycan synthesis and the formation of O-linked proteins thus 
altering the function of cytosolic and nuclear proteins via O-linked glycosylation modification. 
O-glycosylation of the ubiquitous transcription factor SPl, the first identified member of the 
Sp/XKLF11 family, increases its activity and thus the transcription of SPl-regulated genes such 
as PAI or NF-KB p65 [88]. Blocking the rate-limiting enzyme in this pathway namely the 
fructose-6-phosphate amidotranferase (GF AT) abolishes hyperglycemia-induces upregulation of 
transcription of transforming growth factor (TGF) a, TGF-~1 and PAI-1. Many other proteins 
11 Sp/XKLF , Specificity protein/Krilppel-like factor 
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modified by glucosamine may be relevant to diabetic complications and thus O-linked 
glycosylation might represent a general mechanism for hyperglycemia-induced hexozamine 
mediated changes m cellular function and sensitivity to INS. For example 0-
acetylglucosaminylation of eNOS at Akt binding site may be inhibitory to the enzyme. 
Conversely, several PKC isoforms are activated by glucosamine without membrane 
translocation. O-acetylglucosaminylation directly impacts the metabolic signaling of INS by 
altering the INS receptor (IR)-mediated activation of the IR substrate (IRS)/ phosphoinositide 3-
kinase (PBK)/ Akt pathway. This reduces endothelial nitric oxide synthase ( eNOS) activity, 
increases matrix metalloproteinase (MMP) 2 and 9 activity, and decreases expression of tissue 
inhibitor of metalloproteinases (TIMP) 3 [99]. 
2.1.4. PKC Pathway 
Activation of PKC by hyperglycemia occurs primarily as a consequence of converting 
triose-phosphates that accumulate upstream of GAPDH in glycolysis into dihydroxyacetone 
phosphate and subsequently into the lipid second messenger DAG. At least nine members of the 
PKC family can bind DAG in the presence of calcium (Ca2+) and change conformation to open 
the active site and thus interact with the substrate. Some PKC isoforms can also be activated in 
the absence of Ca2+. In the presence of insulin the hyperglycemia-dependent PKC activation is 
enhanced through phosphorylation of phosphatidylinositol-( 4,5)-biphosphate through PBK that 
results in release of phosphatidylinositol-3,4,5-triphosphate (PIP3) and DAG, which in tum 
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activate the PKC<; isoform. As a consequence of excessive PKC activation the phospholipase A2 
(PLA2) is phosphorylated, translocated and activated to release arachidonic acid (AA) and thus 
increase the production ofprostaglandin (PG) E2 that are known inhibitors ofNa +/K+ ATPase. 
Another consequence of excessive PKC activation is impaired phospholipase-C (PLC)-mediated 
Ca2+ signaling and reduction of NO generation in ECs. This ultimately leads to one of the earliest 
microvascular changes in diabetes, increased permeability to circulating macromolecules 
manifested primarily in the retinal and renal vascular beds [ 439]. The PKC~ isoform activation 
in hyperglycemia was associated with increased neovascularization and pharmacological 
inhibition of PKC~ normalizes the impaired retinal blood flow in diabetic rats [ 165]. PKC 
activation also leads to activation ofNADPH oxidase increasing the production of ROS and thus 
induces EC apoptosis. Expand for NADPH oxidase in PMN. Nonetheless, PKC mediates 
activation and nuclear translocation of NF-KB with subsequent expression of genes involved in 
cell adhesion, thrombosis and ECM synthesis: intercellular adhesion molecule (ICAM)-1, E-
selectin, fibrinolysis inhibitor PAI- I, fibronectin and collagen type IV [ 108, 315, 48]. 
2.1.5. AGEs 
The environment in which post-translational modification of proteins occurs can have a 
significant impact on their final structure and function. There are several types of modifications 
that occur primarily in the cytoplasm inside the ER including: 1) addition of functional groups 
such as phosphates, sulfates, acetates, carboxyl, hydroxyl, iodine, alkyls, lipids and 
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carbohydrates, 2) changing the chemical nature of an amino acid e.g. through citrullination, or 3) 
the structure of the entire protein e.g. by forming disulfide bridges. Additionally, amino acids can 
be inserted or removed from a protein either individually or grouped in peptides as seen in the 
processing of insulin or other pro-hormones to their active forms. Few of these modifications 
may occur outside the cellular environment such as lysyl-oxidase-mediated cross-linking in 
collagen maturation. 
Addition modifications may occur through enzymatic or non-enzymatic reactions. 
Enzymatic glycosylation of certain residues like serine, asparagine and hydroxylysine is under 
tight genetic control and serves a variety of functions including formation of specific hormone 
receptors, facilitation of protein secretion in the extracellular environment, diversifying 
antibodies and prolonging life or circulating proteins. In the presence of high levels of free 
sugars in the body non-enzymatic glycosylation of proteins takes place in a sequence of 
condensation-oxidation reactions resulting in formation of so-called advanced glycation end 
products (AGEs). Similarly advanced lipoxidation end products (ALEs) can form from fatty 
acids [24 7]. Glycation is used to differentiate non-enzymatic glycosylation from enzymatic 
glycosylation. Louis-Camille Maillard has described for the first time in 1912 the reaction of 
non-enzymatic protein glycosylation hence its name of Maillard reaction. It is initiated by 
carbonyl groups (either aldehyde of ketone) of reducing sugars acting on ammo groups of 
proteins to form a reversible Schiff bases. Successive intramolecular rearrangements in Schiff 
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bases lead to formation of other intermediates called Amadori products, which may further be 
processed, by dehydration and condensation to generate irreversible brown or fluorescent end 
products called AGEs. There are several glucose-derived reactive intermediates called reactive 
carbonyl compounds (RCO) that mediate formation of cross-linked AGEs: glyoxal, 
methyglyoxal and 3-deoxyglucosone. RCO will interact with amino groups in proteins, 
specifically belonging to lysine and argmme residues, to generate irreversible complex 
compounds with half-lives from days to years under physiologic conditions. Cross-linked AGEs 
have been well characterized and classified based on structure into bis(lysyl)imidazolium cross-
links, hydroimidazolones, monolysyl adducts and other compounds (table 3, fig. A.2.2.) [2, 293, 
432, 316]. Pentosidine and carboxymethyllysine (CML) are used as markers of disease 
progression in DM as both correlate strongly with severity of retinopathy and nephropathy. 
However, the lack of prospective studies on these correlations limits they ability to predict 
development of diabetic complications [250]. 
The identification of glycated hemoglobin (Hb) was the first proof of protein glycation in 
vivo. Samuel Rah bar had observed for the first time in the 1960' s that hemolysates of blood from 
diabetic patients had a fast-moving hemoglobin variant in cellulose acetate electrophoresis. 
Although this unusual hemoglobin did not form a completely separate band from HbA it was 
initially considered unrelated to other hemoglobin variants as it proved to be a stable molecule 
that resisted the heat denaturation test at 50°C and the isopropanol test [318]. 
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Figure A.2.2. Biochemical Structure of AGEs 
Three main classes of AGEs have been described based on chemical structure: 
bis(lysyl)imidazolium cross-links , monolysyl adducts and hydroimidazolones. The members of 
the first two classes result from condensation reactions involving K residues of proteins and 
members of the third class are R derivatives. A fourth class has been assigned to include other 
AGEs that are structurally R derivatives but unrelated to hydroimidazolones or to each other. 
CML and pentosidine are the two main AGEs used as markers of disease progression in diabetes. 
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Amino Acid Cilycatl'll Ci lycating Agent ( RCO) Cross-linked ACil: 
Bis(lysyl)imidazolium crosslinks 
Lysine Glyoxal 1. GOLD: glyoxal-derived lysine dimer 
Lysine Methylglyoxal 2. MOLD: methylglyoxal-derived lysine dimer 
Lysine 3-deoxylucosone 3. DOLD: 3-deoxyglucosone-derived lysine dimer 
Hydroimidazolones 
Arginine Glyoxal 1. G-H: glyoxal-derived hydroimidazolone 
Arginine Methylglyoxal 2. MG-H: methylglyoxal hydroimidazolone 
Arginine Glucosone 3. 3DG-H: 3-deoxy-glucosone hydroimidazolone 
Monolysyl adducts 
Lysine Glyoxal, Methylglyoxal 1. N -carboxymethyl-lysine* (CML) 
Lysine Glyoxal , Methylglyoxal 2. N -carboxyethyl-lysine (CEL) 
Lysine 3-deoxylucosone 3. Pyrraline 
Others 
Lysine, arginine Multiple origin** 1. Pentosidine* ( fluorophore) 
Arginine Methylglyoxal 2. Argpyrimidine ( fluorophore) 
Arginine Methylglyoxal 3. Tetrahydropyrimidine 
RCO , reactive carbonyl compound ; *Used as biomarkers for severity of diabetic complications ; **D-ribose (via 
ribated lysine) , D-glucose (via glucated lysine) , D-fructose , ascorbate 
Table 3 Classification of AGE 
It was later shown that m normal individuals up to 4% of hemoglobin undergoes 
glycation at the amino-terminal valines of the B-chain forming the HbA 1c subfraction. HbA1c is 
elevated two-threefold m untreated diabetic patients and 1s currently considered a reliable 
biomarker for control of glycemia in diabetes since it circulates within red blood cells (RBC) for 
up to 120 days. The American Diabetes Association recommends that patients with DM maintain 
HbA1c levels <7% and according to the 2010 Standards of Medical Care in Diabetes a HbA1c 
~6.5% is another criteria for the diagnosis of DM [11]. 
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Other proteins that undergo glycation in high glucose environments have since been 
described including numerous serum and cell membrane proteins [ 456], type I collagen in 
connective tissue and skin, IV collagen in basement membranes, fibroblast growth factor 2 
(FGF2) and other ECM proteins [ 432, 249]. The irreversible modification of these proteins 
impacts ECM structure and function contributing to progression of diabetic microagiopathy. 
The discovery of specific receptors for AGEs (RAGE) has oriented AGEs research 
towards the interaction of soluble AGEs with RAGE and characterization of the RAGE axis. 
RAGE belongs to the immunoglobulin superfamily of receptors with a variable (V) extracellular 
domain linked to two constant C-type domains. The extracellular component is attached to a 
transmembrane domain (TMD) linked to a charged cytoplasmic domain (CYTD) recently shown 
to bind diaphanous- I (mDia-1 ), a Rho family GTPase effector that may initiate translation of 
extracellular signals to cellular pathways involved in upregulation of inflammatory and 
prothrombotic factors [ 157, 208, 446]. RAGE binds to a variety of ligands grouped in five main 
families: AGE, amphoterin or high mobility group box-1 (HMGB 1 ), advanced oxidized products 
(AOP) including advanced oxidation protein products (AOPP) and oxidized low density 
lipoprotein (oxLDL), S100/calgranulins, amyloid-b and b-sheet fibrils [446]. The activated 
pathways downstream of RAGE that mediate pro-inflammatory states include NF-KB, NAPDPH 
oxidase assembly, PI3K mediated Akt phosphorylation and mitogen-activated protein kinases 
(MAPKs) namely extracellular-regulated kinase (Erk) 1/2, Jun N-terminal kinase (JNK) and p38 
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[371]. NF-KB activation through RAGE has a particular importance because it induces de nova 
synthesis of p65 mRNA that results in a constantly growing pool of excess transcriptionally 
active NF-KB p65 [41]. One of the cytokines induced by NF-KB is IL-6, which in turn activates 
C reactive protein (CRP)12 a classical acute phase reactant and marker of acute inflammatory 
response [ 405]. 
The soluble form of the receptor (sRAGE), lacking both the TMD and CYTD can either 
be a result of alternative splicing or proteolytic cleavage of membrane-anchored RAGE (Fig. 
A.2.3.). Soluble RAGE has beneficial actions in reducing vascular pro-inflammatory phenotypes, 
enhancing wound healing in diabetic mice and stabilizing atherosclerotic lesions by acting as a 
natural decoy for RAGE. [371, 211, 137, 210, 53]. Conversely, in a recent 12-years prospective 
follow-up including 339 patients aged ~ 18 years, sRAGE levels have recently been correlated 
with incidence of cardiovascular death in Tl DM which may be explained by sRAGE-associated 
renal dysfunction [273]. 
12 CRP, highly conserved normally occurring plasma protein that rises dramatically in a cytokine-mediated 
inflammatory responses (see glossary for details) 
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Figure A.2.3. RAGE axis 
Several ligands for RAGE have been identified to bind the variable (V) domain of the receptor 
and activate downstream intracellular pathways apparently thorough mDia-1 linker proteins. 
This ultimately leads to activation of pro-inflammatory and pro-thrombotic pathways. The 
soluble form of RAGE (sRAGE) lacks the transmembrane (TM) and cytoplasmic (CYTD) 
domains most probably acting as scavenger for ligands although high sRAGE levels were 
recently correlated with incident fatal and non-fatal CVD in TlDM. 
Abbreviations: RAGE, receptor for advanced glycation end products; sRAGE, soluble RAGE; 
HMGBl, high mobility group box-1; AOP, advanced oxidation products (proteins and LDL); V, 
variable domain; C, constant domain; cyt, cytoplasmic domain; TM, transmembrane domain; 
mDia-1 (diaphanous-I); MAPK, mitogen-activated protein kinase; NADPH, nicotinamide 
adenine dinucleotide phosphate. 
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2.2. Leukocyte Recruitment and Pathogen Clearance 
The immune system is a decision-making and action-taking self-governed biological 
complex ubiquitously present in a living organism situated at the intersection between what 
nature has programmed to be "normal" and the rest of environment. The essential role of 
recognizing and eliminating possible causes of imbalance makes immunity a key coordinator of 
body homeostasis 13. The general pattern of human response to injury and non-self involves a 
non-specific recognition of the unknown by the innate immune system followed by a humoral-
cellular reaction to neutralize and evacuate non-self. Resident cells and recruited mononuclear 
cells actively restore homeostasis once the inducing agent has been efficiently removed. 
Inflammation is an essential function of the immune system resulting from the 
coordinated interactions among inducers (non-self), sensors (pattern recognition receptors), 
mediators (serum- and cell-derived substances) and effectors (immune cells and toxic products) 
(table 4) [241]. Immunity is divided into innate and acquired (adaptive) based on dependence on 
inducer-specific memory generation. Thus, innate immunity is non-specific and does not require 
previous encounter with inducer while acquired immunity is inducer-specific and relies on the 
memory of previous encounter with inducer in that system. Both innate and acquired immunity 
have humoral and cellular components that act synergistically to eliminate the non-self. 
13 From Greek (homios, "similar" and histemi , "standing still"); The ability of a system or living organism to adjust 
its internal environment to maintain a stable equilibrium 
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Inducers Sensors Mediators l-:.ffectors 
PRR: 
Bacterial: 
PAMPs 
TLR (membrane-bound) 
Virulence factors 
MR (membrane-bound) 
r.,J 
;::::s NLR (cytoplasmic) 1. Vasoactive amines 0 
i::: 
Q) Non-bacterial: bl) 
0 
::< Allergens 2. Vasoactive peptides ~ 
Irritants NALP3 (cytoplasmic) Primary: 
Foreign bodies 3. Complement proteins Immune cells 
Toxic compounds N euro-endocrine 
Deseqestration: 4. Lipid mediators system 
HMGBl RAGE (membrane-bound) 
S 100 proteins RAGE 5. Cytokines Secondary: 
Heregulin HER2, HER3, HER4 Local cells 
r.,J 
;::::s Hageman factor Collagen/other ECM 6. Chemokines 0 
i::: 
Q) Others bl) 
0 
"'O 7. Proteolytic enzymes i::: AGEs ~ RAGE (membrane bound) 
AOPs 
ECM products TLR4 
Monosodium urate 
NALP3 
Other crystals 
Adapted from: "Origins and Physiological Roles of Inflammation" (Medzhitov 2008) 
Table 4 Components of Inflammatory Reaction 
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Humoral immunity consists of complement system (innate), immunoglobulins 
(antibodies) IgG, IgA, IgE (adaptive) as major humoral players, and other serum substances, 
which help neutralize and opsonize 14 pathogens to facilitate their clearance by leukocytes. 
Leukocytes are the maJor cellular players of immunity. Phagocytic leukocytes namely 
polymorphonuclear neutrophils (PMN) and macrophages (M<I>) are the effectors of cell-mediated 
innate immune responses while lymphocytes namely NK, T-, B-cells and plasma cells are the 
effectors of cell-mediated adaptive immune response (Fig. A.2.4). 
Leukocyte infiltration is preceded by hemodynamic changes primarily coordinated by 
local mast cells-derived mediators that result in local accumulation of transudate and initiation 
of classical signs of inflammation: rubor (redness), tumor (swelling), ca/or (heat), dolor (pain) 
andfunctio laesa (loss of function). Local protein leakage, cytokine production and immune cell 
migration generate an inflammatory exudate that represents the host's first complex arsenal 
against pathogens. Leukocyte entry at site of inflammation is chemokine-mediated. PMN 
represent the first line of cell-mediated innate immunity. The primary chemoattractant molecules 
for PMN are complement components C3a and C5a, plateles activating factor (P AF), leukotriene 
B4 (LTB4), 11-8 and N-formyl-methionyl-leucyl-phenylalanine (fMLP) [169]. PMN are followed 
by monocyte infiltration induced by monocyte chemoattractant protein 1 (MCP-1) and IL-8 to 
become M<I> inside the tissue and clear dying PMN and their digestion byproducts [339, 114]. 
14 Surface coating of pathogens by host substances (opsonins) to mediate their attachment to phagocytes. 
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Figure A.2.4. Inflammatory Response to Pathogens 
A pathogen present in the body triggers an inflammatory response that results in non-specific 
recognition and clearance by the innate immune system. Professional phagocytes work together 
to eliminate the non-self with the help of complement and IgG antibodies as opsonins. Resident 
M <I> will be activated to a M 1 phenotype by the pathogen and recruit PMN to clear pathogens. 
PMN will trigger pro-resolution pathways by initiating recruitment of monocytes to become M 1-
type M<I> and clear apoptotic PMN and debris once pathogens have been neutralized (innate 
inset). As part of adaptive immune response tissue APC will process pathogen specific antigenic 
peptides and present them to B and I-cells (adaptive inset, 1,2) to generate memory of the 
pathogen. At a second encounter of the antigen B-cells will mature into specific antibody 
producing plasma cells with co-stimulation from activated T h2 cells that have previously met the 
antigen (3-6). An adaptive immune response will be triggered if innate immunity is unable to 
efficiently remove non-self. Thi cells will be activated and act synergistically with Ml-type M<I> 
to facilitate pathogen neutralization. Tc cells will be activated by transformed host cells that fail 
to identify as self through MHCl molecules (bottom, innate inset). 
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The current paradigm for initiation of inflammation states that circulating monocytes 
originating in the bone marrow (BM) patrol blood vessels to eventually migrate into the tissues 
when damage is sensed becoming M<I> or dendritic cells (DCs) upon entry. A recent study has 
initiated a paradigm shift in physiology of inflammation by demonstrating that a significant 
splenic reservoir of monocytes but not PMN is readily available to exit the spleen during acute 
injury. These monocytes are assembled in clusters in the cords of the subcapsular red pulp and 
are distinct from M<I> or DCs [388]. Regardless of their primary site of origin, tissue resident M<I> 
and other antigen presenting cells (APCs) recognize the non-self including microorganisms, 
foreign bodies and stress-induced transformation of self, using membrane-bound signaling 
pattern recognition receptors (PRRs) including the Toll-like receptor (TLR) and the mannose 
receptor (MR). TLRs, MRs and the cytoplasmic NOD-like receptors (NLRs) are the three classes 
of signaling PRRs. Endocytic PRRs are the only non-signaling class of PRRs and they are 
involved in phagocytosis. TLRs and NLRs bind molecules characteristic to microorganisms 
called pathogen-associated molecular patterns (P AMP) and to cellular stress called damage-
associated molecular patterns (DAMP). PAMP include lipopolysaccharide (LPS) characteristic 
to Gram-negative bacteria, lipoteichoic acids (LT As) characteristic to Gram-positive bacteria, 
glucans, mannose, bacterial or viral DNA or RNA, peptides (flagellin), lipoproteins and fMLP 
[240]. DAMP include HMGBl, DNA, Sl00 molecules and purine metabolites (ATP, adenosine, 
uric acid) [217]. 
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Resident M<l> activated to a Ml pro-inflammatory phenotype secrete cytokines, 
particularly M<l> inflammatory protein (MIP)-la, granulocyte colony-stimulating factor (G-CSF) 
and granulocyte-monocyte colony-stimulating factor (GM-CSF) to directly attract PMN, and IL-
1 B, IL-6 and TNFa for activation of endothelial cells (EC) to capture circulating PMN for 
rolling, adhesion and transmigration, the major steps in leukocyte recruitment. Furthermore, 
macrophages, EC and other local cells produce MCP-1 for recruitment of circulating monocytes 
to differentiate locally into M2-type macrophages and clear the debris (Fig. A.2.5.) [376]. Once 
activated EC undergo two major changes: increase in adhesion molecules to favor leukocyte 
rolling and attachment, and expression of chemokines on their surface (IL-8) to activate 
circulating leukocytes. In response to pro-inflammatory cytokines millions of PMN are released 
en masse from BM. Activated peripheral circulating phagocytes upregulate their surface 
adhesion molecules for attachment, diapedesis, and migration inside the tissue to encounter the 
pathogen [440] (Fig A.2.6.). 
At sites of inflammation PMN recognize, phagocytose, neutralize, digest pathogens and 
eliminate the remnants via exocytosis. Professional phagocytes including PMN and macrophages 
use endocytic PRRs to recognize P AMP on pathogens and initiate their uptake. While 
phagocytes can engulf some particles without additional help, some pathogens and most 
encapsulated bacteria are resistant to phagocytosis and require specific coating called 
opsonization to facilitate ingestion by leukocytes. 
64 
4 
N 
ge 3 
0 
-
0 
M 1 macrophage 
PMN 
€., Tm ax 
., 
,' · , Monocyte 
I \ 
I \ 
I \ 
Tmax I \ I \ f \ M2 macrophage ... __ • - ..... 
I \ ,,"' ', 
I \ ,, ', 
: \ \ ,,,' ', 
Tmax \ '\ .. -"" ', 
..... ' 
: . \\ ,,,,' ', 
, Ri , T ..... ' T , , 112 ..... , 
112~:-:::.":'.-:-. . __ ~ --- Complete Restoration ', 
,, ' ' I ; ' ' 
' ' Resolution ' ,, ... of Homeostasis ',, 
...... 
...... 
..... 
4 12 24 
- PMN (10 µgZ) 
--- PMN (1000 µg Z) 
.... 
.... -,_, ...____________ __ 
.... 
48 
Time (h) 
........ 
.... :...., ........  
..... 
.... ,, ~ 
...... y 
72 96 
- Monocytes (10 µg Z) 
--- Monocytes (1000 µg Z) 
Introduction 
16 
14 
12 
N 
ge 
0 
0 
10 0 
-
--'& 
8 0 
I,., 
11.) 
6 ..0 § 
i:: 
4 d 
2 
0 
Z, zymosan ; Ri, resolution interval ; T 112 and T max, times of half and maximum numbers of cells recruited 
Early Apoptosis ,,,_..-' 
_____ ... ------·· 
( 
• .. 
',,,,...., 
.............. 
.... 
,,--
Late Apoptosis* ..............  
"leaky" ........ ~ 
caspase 
pathway 
8 
carbohydrate 
surface 
phospholipid 
surface 
markers 
CRP 
1 
~ 
chromatin 
degradation 
Figure A.2.5. 
© 
65 
Introduction 
Figure A.2.5. Inflammation and Resolution 
During inflammation Ml-type activation of M<I> leads to local recruitment of PMN to clear 
pathogens. Mononuclear cells follow PMN and are activated to M<I> with M2 phenotype to clear 
apoptotic PMN and other debris. The timing, quantity and quality of the phagocytic infiltrate and 
associated chemical mediators depend on the local concentration and pathogenicity of the 
inducing agent. Generally, a severe infection leads to massive PMN infiltration that peaks at 12 h 
post-exposure compared to 4 h in mild infections. This difference in local PMN numbers and 
subsequent qualitative change in the entire inflammatory milieu leads to greater monocyte 
recruitment and longer time for complete resolution in severe infections (Fig. A.2.5.) [60] 
Adapted from various sources: see ref. (27, 60, 347) 
Abbreviations: NAG, N-acetyl-glucosamine; PRM, pattern recognition molecule; PS, 
phosphatidyl serine; PSR, PS receptor; CRP, C-reactive protein. 
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Figure A.2.6. Leukocyte Recruitment Cascade 
Inflammation is triggered by the presence of non-self in the body. When exogenous agents such 
as bacteria are present in the tissue local resident M <I> will recognize it and trigger an 
inflammatory response by secreting interleukins and chemokines. This leads to release of 
neutrophils from the BM and activation of EC and circulating PMN. Activated PMN will be 
captured by EC and marginate along endothelium to transmigrate and encounter the pathogen in 
the tissue for neutralization and clearance. Once they accomplished their mission they trigger an 
active resolution process leading to restoration of tissue homeostasis. 
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Opsonization of foreign particles is an essential step in phagocytosis and is primarily 
done by two major opsonins, IgG and complement protein C3b that are able to form a coating on 
their surface. Following recognition of an opsonized pathogen the PMN forms a phagocytic cup 
around it eventually resulting in an endocytic vacuole called phagosome. Tyrosine motifs 
associated with cytoplasmic domain of FcR will mediate both formation of phagosome through 
initiation of actin polymerization and NADPH oxidase assembly through phosphorylation and 
translocation of p4 7 to the membrane. Subsequently, lysosomes and specific granules will fuse 
with the phagosome and release their arsenal of antimicrobial compounds including lactoferrin, 
lysozyme, B2-microglobulin, MMP 2 and 9 ( collagenase and gelatinase ), histaminase, 
heparinase, sialidase, PKC inhibitor and others [440]. In addition to the chemotactic properties 
LTB4 is also a potent secretagogue of PMN granule proteins and a powerful inducer of 02-
production [389]. Formation of the digestive vacuole is accompanied by activation of membrane-
bound reactive species producing enzymes, NADPH oxidase and inducible nitric oxide synthase 
(iNOS) to generate a toxic milieu for pathogen destruction. In the presence of 02- the 
myeloperoxidase-mediated peroxidation of chloride ions generates hypochlorous acid (HOCl), a 
potent antimicrobial agent. Together with 0 2- and peroxynitrite (ONOOl, HOCl are the main 
weapons the PMN uses against pathogens [96, 364] (Fig. A.2. 7.). 
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Figure A.2. 7. Bacterial Phagocytosis and Killing by PMN 
In most cases, the help of serum proteins like C3b and IgG for opsonization is indispensable for 
efficient uptake of bacteria by PMN. Specific receptors on PMN surface including FcR (for IgG) 
and CR (for C3b) together with PRR (for PAMP) recognize opsonized pathogens and trigger 
intracellular changes to initiate phagocytosis. FcR cytoplasmic domain-associated tyrosine 
motifs activate Syk signaling resulting in actin polymerization necessary in formation of 
phagocytic cup, and translocation of cytoplasmic p4 7 to mediate assembly of membrane 
anchored NADPH oxidase. Fusion of phagosome with lysosomes and granules creates a 
digestive vacuole loaded with an enzymatic arsenal highly efficient in digesting pathogens. 
Abbreviations: FcR, Fe receptor; PAMP, pathogen-associated molecular patterns; PRR, pattern 
recognition receptors; IT AM, immunoreceptor tyrosine-based activation motif; WASP, Wiskott-
Aldrich syndrome protein; Arp2/3, actin-related proteins 2 and 3; PIP2, phosphatidylinositol 4,5-
bisphosphate; iNOS, inducible nitric oxide (NO) synthase; MPO, myeloperoxidase; Syk, spleen 
tyrosine kinase; Rae, subclass of Rho family of GTPases; NADPH, nicotinamide adenine 
dinucleotide phosphate; ONOO-, peroxynitrate; 0 2-, superoxide. 
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2.3. Resolution of Inflammation 
Resolution of inflammation is a tightly regulated active process that follows successful 
removal of non-self. It consists of switching-off pro-inflammatory pathways and clearing local 
tissue debris ultimately leading to complete restoration of homeostasis. Essential signals from 
front line PMN are needed to initiate resolution processes. Once it has accomplished its mission, 
the PMN triggers self-destroying mechanisms in a non-flogistic manner initiating apoptosis 
through sequential activation of caspases 8, 9, 7 and 3 activation of calpains and ubiquitin-
proteasome complexes [424, 391, 170]. This results in destruction of essential cytoplasmic 
proteins including the ubiquitously present actin, and chromatin inter-nucleosomal degradation 
in the nucleus [339]. Aged or dying PMN simultaneously expose phospholipids 
phosphatidycholine (PC), phosphatidylethanolamine (PE) and phosphatidylserine (PS), oxidized 
phospholipids and carbohydrates including fucose and N-acetyl-glucosamine (NAG) on their 
surface [70, 329]. Several pattern recognition molecules (PRM) bind some of the apoptotic cell 
surface markers and act as bridging molecules to enhance phagocytosis of apoptotic PMN by 
M <I>. PRM that have been correlated with apoptotic cells include thrombospondin 1, C 1 q, 
mannose-binding lectin (MBL) and surfactant proteins (SP-A, SP-D) with affinity for 
carbohydrates, and pentraxins CRP, PTX3 and serum amyloid (SAP) that probably bind 
chromatin released from dying cells [ 40]. Specific scavenger receptors including scavenger 
receptors A, B, CD36 and CD68, av~ 3 integrin, PS receptor and complement receptors (CRl, 
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CR3, CR4) will bind to these molecules activating M<I> and dendritic cells to phagocytose and 
clear dying PMN from the tissue [268] (Fig A.2.5.). Some non-professional phagocytes like 
mesangial and epithelial cells may also help in clearance of apoptotic PMN. This physiological 
"start of the end" allows the PMN to die silently while sending "find me" and "eat me" signals to 
be cleared without release of intracellular milieu that is highly toxic for both pathogens and host 
tissues. Nevertheless, a late secondary apoptotic phenotype of PMN can be induced by 
persistence and increase in pro-inflammatory lipid mediators like LTB4. This late apoptosis 
characterized by selective leakage of intracellular content particularly DNA fragments is distinct 
from primary necrosis but it may lead to secondary necrosis in the absence of efficient resolving 
mechanisms [140]. The local and newly recruited monocytes become M2-type M<I> inside the 
tissue and phagocytose apoptotic PMN and other debris. Ultimately M <I> drain via lymphatic 
vessels into the circulation to be cleared in the spleen [339, 352, 34]. 
In some instances there is an imbalance between quantity and virulence of pathogens, and 
efficiency of primary response by the host. In these circumstances innate immunity is 
accompanied by an adaptive reaction that is highly antigen-specific and involves both humoral 
and cellular pathways. T lymphocytes originate in lymphoid organs (lymph nodes, spleen, 
thymus and MALT 15) where they also undergo maturation and are involved in both cellular (Tc 
➔ infected cell; Thi ➔ Ml macrophage) and humoral (Th2 ➔ B-cell activation) immune 
15 MALT, mucosa-associated lymphoid tissue 
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responses. The first encounter between mature nai"ve T-cells and specific antigens takes place in 
the first lymphoid "station" (generally a lymph node) along lymphatic system where APCs 
(normally dendritic cells) travel to present the antigen. Activation of T-cells generates memory 
(Tm), clone expansion and further differentiation into T-helper (Th) cells and T-cytotoxic (Tc) 
cells. B-lymphocytes originate in the bone marrow where they undergo their maturation in 
several steps and respond to antigen presentation by producing antibodies either independent of 
T-cells or in most cases, with co-stimulation from T h2 lymphocytes. Production of cytokines by 
T h2 cells (IL-4, IL-10) necessary for maturation of B-cells into antibody producing plasma cells 
depends on B-cells presenting to T-cells an antigen for which the latter has memory (the antigen 
was previously presented to the T-cell by an APC) [169] (Fig. A.2.4.). 
2.4. Leukocyte Adhesion Molecules 
The discovery and characterization ofleukocyte adhesion molecules in the 90's has led to 
a detailed understanding of essential events in leukocyte trafficking with significant impact on 
therapeutic approaches to inflammatory diseases that are now being investigated [383, 349, 39]. 
From a physiological point of view it became clear that the initial leukocyte rolling on EC inside 
post-capillary venules is a prerequisite for their capture and activation by EC since it favors a 
proximity of the two cell types that allows for their subsequent interactions. Studies of mice null 
for leukocyte adhesion molecules or therapeutically blocked with antibodies have found a severe 
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impairment in recruitment without decrease in leukocyte numbers, a general reduced ability to 
fight infections and reduced survival [106, 232, 243, 373, 182, 90,222,260,259]. 
The two major classes of adhesion molecules involved in leukocyte migration are 
selectins16 that mediate rolling and integrins that mediate firm attachment to EC. The selectin 
family consists of P-selectin (Platelet) or CD62P, E-selectin (Endothelial cell) or CD62E and L-
selectin (Leukocyte) or CD62L. The genes encoding all three selectins are located on 
chromosome 1 in both mice and humans and are strongly linked in singenic regions. Selectin 
genes evolved from exon duplication and shuffling being a classic example for the use of such 
genetic processes to generate a new gene/protein family. Their close proximity to genes encoding 
for complement-regulatory proteins suggests that several genes involved in physiology of 
immune responses developed coordinately [ 17 5, 431]. Structurally, selectins are characterized by 
a NH 2-terminal C-type (Ca2+ -dependent) lectin-like binding domain, an epidermal growth-factor 
(EGF)-like region, a variable number of consensus repeats similar to those found in complement 
proteins, a TMD and a short CTD [38] (Fig. A.2.8.). Selectins are >60% identical in their NHr 
terminal domain. The presence of the lectin-like domain has focus research on finding 
carbohydrate ligands for these molecules. Lewis X (Lex) and sialyl-Lewis X (sLex) were the first 
two characterized ligands for selectins [303, 203]. 
16 Selectins, derived from "/ectins " that are structural parts of these molecules ; also emphasizes their selective 
nature and function 
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P-selectin (140 kDa), previously named PADGEM 17 and GMP 18-140 is synthesized and 
stored in cytoplasmic a-granules of megakaryocytes/platelets and EC (Weibel-Palade bodies) 
and is released on the surface within minutes after cell stimulation. P-selectin surface expression 
is constitutive from preformed granules and may be increased by transcriptional regulation. 
Normally, only the ECs of postcapillary venules express P-selectin. In mice and other mammals 
TNF-a, IL-IP and LPS significantly increase the transcription of the P-selectin gene with mRNA 
transcripts peaking within 4 to 6 hours, and declining to basal levels within 12 to 24 hours [119]. 
In humans on the other hand, TNF-a, IL-IP and LPS fails to upregulate transcription of the P-
selectin gene. This discrepancy in regulation is explained by the presence of binding sites for 
NF-KB and ATF-2 in the 5'-flanking region ofmurine P-selectin gene, similar to E-selectin gene, 
which makes the gene responsive to pro-inflammatory transcriptional regulation [297]. Primate 
and human P-selectin gene lacks these regulatory sequences in the 5'-flanking region [296, 450]. 
Recycling of P-selectin takes place by internalization in clathrin-coated pits and return to the 
trans-Golgi network for reincorporation into Weibel-Palade bodies. 
Several sorting determinants in the cytoplasmic domain of P-selectin direct the protein 
from late endosomes to lysosomes, where it is degraded [362]. The primary function of P-
selectin is adhesion to specific glycoconjugates on surface of leukocytes through their distal C-
17 P ADG EM, platelet activation-dependent granule-external membrane protein 
18 GMP , granule membrane protein 
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type lectin domain to mediate rolling along endothelium. The preferential binding of P-selectin 
to a single glycoprotein was initially observed on HL 19 -60 neutrophil-like cells using ligand 
blotting and affinity chromatography [252]. This ligand was later structurally characterized and 
named P-selectin glycoprotein ligand 1 (PSGL-1 ). 
PSGL-1 (CD162) is a homodimer type-I transmembrane glycoprotein of 402 amino 
acids with a disufide bond linking the two monomers in the extracellular domain (ECD) close to 
the cell membrane. PSGL-1 mRNA was identified in many human and murine tissues but in low 
quantities except for bone marrow and circulating myeloid cells. All leukocytes express PSGL-1 
with lowest levels in B-cells [334, 447, 216]. Of all T-cells though, P-selectin binds only a 
specific subset, the Tm-cells suggesting that T-cells modify posttranslational modifications of 
PSGL-1 during differentiation to confer high affinity binding to P-selectin [253]. The coding 
region for human PSGL-1 is contained entirely in exon 2 of its gene located on chromosome 
12q24. ECD of human PSGL-1 starts at residue 42 and contains 16 decameric repeats rich in T 
and P. The NH2-terminal domain of ECD contains three important Yin positions 46, 48, and 51 
located in an anionic consensus sequence that favors tyrosine sulfation. Human and mouse 
PSGL-1 have an overall similarity of 67% and identity of 50% with highest identity for TMD 
domains (Table 5) [447]. The three terminal Y residues are essential for transitory non-covalent 
interactions between PSGL-1 and P-selecting during rolling ofleukocytes on EC (Fig. A.2.9.). 
19 HL, human promyelocytic leukemia cells 
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Binding of P-selectin occurs preferentially to the N-terminal region that has at least one sulfated 
Y and at least one core-2 O-glycan that has been sialylated and fucosylated. PSGL-1 must be 
modified with a2,3- linked sialic acid and al,3-linked fucose on terminal domain O-glycans to 
bind P-selectin [233]. Some of these O-linked oligosaccharides appear to contain poly-N-
acetyllactosamine with varying degrees of substitution. Sulfation of the three clustered Y 
residues is essential for binding to P-selectin. Enzymatic removal [437] or blockage of sulfates 
[312] eliminates this binding ability. 
PSGL-1 structure Mouse Human 
Peptide length (aa) 397 402 
Domain ~ (%) = (%) Length Length 
s 66 41 18 18 
p 69 58 23 23 
ECl 46 31 91 86 
CR 68 48 100 140 
EC2 46 31 74 42 
TM 91 83 24 24 
CT 86 76 67 69 
Sequence in N-terminal Q-V-V-G-D-D-D-F-E-D-P-D-Y 54- Q-A-T-E-Y4 6-E-Y 4s-L-D-Ys1-D-F-L-
domain Tss-Y s6-N-T 58-D-P-P P-E-T57-E-P-P-E 
Consensus sequences in 
E-T-S-Q-P-A-P-T-E-A Q-T-T-P-P-A-A-T-E-A 
ECD repeats 
Signaling sequence ill 
RLSRKTHMYPVRNY.S.PTEM RLSRKGHMYPVRNYSr_TEM 
CTD 
Abbreviations: aa, amino acid ; ~, similarities; =, identities ; S, signal peptide ; P, propeptide; ECl , 
extracellular distal; CR , consensus repeats; EC2 , extracellular proximal; TM , transmembrane ; CT , 
cytoplasmic; TMD , TM domain; CTD, CT domain ; underlined , ERM-binging domain; italics , NAFl-
binding 
Table 5 Comparison Between Human and Mouse PSGL-1 Structure 
78 
NH/ 
Ca 
E-selectin 
Inducible [ 
Intermediate 
affinity 
Outside-in 
coo-
Introduction 
NHt ] NH + Rolling 3 a 
L-selectin 
P-selectin 
0 0 0 ] Constitutive 00 
5 
mRi A 
Storage in granules 
Chemokine 
Receptor 
Signaling 
Low affinity 
(closed) 
a p 
Figure A.2.8. 
a 
Adhesion 
High affinity 
(open) 
J Inside-out 
© 
79 
Introduction 
Figure A.2.8. Selectins and Integrins 
Selectins are structurally characterized by a N-terminal C-type (Ca2+ -dependent) lectin-like 
binding domain, an EGF-like region, a variable number of consensus repeats similar to those 
found in complement proteins, a TMD and a short CTD. P- and L-selectin are constitutively 
expressed on the surface of EC and leukocytes respectively. They are stored in membrane-bound 
vesicles (top right). E-selectin is expressed on the surface of activated EC as a result of 
transcriptional upregulation (top left). Integrins are heterodimer adhesion molecules consisting of 
an a and a~ subunit. ~2-integrins have are present on the surface of leukocytes in different states 
of affinity for immunglobulin-like ligands on EC. Binding of chemokines such as IL-8 to GPCR 
receptors on leukocytes induces a conformational change in ~2-integrins from low to high 
affinity via outside-in signaling. High affinity conformation favors firm attachment of leukocytes 
to EC. In intermediate affinity conformation ~2-integrin binding to immunglobulin-like ligands 
can mediate signaling pathways in leukocytes necessary for their activation (bottom). 
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Beside the morphologic characteristics of P-selectin and PSGL-1 three mam factors 
control P-selectin-dependent rolling: dimeric interactions (longer lifetimes than monomeric), 
clustering of P-selectin in clathrin-coated pits of ECs and PSGL-1 in the tips of microvilli of 
leukocytes [3, 251]. Shedding of the N-terminal ectodomain is the main mechanism for 
regulation of PSGL-1 binding to P-selectin. Several mechanisms for proteolytic cleavage of the 
terminal sequence in PMN PSGL-1 have been proposed including MMPs 2, 9 and Mocarhagin 20 , 
~ secretase BACE-1 and members of the a-disintegrin-and-metalloprotease (ADAM) family of a 
secretase proteases, particularly ADAM8 [77, 207, 112, 267] 
E-selectin (115 kDa), previously named ELAM 21-l is exclusively synthesized in EC and 
is expressed on the surface within hours after stimulation. E-selectin surface expression on EC is 
cytokine inducible being primarily regulated at mRNA level. 
20 Mocarhagin , snake venom MMP 
2 1 ELAM , endothelial-leukocyte adhesion molecule 
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Figure A.2.9. Leukocyte PSGL-1 
Rolling of neutrophils is mediated by the transitory binding of PSGL-1 on neutrophils to P-
selectin on EC. PSGL-1 is a carbohydrate-rich glycoprotein composed of two monomers bound 
by a disulfide bond in the proximal segment of EC domain. N-terminal domain has three 
essential sulfated Y residues involved in transitory non-covalent interactions with the lectin 
domain of P-selectin. The sLe~ moiety present next to the sequence containing the sulfated Y 
residues may explain the binding of PSGL-1 to E- and L-selectin although with lower affinity 
than to P-selectin. Both PSGL-1 and P-selectin are constitutively expressed. PSGL-1 is clustered 
on the tips of leukocyte microvilli in lipid rafts dependent on activation of the cell. Enzymatic 
shedding is another mechanism of regulation for PSGL-1. 
83 
Introduction 
Activated ECs increase E-selectin protein synthesis markedly within 3 to 4 hours and 
diminish mRNA expression significantly by 6 to 8 hours returning to near-basal levels within 24 
to 48 hours [3]. Murine E-selectin has > 70% homology to human E-selectin [57]. Although 
binding to ligands bearing Lex or sLex is similar to P- and L-selectins, meaningful interactions 
occur only with specific leukocyte receptors suggesting unique structural features most probably 
in the EGF-like domain [179]. Upon binding to leukocytes ligands E-selectin clusters in lipid 
rafts and the CTD activates PLC and downstream pathways inducing an inflammatory phenotype 
in EC [258]. 
L-selectin, previously named LECAM 22 -1 is exclusively synthesized in leukocytes and 
expressed constitutively on their surface. The lack of serine- or threonine-rich regions explains 
the absence of O-linked glycans. Differences in posttranslational glycosylation among leukocyte 
subtypes results in variable molecular weight: 75, 95 and 110 kDa in lymphocytes , PMN and 
monocytes respectively. The high number of cysteines in the consensus repeat and EGF domains 
suggests importance of disulfide bonds for proper spatial conformation of the molecule. There is 
an 80% homology between murine and human L-selectin (Fig. A.2.8.). L-selectin binds to 
sequences bearing sLex including PSGL-1 and other sulfated glycoproteins like GlyCAM-1 23, 
CD34 and MUC-1. Binding of L-selectin to PSGL-1 was proposed as a mechanism for 
22 LECAM , leukocyte-endothelial cell adhesion molecule 
23 GlyCAM-1 , glycosylation-dependent cell adhesion molecule 1 
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secondary capture ofleukocytes by activated PMN attached to EC [159]. L-selectin expression is 
regulated through proteolytic shedding by enzymes of the ADAM family [38, 118] 
Integrins of the ~2-class are a family of membrane anchored heterodimers and tyrosine 
kinase receptors that serve the firm adhesion and intracellular leukocyte signaling. There are 
three main types of integrins on leukocytes that share a common ~2-chain (CD18) non-
covalently linked to a distinct a-chain CDlla (aL) (CD1 la/CD18, LFA-1, lymphocyte function-
associated antigen 1), CDllb (aM) (CD1lb/CD18, Mac-I, macrophage antigen 1) or CDllc 
(ax) (CD1 lc/CD18) [344]. Expression of ~2-integrins is restricted to leukocytes. Peripheral 
blood lymphocytes express primarily LF A-1 while PMN and monocytes express all three ~2-
integrins although only CD 11 b/CD 18 and CD 11 c/CD 18 are available in intracellular storage 
pools. LTB4, TNFa, fMLP, C5a and other pro-inflammatory molecules upregulate expression of 
~2-integrins in leukocytes [57]. Furthermore, chemokines like PAMPs or IL-8 binding to their 
leukocyte counter-receptors induce changes in ~2-integrins from a closed to an open 
conformation via inside-out signaling. This change increases their affinity for ligands [ 1] (Fig. 
A.2.8.). Integrins on leukocytes bind intercellular adhesion molecules (ICAMs) on EC to mediate 
attachment. LF A-1 but not Macl is essential for P MN recruitment as demonstrated by blocking 
antibody studies [333, 120, 218]. 
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2.5. Diabetes-Associated Low-Grade Inflammation 
A chronic low-grade inflammation is characteristic to the onset of T2DM in obese 
patients. Studies with specific M<I> knockout mice have shown that obesity does not correlate to 
IR in the absence of local inflammation triggered by resident M<I> [22, 377, 378, 154]. The 
discovery of adipose tissue M<I> (ATM) and their relationship to adipocytes has led to a better 
understanding of inflammatory mechanisms in T2DM. While bone marrow-derived M <I> make 
up ~ 10% of total adipose tissue in lean individuals they represent 40% of it in overweight 
individuals [ 434]. 
Recruitment of M <I> into obese adipose tissue seems to be mediated through secretion of 
MCP-1 by adipocytes in the context of high-fat diet [61, 178]. It is now clear that in obesity 
ATM undergo a Ml type activation leading to cytokine (TNFa, 11-6 and IL-1~)-mediated 
paracrine induction of inflammation and IR in INS-sensitive cells mainly through activation of 
JNK, inhibitor of Kl3 kinase (IKK) p and interferon-regulatory factor (IRF) family members. 
Moreover, dysregulated secretion of adipokines (PAI- I-increased) and adipose derived 
hormones (resistin-increased; adiponectin- decreased) in visceral fat adipocytes favors an 
inflammatory and pro-coagulant state [289, 146, 366]. 
Activation of A TM occurs mainly as a result of ER stress in response to fatty acids, 
excess of nutrients, improperly folded proteins, microhypoxia and lipopolysaccharide (LPS). ER 
stress in response to extracellular nutrients is central to inflammatory basis of IR and T2DM 
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through three main ER membrane-bound proteins involved in the unfolded protein response 
(UPR): RNA-activated kinase (PKR)-like ER kinase (PERK), activating transcription factor-6 
(ATF6) and inositol requiring enzyme 1 (IREl). All three pathways enhance local inflammation 
and IR through activation of NF-KB and inhibition of INS receptor substrates (IRS 1 and IRS2) 
by phosphorylation, respectively [153, 93]. Moreover, several lymphocytes subtypes accumulate 
in obese adipose tissue and modify the M <I> behavior to promote IR. LPS, saturated and to a less 
extend polyunsaturated fatty acids and activate ATM to a Ml phenotype via TLR4 while Q-3 
fatty acids are anti-inflammatory mediating activation of ATM to a M2 phenotype. Similarly, 
activated Kupffer cells induce IR in liver although hepatocytes are less dependent on INS for 
glucose uptake. MCP-1 knockout mice are protected from high-fat-induced hepatosteatosis 
indicating a role ofmonocytic cells in obesity-related liver dysfunction [178]. (Fig. A.2.10.). 
Several negative feedback loops to repress the M 1 phenotype or mediate the switch to a 
M2 phenotype have recently been described including intracellular and intercellular mechanisms. 
The three main intracellular loops are IKBa-mediated KB pathway attenuation, activating 
transcription factor-3 (ATF3)-mediated pro-inflammatory gene suppression and an orphan 
nuclear receptor Nurrl (NR4A2)-mediated turnover of p65 component of NF-KB. Intercellular 
pathways are IL-IO-mediated suppression of TNFa-induced IR, TAM group of receptor tyrosine 
kinases-mediated inhibition of TLR signaling and adiponectin-mediated suppression of M<I> 
LPS-induced responses and stimulation of IL-10 and IL-1 receptor antagonist production. Long-
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chain Q-3 fatty acids also inhibit responses to LPS, TNFa and saturated fatty acids possibly 
through their endogenously derived lipid mediators resolvins and protectins. The exact 
mechanism of this pro-resolving loop in DM are unclear [289]. 
On the other hand hyperglycemia as a result of either IR or ~-cells destruction activates 
pro-inflammatory pathways through glycolysis-derived mediators and nutrient sensing 
mechanisms. ER stress-activated PERK and IREl pathways mediate apoptosis in several cell 
types including pancreatic ~-cells through activation of pro-caspases [93]. TXNIP 24- mediated 
NLRP3 25 inflammasome activation by excess glucose results in production of inflammatory 
mediators by pancreatic M <I> and apoptosis of ~-cells leading to hypoinsulinemia. This closes a 
vicious cycle of inflammation-IR-hyperglycemia [346]. 
24 Thioredoxin-interacting protein 
25 NLRP3, nucleotide-binding domain leucine-rich repeat containing receptors (NLR) family protein 3 
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Figure A.2.10. Pathogenesis of T2DM 
Adipose tissue production of chemokines is considered one of the earliest events in pathogenesis 
of T2DM (]). Subsequent recruitment of mononuclear cells predominantly monocytes in adipose 
tissue (2) generates a local pro-inflammatory state (3) inducing IR in adipocytes that contributes 
to hyperglycemia and compensatory hyperinsulinemia ultimately favoring NLPR3 
inflammasome activation and pancreatic stress (4,5). Pancreatic insufficiency generates chronic 
hypoinsulinemia that generally characterizes advanced stage T2DM (5, crossed INS). In response 
to hypoinsulinemia and activation of Kupffer cells with subsequent inflammatory-induced 
hepatocyte IR the liver releases massive amounts of glucose into the circulation ( 6, 7). The 
resulting chronic hyperglycemia leads to AGE formation that further activates immune cells to a 
pro-inflammatory phenotype closing a negative self-amplifying vicious circle (8). IR and leptin 
resistance (LR) in hypothalamic neurons leads to loss of vagal inhibition of hepatic 
gluconeogenesis and increased appetite (9,10) [401, 282]. Glial cells may contribute to LR 
during sustained low-grade inflammation through synthesis of cytokines for survival (IL-10) and 
inflammation (TNFa , IL-1(3, IL-6) although it is still controversial [401]. High-fat diet may also 
induce apoptosis of hypothalamic neurons through ER stress mediated mechanisms [255]. 
Abbre viations: CCR2 , chemokine C-C motif receptor ; TNFR , TNF receptor ; LR, leptin receptor ; RAGE , 
receptor for AGE ; TLR, Toll-like receptor ; NLR , NOD-like receptor ; IR, INS receptor ; GLUT, glucose 
transporter ; MCP-1 , monocyte chemotactic protein-I = CCL2 ; IRSl , INS receptor substrate 1; SOCS, 
Suppressor of cytokine signaling. 
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3. Periodontal Disease in Diabetes 
3.1. Periodontium 
Periodontium is a unique ecological niche in the human body where teeth are emerging 
through mucosal surfaces into an oral environment hosting over 400 bacterial species. These 
microorganisms will contaminate any wound in the oral tissues requiring a very efficient local 
inflammatory and healing process to resolve infection and restore homeostasis. Even in the 
absence of a discontinued physical barrier there is a constant relationship between a biofilm 
covering intraoral surfaces and the underlying host tissues. Several anatomical and 
environmental factors predispose the soft tissues in the immediate vicinity of the teeth to specific 
bacterial colonization and initiation of periodontal inflammation. As a physiological response to 
a continuous variation in local virulence of oral biofilm human innate immunity has evolved to 
meet the higher demands in this part of the body. Particularly, under normal health conditions, 
inside gingival crevice located between tooth surface and gingiva resides the gingival crevicular 
fluid (GCF) that consists of a pseudo-inflammatory exudate comprising of serum inflammatory 
mediators such as immunoglobulins, complement proteins and cytokines, leukocytes, bacteria, 
desquamated epithelial cells and their products including endotoxins and chemotactic agents 
[330]. 
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3.2. Epidemiologic Considerations 
Chronic inflammation of gingival tissues called gingivitis represents the initial reversible 
stage of periodontal disease (PD). Gingivitis, diagnosed based on gingival bleeding on probing 
(BOP) of the gingival crevice in one or more sites, impacts 50% of adults 30 years of age or 
older in the USA. Approximately 10.5 % of these individuals have extensive gingivitis including 
5 or more teeth with gingival BOP [6]. Although in some individuals gingivitis never progresses 
to PD [319], data suggests that gingivitis always precedes PD and more importantly it represents 
a clinically relevant risk factor for periodontal attachment loss [201]. PD represents the 
advancement of tissue destruction m the underlying periodontal structures including the 
periodontal ligament (PDL), cementum that covers the roots of teeth, and alveolar bone 
compromising tooth stability in the socket (Fig. A.3.1.). According to the National Health and 
Nutrition Examination Surveys (NHANES III) prevalence of PD among US adult population 
aged 20-64 years, diagnosed based on at least one periodontal site with 3 millimeters or more of 
attachment loss (AL) and 4 millimeters or more of pocket depth26, has decreased from 15% to 
8.5% between 1994 and 2004. In seniors aged 65 years or more incidence has decreased from 
19.53% to 10.58% [92]. Severe PD is characterized by loss of supporting structures around teeth 
leading to formation of deep pockets and increased tooth mobility. The prevalence of severe PD 
among US adult population, diagnosed based on at least two teeth with interproximal ( areas 
26 NHANES definition of PD 
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between two adjacent teeth) AL of 6 millimeters or more and at least one tooth with 5 
millimeters or more of pocket depth at interproximal sites27, has also decreased from 9.63% to 
5.08%. Similarly, prevalence of severe PD among seniors aged 65 years or more has decreased 
from 25.56% to 17.20% [92, 54]. 
3.3. Definition, Etiology and Classification 
PD 1s characterized by a dysregulated local inflammatory reaction and progressive 
destruction of periodontal supporting tissues as a result of breaking the gingival seal that protects 
against local invasion by periodontal pathogenic bacteria. Gingivitis is the initial reversible stage 
of PD characterized by inflammation of gingival tissues without detectable evidence of clinical 
attachment or bone loss [55]. Progression of PD results from a failure of the immune system to 
clear infectious agents and to restore periodontal homeostasis [ 414, 180]. Socransky et al. have 
grouped the microorganisms that colonize the subgingival plaque into five main color-coded 
complexes based on similarities between pairs, associations and clustering of species using 
cluster analysis, community ordination and checkerboard DNA-DNA hybridization: red 
complex (Bacteroides forsythus, Porphyromonas gingivalis and Treponema denticola), orange 
complex (Fusobacterium nucleatum/periodonticum subspecies, Prevotella intermedia, 
Prevotella nigrescens and Peptostreptococcus micros), yellow complex (Streptococcus sanguis, 
27 CDC-AAP (American Association of Periodontology) definition of moderate and severe periodontitis 
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S. oralis, S. mitis, S. gordonii and S. intermedius), green complex (Capnocytophaga species, 
Campylobacter concisus, Eikenella corrodens and Actinobacillus actinomycetemcomitans 
serotype) and purple complex (Veillonella parvula and Actinomyces odontolyticus) [374]. 
Several associations were also characterized among species inside microbial complexes, among 
different complexes and with severity of PD. Specifically, the red and orange complexes are 
associated with severe forms of PD [375, 399]. 
Although it was initially considered primarily an infectious disease PD results from a 
combination of specific bacterial colonization with subsequent formation of particular 
microniches as triggering factor and local dysfunctional host immune responses to these 
pathogens. What favors the bacterial inoculation of periodontal tissues is still unclear. What we 
know with certainty though is that several oral microorganisms including Candida albicans, 
Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans induce local synthesis 
of chemokines such as MCP-1 and IL-8 by ECs and monocytes resulting in accumulation of 
mononuclear cells [ 191, 13 5, 172]. Furthermore, there is growing evidence that bacterial species 
characteristic to chronic infections induce pathogen resistance by acting on specific signaling 
pathways of innate immunity supporting the concept of PD being primarily an infectious disease 
[85, 47]. On the other hand, the recent concept of biofilm composition being a result of host 
inflammatory response questions the infectious etiology of PD pointing at dysfunctional innate 
immunity as the main cause for PD onset [415, 103, 47]. 
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Figure A.3.1. Periodontal Anatomy in Health and Disease 
In health, periodontal tissues ensure adequate protection of tooth root surfaces, anchorage and 
support for the tooth, absorption and transfer of masticatory forces to the underlying bone. 
Periodontium is formed of gingival tissues, alveolar bone, periodontal ligament (fibers, cells and 
extracellular matrix) and cementum covering the root surfaces. The crevice formed between the 
tooth and gingiva contains an inflammatory exudate that helps protect the junctional epithelium 
from dental plaque byproducts and other irritants. Persistence and composition changes in dental 
plaque for up to 21 days induces gingivitis characterized by hyperemic tumefaction of free 
gingiva, an inflammatory P MN infiltrate and relatively high numbers of T-lymphocytes in the 
corion. Removal of irritants restores gingival homeostasis whereas its persistence in susceptible 
patients may lead to PD. The latter is characterized by an irreversible progressive destruction of 
periodontal structures and a mononuclear cell infiltrate with B- and plasma cells predominating. 
This results in compromised tooth stability in the socket. 
Note: for the purpose of simplification only the most common form of gingivitis i.e. plaque-
induced gingivitis is presented; this form also has the highest rate of progression into PD. 
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Classification of PD has changed over the years as we progressed in understanding the 
pathogenesis of this disease. Regardless of the mechanism of onset PD manifests as a local 
chronic inflammation of periodontal tissues. The 1999 International Workshop for a 
Classification of Periodontal Diseases and Conditions divided periodontal diseases into 
Aggressive Periodontitis (formerly Early Onset Periodontitis, EOP), Chronic Periodontitis 
(formerly Adult Periodontitis) and Periodontitis as Manifestation of Systemic Diseases (table 6) 
[10]. Although Aggressive Periodontitis is seen more often in younger population (<35 years 
old) and Chronic Periodontitis in adults, the terms EOP and Adult Periodontitis were abandoned 
to eliminate age-related restrictions in diagnosis and treatment planning for these entities. 
Disease Class Types 
Aggressive Localized 
Periodontitis (EOP) Generalized 
Chronic Periodontitis 
Slight= 1-2 mm CAL 
Localized ( <30% of sites affected) 
Moderate = 3-4 mm CAL 
(Adult Periodontitis) Generalized (> 30% sites affected) 
Severe = > 5mm CAL 
Associated 
with 
1. Acquired neutropenia 
2. Leukemias 
Periodontal 
hematological 
3. Other 
disorders 
Disease 
Periodontitis as a 1. Familial and 
6. Glycogen storage 
disease 
Manifestation of cyclic neutropenia 
Systemic Diseases Associated 2. Down's 
7. Infantile genetic 
with genetic 3. LAD syndromes 
8. agranulocytosis 
9. Cohen 
disorders 4. Papillon-Lefevre 1 
10 Ehlers-Danlos 
5. Chediak-Higashi 
(Types IV and VIII) 
Histiocytosis 
11. Hypophosphatasia 
Adapted from: International Workshop for a Classification of Periodontal Diseases and Conditions (1999) [10] 
Table 6 Classification of Periodontal Diseases and Conditions 
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3.4. Clinical Context 
The onset of PD in a systemic predisposing context has been extensively studied since 
immunity was found to be an essential contributor to both initiation and progression of 
periodontal destruction [ 418, 41 7, 3 96]. It became clear that both genetic and epigenetic factors 
contribute to the periodontal clinical phenotype seen in PD. Genetic traits such as specific 
polymorphisms in the interleukin (IL)-1 gene cluster and HLA-DR4 antigens impact the potency 
of immunity in an individual thus setting a threshold for severity of PD [193, 266, 43]. 
Furthermore, several monogenetic syndromes including congenital neutropenias, leukocyte 
adhesion deficiencies (LADs), Chediak-Higashi, Ehlers-Danlos, Kindler, Papillon-Lefevre and 
other periodontitis-associated palmoplantar keratoderma syndromes and others are associated 
with severe forms of PD called Mendelian forms of periodontitis (see table 4) [138]. 
Epigenetic contributions including bacterial colonization, smoking, DM and osteoporosis 
induce significant changes in local tissue behavior favoring the onset and progression of PD 
[283, 109]. While smoking clearly increases periodontal bone loss as shown in several 
longitudinal studies [300, 25, 26, 37], the role of osteoporosis in onset and progression of PD is 
still debated. Some evidence suggests a possible impact of osteopenia on PD particularly in 
women suggesting a hormonal mechanism involved [23, 390]. In fact estrogen replacement 
therapy in postmenopausal women was associated with lower incidence of tooth loss in a large 
cohort study that included 13,979 women aged 81 years on average [294]. A longitudinal study 
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has assessed the relationship between bone mineral density and loss of periodontal attachment 
and found systemic osteopenia to be associated with sites of progressing PD [ 451]. However, 
other studies have reported no correlation between bone density and PD [94, 189]. Although 
there is some evidence to suggest that osteoporosis is a risk factor for PD further prospective 
studies with better control of variables assessed are needed to understand this association [427]. 
Nonetheless, established PD is characterized by transient bacteremias that may initiate 
lesions in other parts of the body such as the heart valves and arteries both through direct 
infectious pathogenicity and contribution to a systemic low-level inflammation that has been 
correlated with atherosclerosis and cardiovascular diseases [452, 257, 74, 109, 287, 214, 276, 
32]. In support of this temporal relationship between PD and systemic inflammation periodontal 
therapy was associated with long-term reduction in inflammatory markers including CRP, 
TNFa, and PAI-1 and improvement of endothelial function by decreasing the levels of soluble 
E-selectin [199, 407]. However an increase in CRP levels after intensive periodontal therapy 
imposes precaution measures for patients at risk [ 187]. Periodontal pathogens including P. 
gingivalis, P. intermedia, B. forsythus and A. aggregatibacter have been identified in significant 
quantities in atheromatous plaques suggesting colonization of emigrated oral bacteria in systemic 
macrovasculature [136]. Furthermore, the Oral Infections and Vascular Disease Epidemiology 
Study (INVEST) has analyzed 657 dentate subjects with no history of stroke of MI aged 69 years 
on average to investigate the relationship between oral microbiota and subclinical 
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atherosclerosis, and found a positive correlation between the four bacterial species mentioned 
above and carotid artery intima-media thickness (IMT) [82]. This suggests a possible 
colonization of oral microorganism in healthy arterial walls where they induce structural changes 
eventually resulting in atherosclerosis. The INVEST group has recently reported a direct positive 
correlation between levels of subgingival bacteria and prevalence of hypertension [81]. 
Virulence factors of P. gingivalis particularly the fimbriae and LPS are potent inducers of 
cytokine release by host cells including IL-1, IL-6, IL-8 and TNF a [9]. The detection of P. 
gingivalis more frequently in T2DM patients with higher HbA1c levels after therapy compared to 
those with lower values has raised the question whether PD plays a role in control of BG [225]. 
Indeed it was reported that periodontal therapy improves glycemic control in DM patients [124]. 
A recent review by The Cochrane Collaboration has concluded that according to current 
evidence treatment of PD particularly mechanical root scaling/planing improves metabolic 
control measured by HbA1c levels in patients with DM although larger randomized trials are 
needed to understand the impact of PD treatment on glycemic control [370]. 
Overall genetic factors seem to play an important role in predisposition for PD. 
Epigenetic factors including systemic conditions and complex associations among them 
predispose to PD through both immunological and metabolic mechanisms. On the other hand 
PD is considered a potential risk factor for metabolic diseases including T2DM although further 
research is needed to understand the mechanisms involved. 
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3.5. Periodontal Disease as Diabetic Complication 
Particular attention has been given to the connection between PD and diabetes since they 
were shown to exhibit a bidirectional relationship centered on a dysregulated inflammatory 
response manifested both locally and systemically [186, 419, 380, 237, 436, 235]. The impact of 
DM on periodontal health has been addressed in numerous cross-sectional and longitudinal 
studies. Although there was significant heterogeneity among these studies in design and aims 
increasing evidence suggests that poorly controlled DM correlates with higher prevalence, 
severity and progression rate of PD when compared to controlled DM or health. [239, 397, 379, 
398, 80]. In general, three main parameters were measured to evaluate periodontal status: 
bleeding on probing (BOP) as indicator of gingivitis, and clinical attachment loss (CAL) and 
alveolar bone loss (ABL) as indices for monitoring PD progression (Fig. A.3.2.) Most studies 
have aimed at finding correlations among indicators for PD onset, progression and severity, and 
several diabetic parameters including glycemic control, duration of disease, presence of other 
diabetes-associated complications and population studied. 
Several cross-sectional studies have found that regardless of dental plaque index (PI)28 
gingivitis is more prevalent in diabetic patients than healthy controls suggesting an impact of DM 
on local inflammatory response to the bacterial biofilm [198, 231, 219, 336, 279, 307]. In 
support of this observations gingival levels of cytokines measured in the tissue or GCF, in 
28 Method for quantification of dental plaque, measured as score (0,1,2 or 3)/tooth (Silness and Loe, 1964) 
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particular IL-1 ~' were found increased in patients with poorly controlled DM in the absence of 
PD when compared to well-controlled and nondiabetic patients [73, 15]. 
A recent longitudinal study has reported increasing IL-1 ~ levels in GCF of patients with 
or without T 1 DM during 21-day experimental gingivitis with significant increase in diabetic 
patients on day 7 and one week later in healthy individuals. Furthermore, matrix 
metalloproteinase (MMP) 8 and 9 were significantly increased in diabetic patients by day 21 
[335]. Several recent studies have found associations between PD and polymorphisms in IL-1 
gene cluster (IL-IA -889, IL-1B +3954, IL-1B -511) in healthy and diabetic patients [384, 215, 
128]. A strong association between IL-1B +3954 SNP and susceptibility to PD in patients having 
rheumatoid arthritis (RA) compared to healthy individuals was also reported [190]. Similarly, a 
cross-sectional study that included 80 patients of Caucasian origin aged 38.9 years on average 
with TlDM and 178 healthy controls aged 39.4 on average reported a polymorphism in the IL-6 
gene (IL-6 -174) to be associated with both gingivitis and AL ~ 4 mm in diabetic patients. It was 
also found that PD correlated with control of TlDM over 3 years measured as HbAic average 
levels in this interval [320]. A similar study on 110 patients of Asian origin with T2DM and PD 
(average age 57), 88 with T2DM alone (average age 59.7), 159 with PD alone (average age 51.8) 
and 135 healthy controls (average age 51.6) has shown that another IL-6 gene polymorphism 
(IL-6 -572) had the lowest frequency in patients with both T2DM and PD followed by those 
having only PD. This indicates a potential protective role of IL-6 -572 against development of 
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PD m some diabetic patients [ 443]. Both IL-1 and IL-6 SNPs have been associated with 
numerous immune-mediated diseases including systemic onset juvenile arthritis (silA) [105] and 
RA [174], Systemic Lupus Erythematosus (SLE) [345], Sjogren's syndrome [158], TlDM [263, 
168], T2DM [448, 100] and CVD [59, 49]. On the other hand polymorphisms in the anti-
inflammatory cytokine such as IL-4 (-33, -590) [148] and IL-10 (-1087, -819, -592) [36, 341, 67] 
may explain a predisposition for inability to resolve inflammation triggered by periodontal 
pathogens. Altogether there is growing evidence that genetic predisposition plays a major role in 
setting a threshold for periodontal immune response to bacterial biofilm and that DM and other 
conditions that impact the immune system are risk factors for a dysregulated local inflammatory 
response. 
Progression of gingivitis to PD generally measured by CAL and ABL parameters also 
correlates with diabetes and control of BG. Several studies have shown that there is a correlation 
between HbA1c levels in diabetic patients and prevalence of PD measured in general as probing 
depth and AL. The majority of studies have shown that AL is more severe with more probing 
depths greater than 3.5 mm in uncontrolled DM patients [104, 290, 278, 408, 351]. Few of these 
studies have divided the patients based on type of diabetes but most have included individuals 
aged either 30 years and older or 45 years and older mostly having T2DM. Nevertheless, some 
studies have found little or no correlation between glycemic control and periodontal health 
although most of them have included younger populations that have a generally lower prevalence 
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of PD [338, 78, 46]. Interestingly, subgingival microflora in some diabetic patients is 
predominated by Gram-negative bacteria particularly rods and fusiforms partially explaining the 
higher risk for AL [338, 125]. The discrepancy in findings among studies that investigated 
correlations between BG control and periodontal parameters despite general observation of 
higher prevalence of PD in diabetics may be due to other metabolic variables that have not been 
taken into account. In fact, one study has found a higher correlation between dyslipidemia and 
PD than BG control in diabetic patients [73]. Others have reported positive correlations among 
obesity, dyslipidemia, prevalence and severity PD in different age groups [4, 113, 271]. Systemic 
markers of inflammation including CRP, TNFa , IL-6 also correlate with severity of PD in DM 
although temporal relationships among multiple variables are unclear [109]. 
Several mechanisms by which DM influences periodontal tissues have been proposed 
including immunological dysfunctions, microvascular changes and changes in extracellular 
matrix [238]. The observation of high levels of albumin-AGE in gingival tissues of diabetic mice 
has led to the hypothesis that AGE-mediated activation of inflammatory pathways in 
periodontium may explain in part the role of chronic hyperglycemia in PD [200]. In support of 
this finding a cross-sectional study including 69 patients with T2DM and PD aged 57.8 years on 
average has found a significant association between serum AGE and severity of PD [395]. In 
addition , advanced glycation of fibronectin and type I collagen significantly impaired human 
periodontal ligament fibroblasts by reducing their migratory and attaching properties [261]. 
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Nonetheless, high glucose concentrations impact collagen and glycosaminoglycan production by 
human gingival fibroblasts (hGF) [ 43 8]. AG Es also inhibit production of type I and III collagen 
by hGF and suppressed their overall viability [323]. 
PD was associated with defective PMN in isolated patients with uncontrolled TlDM 
without a clear explanation of mechanisms involved [71, 95]. Since reduced PMN chemotaxis is 
an important pathogenic mechanism in aggressive periodontitis [177, 420, 123] and is also seen 
in TlDM patients [436, 188] a plausible question raised was whether common HLA-DR antigens 
might explain PMN dysfunction observed in these diseases. A study on 41 patients with TlDM 
has confirmed reduced chemotaxis of PMN although no correlation with HLA alleles was found 
[127]. These findings suggest a phenotypic modification of circulating PMN by metabolic 
imbalances characteristic to DM. 
Loss of alveolar bone is increased in patients with TlDM although it does not correlate 
by itself with control of BG suggesting immunological mechanisms [ 400]. The imbalance 
between the receptor activator for nuclear factor K B ligand (RANKL) and osteoprotegerin 
(OPG) has been proposed as mechanism for the inability of patients with DM to rebuild alveolar 
bone when PD is progressing [134, 202]. The emerging field of osteoimmunology is currently 
defining the relationships between immune and bone cells. RANKL/OPG axis seems to be 
central to these relationships [242, 394, 30]. 
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4. Lipid Mediators of Inflammation 
4.1. Lipid Mediaors 
Lipid molecules play several roles in living organisms mainly through their amphipathic 
nature. They are major constituents of biological lipid bilayer membranes, serve as the most 
efficient energy source, are covalently or non-covalently linked to proteins by post-translational 
modifications to facilitate protein-protein and protein-lipid interactions and some lipid molecules 
serve as intercellular mediators in immune functions and maintenance of homeostasis. The latter 
category includes lipid mediators that are divided into several subclasses base on their structure: 
fatty acids ( e.g. eicosanoids ), phospholipids ( e.g. P AF), lysophospholipids ( e.g. LP A 29) , and 
others ( e.g. ceramide) [365]. 
Lipid mediators are synthesized from cell membrane phospholipids with contribution of 
several key enzymes including 1) phospholipase A2 (PLA2) that releases arachidonic acid (AA) 
or another polyunsaturated fatty acid (PUFA) from position sn-2 of phospholipids and the 
remaining lysophospholipid, 2) acyl-CoA lysophospholipid acyltransferase (acyltransferase, 
LPLA1) that incorporates a PUFA in position sn-2 of glycerophospholipids, 3) acetyl-CoA lyso-
PAF3° acetyltrasnferase (lysoPAF AT) that converts lysophospholipids with alkyl-ether bond at 
sn-1 to PAF and incorporates arachidonyl-CoA into lysophosphatidyilcholine (LPC) (LPCAT2) , 
29 LP A, lysophosphatidic acid 
30 P AF, platelet activating factor 
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4) cyclooxygenases 3 1 (COX) that incorporates two oxygen molecules into AA to generate 
thromboxanes (TXs) and prostaglandin (PG) endoperoxydes subsequently converted to PGs by 
cell-specific PG synthases , and 5) lipoxygenases (LOX) that incorporates a single oxygen 
molecule into PUF A to generate hydroperoxyeicosatetraenoic (HpETEs) and 
hydroeicosatetraenoic acids (HETEs) precursors for leukotrienes (LT) and lipoxins (LX) 
respectively when PUFA is AA, and resolvins (Rv) of E and D series, protectins (PT) and 
maresins when PUF A is eiscosapentaenoic acid (EPA) or docosahexaenoic acid (DHA). Other 
enzymes also contribute to generation of lipid mediators: cytochrome P450 yielding 
epoxyeicosatrienoic acids (EETs) , 19-HETE, 20-HETE , dihydroperoxytetraenoic acids 
(diHETEs), phospholipase C (PLC) yielding DAG, IP3 and D (PLD) yielding phosphatidic acid , 
and sphingomyelinase yielding ceramide. Phospholipases and lysophospholipid acyltrasferases 
facilitate membrane phospholipid recycling during generation of lipid mediators in Lands ' cycle 
[280, 365] (Fig. A.4.1-2). 
There are two main COX isoforms in mammals, a constitutive form COXl and an 
inducible form COX2 with their encoding genes located on chromosomes 9 and 1 respectively 
[3 31, 326]. COX 1 is ubiquitously expressed in cells and helps maintain tissue homeostasis and 
COX2 expression is induced during injury by LPS , IL-1 ~' TNF a , IFNy to generate pro-
31 Cyclooxygenase is one of the two sites of PGH2 synthetase (PGHS) along with the peroxidase (POX) site; the 
latter is responsible for reduction of PGG2 to PGH2 
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inflammatory eicosanoids. Three main mechanisms contribute to induction of COX2 expression: 
transcriptional regulation through NF-KB and CREB, mRNA stabilization through the proximal 
AT-rich sequence of the 3 '-untranslated region, and expression of microRNAs. In recent years a 
third isoform acetaminophen-sensitive COX3, which apparently is a splice variant of COX2 has 
been reported [369]. This isoform has low sensitivity to non-steroidal anti-inflammatory 
(NSAIDs) drugs. Aspirin modifies both COX enzymes through acetylation of serine residues 
near the catalytic pocket. Although aspirin and other NSAIDs were previously thought to abolish 
the enzymatic activity of COX it became clear that they rather change COXs to a LOX-like 
acting enzyme generating precursors for different classes of lipid mediators with particular 
activities during the resolution phase of inflammation [357, 356]. 
There are six main LOX enzymes coded by separate genes and named after the position 
of the carbon where the oxygen is inserted: 5-LOX (5S-LOX) mainly expressed in leukocytes, 
8/12R-LOX mainly expressed in epidermis, two types of 12-LOX (12S-LOX and 12R-LOX) 
mainly expressed in megakariocytes/platelets (12S-LOX), and two types of 15-LOX (15-LOX-1 
and 15-LOX-2) mainly expressed in erhythroid and epithelial cells respectively [197, 110, 111]. 
Nonetheless, IL-4 induces upregulation of 15-LOX-1 expression in epithelial and EC [205,314]. 
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Figure A.4.1. Lands' Cycle 
PUF As in position sn-2 of membrane PL are released by PLA2 and further processed to lipid 
mediators. The remaining LPL depending on X in PO3X may generate LPA (X=O 2-), PC or 
PAF32 (X=choline), PS (X=serine), PE (X=ethanolamine) or PI, PIP2, PIP3 (X=inositol). 
Alternatively LPLs may receive a new PUFA through LPLAT closing the Lands' cycle. In 
general PC, PE and PS are not released from the membrane but may be exposed on the outer 
leaflet during apoptosis by and enzyme called flippase 33 . 
Abbreviations: AA, arachidonic acid; EPA, eicosapentaenoic acid; PLA2, phospholipase A2; 
LPLAT, lysophospholipid (LPL) acyltransferase; LP A, lysophosphatidic acid; P AF, platelet 
activating factor; PI, phosphatidyl inositol; PIP, PI phosphate; PIP2; PI diphosphate; PIP3, PI 
triphosphate; PG, prostaglandin; TX, thomboxane; LT, leukotriene; LX, lipoxin; RvE, resolvin E 
series; CoA, coenzyme A. 
32 P AF has an ether-linked FA in sn-1 compared to an ester-linked FA in PC 
33 Flippases belong to P 4-APTases class of transporters ; P5-ATPases are found in ER membrane 
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Figure A.4.2. Lipid Mediators of Inflammation 
During inflammation several lipid mediators are produced to enhance and then to reverse 
inflammation. Most mediators derived from AA promote inflammation (PG and LT) but some 
newly characterized molecules including lipoxins (LX) are anti-inflammatory. LX are considered 
the class switch molecules from pro to ant-inflammatory lipid mediators. The Q-3 fatty acids 
EPA and DHA are processed to resolvins , protectins. Together with lipoxins these lipid 
mediators are synthesized trough a trans-cellular process , meanmg that intermediates are 
synthesized by a cell type and taken by other cell types to produce the final active mediator. 
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4.2. Arachidonic Acid (AA)-derived Lipid Mediators of Inflammation 
The eicosanoids derived from AA can be divided into two main classes based on their 
action: pro-inflammatory and anti-inflammatory. The first category includes PGs of E series 
(PGE2) synthesized through the COX pathway and LTs (LTA4, LTB4, LTC4, LTD4 and LTE4) 
synthesized through LOX pathway. TXA2 and TXB2 result from COX processing and are potent 
vasoconstrictor and stimulators of platelet aggregation. P AF belongs to a third class of AA-
derived mediators resulting from PLA2 processing of membrane phospholipids and mediates 
platelet aggregation, bronchocontriction and vasodilation. The second category includes PGs of 
G, F and I series synthesized through COX pathway, and lipoxins34 (LXs) and aspirin triggered 
15-epi-LXs (ATLs) synthesized through both COX and LOX pathways during trans-cellular 
biosynthesis. AA-derived lipid mediators act through specific G-protein coupled receptors 
(GPCRs) that were phylogenetically grouped into five cluster groups: CL-1, CL-2, CL-3 lipid 
receptors, and CL-4, CL-5 peptide receptors [ 406]. These receptors are part of a larger 
phylogenetic tree that includes proton sensors, chemoattractant receptors, LP A/SIP receptors, 
prostanoid receptors and lipid/nucleotide receptors [365] (table 7). 
34 Lipoxins, first isolated from human PMN and described by Charles Serhan et al. in 1984 
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Patil\\ ay Mediator Receptor lcl 11,lcl I Actions 
PGD2 DP1 [CL-IJ, DP 2 [CL-I] Bronchoconstriction , vasodilation 
j cell survival, t DC chemotaxis /IL-12 synthesis , 
t EO recruitment 
PGE2 EP1 [CL-2]; EP2 [CL-I] Vasodilation, fever , GIT-SM contraction /relaxation , 
EP3 [CL-3]; EP 4 [CL-I] t gastric acid secretion , j mucus secretion , j T -cell 
chemotaxis, maintains PDA 
cox PGF2a FP [CL-2] Bronchoconstriction, uterus contraction 
PGI2 IP [CL-I] Bronchodilation , vasodilation, t platelet aggregation 
PGJ2 DP, [CL-I] Vasodilation 
15d-PGJ2 PPAR DP [CL-I] Y, 2 tiNOS, tMMP, jPMN apoptosis (PPARy) 
j chemotaxis , j CAM expression (DP 2) 
TXA2 TP- (TXA2) [CL-2] Vasoconstriction, j platelet aggregation 
TXB2 TP- (TXB2) [CL-2] Vasoconstriction 
5(S)-HETE BLT2 [CL-SJ j PMN chemotaxis, constriction , j mucus (L) 
12(S)-HETE BLT2 [CL-SJ j PMN chemotaxis 
15(S)-HETE BLT2 [CL-SJ j PMN chemotaxis 
LTA4 Cys-LTl , Cys-LT2 Intermediate compound 
LTB4 BLTl , BLT2 j PMN chemotaxis , degranulation , 0 2-
LTC4 , D4 , E4 Cys-LTl, Cys-LT2 SRS-A 
LOX ALX [CL-5] LXA2 Vasodilation , t PMN chemotaxis , 
LXB2 ALX [CL-SJ t neovascularization 
RvEl ChemR23 [CL-sJ jiNOS, jPGI2, jM<I>~PMN clearance 
BLTl [CL-5] tPMN, EO chemotaxis , j CCR5 on PMN , tDC 
chemotaxis /IL-12 
RvE2 ChemR23, BLTl Equivalent to RvEl in low doses 
EETs TP- (TXA2) [CL-Z] Vasodilation 
CYT 11,12 diHETE Vasodilation? 
P450 19-HETE Vasodilation by t 20-HEPE 
20-HETE Vasoconstriction 
Adapted from various sources: Review PGD2 and PGJ2 [141]; lipid mediator receptors [64, 365]; CYT P450 
metabolites [327] ; RvE review [192]. Abbreviations: DC, dendritic cell ; EO, eosinophil; GIT-SM , gastrointestinal 
tract smooth muscle ; PDA, patent ductus arteriosus ; CAM, cell adhesion molecule; L, lung; SRS-A, slow-reacting 
substance of anaphylaxis ; Note: CYT P450 enzymes may also generate precursors for synthesis ofLX , Rv and PD. 
Table 7 Eicosanoids and Their Actions 
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LXs are the first class of anti-inflammatory and pro-resolving lipid mediators identified 
in vivo. LXA4 and LXB4 result from platelet 12-LOX processing of LTA4 synthesized in 
leukocytes via 5-LOX. Alternatively, both LX can result from leukocyte 5-LOX processing of 
15(S)-HpETE synthesized in epithelial cells via 15-LOX pathway [358]. Similarly, aspirin-
modified COX in EC acting as 15-LOX generates 15-R-HETE that is further processed by 
leukocyte 5-LOX to yield 15-epi-LX [353]. LX have potent anti-inflammatory actions by 
downregulating PMN transmigration [83, 311 ], reducing vascular permeability [393], cytokine 
release and function [132], pain signals [387]. LXs also have pro-resolving actions in vivo by 
promoting phagocytosis and removal of apoptotic PMN by M<I> and inhibiting fibrosis [116, 
246]. Nonetheless, LXs induces prostacyclin (PGI2) and NO synthesis by EC suggesting a direct 
impact on maintaining vascular homeostasis [ 45, 299]. 
4.3. Eiscosapentaenoic Acid (EPA)- and Docosahexaenoic Acid (DHA)-derived Lipid 
Mediators of Inflammation 
In recent years a new class of lipid mediators with potent anti-inflammatory and pro-
resolution properties have been isolated and characterized by the Serhan group. These mediators 
are endogenously synthesized from Q-3 fatty acids including DHA and EPA through trans-
cellular biosynthesis involving aspirin acetylated-COX2 and several LOX. Resolvin (Rv) E 
series are derived from EPA through epithelial or EC (acetylated-COX2 or 15-LOX) crosstalk 
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with leukocytes (5-LOX). Similarly, PGE3 and LTB5 can be synthesized from EPA. RvD series 
(RvDl, RvD2, RvD3, RvD4), protectins (PD) or neuroprotectins (NPD) when produced by 
neural tissues and maresins (MaR) are derived from DHA through several LOX processing steps 
in leukocytes and other cells [359, 354, 360, 150]. 
RvDl reduced murine PMN infiltration in dorsal skin, peritoneum and kidneys [359, 89], 
reduced microglial cytokine expression [150], and reduced inflammation in mice with induced 
colitis [156]. Similarly, RvD2, RvD3 and RvD4 reduced PMN infiltration in skin and peritoneum 
[359]. RvDl binds with high affinity to ALX and GPR32 on monocytes , which may explain the 
pro-resolution actions observed in vivo [196]. RvDl together with RvEl and ATLs reduced 
inflammatory hemangiogenesis but not lymphangiogenesis in a murine model of suture-induced 
inflammatory corneal angiogenesis [173]. Nonetheless, RvDl and RvEl showed potent central 
and peripheral analgesic actions during plantar inflammation possibly through binding ChemR23 
and inactivation of ERK-mediated NMDAR 35 activation in pre- and postsynaptic neurons [444]. 
PDl reduced PMN infiltration in peritonitis and kidney ischemia-reperfusion [359, 89]. 
PD 1 promoted resolution by upregulating of PMN CCR5 expression to clear chemokines for T-
cells and inducting apoptosis in T-cells through lipid raft clustering [17, 18]. PDl reduced lung 
damage, airway hyper-responsiveness and inflammation in a mouse model of asthma [206]. 
35 NMDAR , N-methyl-D-aspartic acid receptor 
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NPD 1 produced by neural tissues has neuroprotective actions in vivo by reducing PMN 
infiltration and ischemic damage in brain suggesting protection against ischemic strokes [227, 
31]. Furthermore, NPD 1 may promote brain cell survival in Alzheimer's disease by inhibiting 
Aj342 peptide-induced apoptosis in neurons and glial cells through upregulation of anti-apoptotic 
genes [220, 295]. 
4.4. Resolvin E 1 
RvEl was first identified in vivo in dorsal air pouch exudates of mice treated with aspirin 
and EPA. The EC-PMN trans-cellular biosynthesis was confirmed by treating HMVEC with 
aspirin and EPA, and subsequent incubation ofresulting products with human PMN [356]. RvEl 
results from EPA modfication by aspirin acetylated COX2 or CYT P450 or 15-LOX-1 in 
endothelial cells and uptake of 18R-HEPE and further processing in leukocytes through 5-LOX 
pathway (Fig. A.4.3). RvEs were characterized and tested in vivo and in vitro demonstrating 
potent anti-inflammatory and pro-resolution properties [359]. 
RvEl (5S, 12R, 18R-trihydroxy-eicosapentaenoic acid) is structurally defined as a Q-3 
eicosanoid with 5 double bonds grouped as one conjugated diene and one conjugated triene that 
confer molecular stability. The three hydroxyl groups are sequentially added to EPA after 
removal from the membrane PL by PLA2 in a trans-cellular biosynthetic process [3 54]. 
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Enzymatic conversion of RvEl generates inactive or less potent compounds with one 
exception, 20-hydroxy-RvEl, in blood and other tissues: 20-carboxy-RvEl, 20-hydroxy-RvEJ 
(major metabolite in PMN, as potent as RvEl), 19-hydroxy-RvEl, 18-oxo-RvEl, 12-oxo-RvEl, 
11,12-dihydro-RvEl and 11,12-dihydro-12-oxo-RvEI. Three compounds namely 20-hydroxy-
RvEl, 18-oxo-RvEl and 11,12-dihydro-RvEl were the major metabolites in human blood [151] 
(Fig. A.4.4.). 
Two GPCR receptors ChemR23 and BLTl have been shown to signal in response to high 
affinity binding by RvEI. ChemR23 binding reduced IL-12 production by DC cells while BLTI 
binding competitively blocked LTB4 suggesting a potential mechanism for its anti-inflammatory 
action [20, 19]. RvEl significantly reduced PMN infiltration during acute peritonitis [359, 27] 
and upregulated CCR5 expression on late apoptotic PMN [ 17]. 
Similarly, RvEl reduced PMN infiltration, express10n of pro-inflammatory genes, 
intestinal damage and improved survival in mouse models of colitis [21, 156]. These 
observations may be in part explained by ChemR23-mediated macrophage modulation of 
inflammatory responses [ 164]. 
118 
Introduction 
18R-hydroxy-EPE 
Trans-cellular Biosynthesis 
OOH 
OH 
1 
H 
5-LOX 
5S(6)-epox - I hydr xy-EPE 
H 
PMN 
© 
Figure A.4.3. 
119 
Introduction 
Figure A.4.3. RvEl Synthesis in Vivo 
RvEl is synthesized through PMN-EC crosstalk from EPA. EC produces an RvEl intermediate, 
18R-hydroxy-EPA, through the 15-LOX pathway (either a 15-LOX or an acetylated COX2 by 
aspirin). The leukocyte processes 18R-hydroxy-EPA through the 5-LOX pathway to produce 
RvEl, the final active mediator that is released to act locally having a short half-life. Synthetic 
RvEl, which has a longer half-life, inhibited PMN infiltration in different disease models 
including peritonitis, colitis, acute lung injury, asthma and periodontal disease. It also promoted 
molecular pathways characteristic to the resolution phase of inflammation. 
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Figure A.4.4. Resolvin E 1 Structure and Metabolome 
RvEl is a 20 carbon fatty acid having conjugated double bonds in a diene and a triene that confer 
molecular stability. Three hydroxyl groups in positions 5, 12 and 18 are added during synthesis 
from EPA (18 in EC and 5, 12 in leukocytes). Endogenously synthesized RvEl has a short half-
life (minutes) and acts locally. Inactivation of RvEl occurs in blood and other tissues by 
enzymatic oxidation or reduction generating several compounds that are inactive or much less 
potent than RvEl. Addition of a methyl or other group at carboxyl group in position 1 
significantly delays enzymatic inactivation. 
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In a more recent study RvEl was shown to inhibit ADP-induced platelet aggregation, 
stimulated L-selectin shedding on human peripheral PMN and monocytes and reduced leukocyte 
rolling in vivo in cremaster muscle postcapillary venules [87]. In another study RvEl enhanced 
phagocytosis of zymosan A36 by macrophages [286]. Nonetheless, RvEl reduced PMN 
recruitment, superoxide production and inflammation-induced bone loss in a rabbit model of 
periodontitis [139] 
Interestingly , RvEl reduced significantly pro-inflammatory markers in human pancreatic 
islets and prevented islet cell cytokine-induced apoptosis. It also prevented LPS-induced 
upregulation ofIL-8, MCP-1 , RANTES (CCL5) , MMP9 and TF [221]. 
The current evidence that chronic hyperglycemia characteristic to DM impacts the 
microvasculature has led us to hypothesize that in uncontrolled TlDM circulating PMN exhibit 
dysfunctional interactions with EC and are inefficient in clearing pathogens. This phenotype may 
contribute to the development of diabetic microvascular changes in periodontium and predispose 
to more severe forms of PD. RvEl can act directly on PMN in vivo and modulate the return to 
microvascular homeostasis under hyperglycemic conditions , thus preventing the development of 
periodontal diabetic complications. 
36 Zymosan A, fungal cell wall antigen 
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Aim 1: Impact of Chronic Hyperglycemia on Leukocyte Recruitment 
The first aim of the present study was to investigate in vivo the impact of chronic 
hyperglycemia on leukocyte recruitment at sites of inflammation. For this purpose Akita diabetic 
mice were used to assess acute inflammatory recruitment inside dorsal subcutaneous air pouches. 
1.1. Materials 
Mice 
Akita mice on a C57BL/6 background were obtained from Jackson Laboratories (Bar 
Harbor, ME), aged 4-6 weeks. Heterozygote Akita males and wild type (WT) C57BL/6 females 
were bred in house in a barrier facility and studied according to institutional and NIH guidelines. 
Offspring were genotyped using ear samples that were further processed for PCR analysis. 
Heterozygous Akita mice (het) were identified based on presence of 2 bands on the PCR gel 
representing the normal INS2 allele at 140 hp also present in WT mice and the mutated INS2 
allele at 280 hp (Fig. B.1.1.1. ). Hyperglycemic phenotype was confirmed by BG measurement 
using a digital glucose meter. Adult mice ( age 8-10 wk) of both sexes were used in all 
experiments in conformity with the standards of the Public Health Service Policy on Humane 
Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use 
Committee of Boston University. Mice were fed standard laboratory chow and water ad libitum. 
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Instruments and Reagents 
Isoflurane (Baxter Healthcare Corp, Deerfield, IL, USA), TNFa (Roche Diagnostics, 
Indianapolis, IN, USA), 0.22µm Millex®-GP syringe-filter (Millipore Corp, Carrigtwohill, Co. 
Cork, Ireland), sterile saline solution (0.9% NaCl), Dulbecco's Phosphate Buffer Saline (DPBS) 
without Ca2+/Mg2+ (Mediatech Inc., Manassas, VA, USA), 22 G, 23 G, 25 G needles, 3 ml, 5 ml 
and 27 G insulin 1 ml syringes (BD, Franklin Lakes, NJ, USA), Accu-Check® Advantage digital 
glucose meter (Accu-Check, Roche Diagnostics, Indianapolis, IN, USA), surgical tweezers, 
forceps, scissors, scalpel (Roboz Surgical Instrument, Gaithersburg, MD, USA), Superfrost® 
plus microscope glass slides, premium cover glass, hemocytometer (Fisher Scientific, Rochester, 
NY, USA), Microtom HM 550 P cryostat (Microtom GmbH, Walldorf, Germany), Cytospin 2 
cytocentrifuge (Shandon Products Ltd, Astmoor, Cheshire, UK),Trypan Blue solution 0.4% 
(MIP Biomedicals, LLC, Solon, OH, USA ), pure sucrose powder, Wright-Giemsa modified 
(Sigma-Aldrich, St. Louis, MO, USA), Neg-50 frozen section medium, hematoxylin and eosin 
(Richard-Allan Scientific, Kalamazoo, Ml, USA), Masson's trichrome regents (American Master 
Tech Scientific Inc., Lodi, CA, USA), Zeiss Axiovert 200 inverted epifluorescent microscope 
(Carl Zeiss Micro Imaging Inc., Thomwood, NY, USA), Olympus Microsuit™ software for 
imaging applications (Leeds Precision Instruments Inc., Minneapolis, MN, USA) were obtained 
commercially as indicated. Hemavet® 1500 machine was used with courtesy of Dr. Daniel 
Remick in the Department of Pathology, Boston University Medical School. 
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Figure B.1.1.1. PCR for Akita Mutation 
Heterozygous Akita males and WT C57BL/6 females were bred in house. DNA was isolated 
from ear samples of offspring and PCR was run to identify heterozygous (het) carriers of Akita 
mutation. Representative PCR gel for Akita genotyping showing the 140 hp band that indicates 
normal INS2 fragment flanking the region where Akita mutation occurs (exon 3, nuceotide 1907) 
seen in all WT mice and the 280 hp that indicates the equivalent fragment of mutated INS2 
identified only in Akita mice. DNA samples from heterozygous Akita mice (het) carry both 
normal INS2 (140 hp) and mutated INS2 (280 bp). 
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1.2. Experiment Design 
Air pouches were raised on days O and 3. On day 6 leukocytes were recruited inside the 
pouches by injecting TNFa at time O (t0). Mice were sacrificed 4 h later at time 1 (t1) and air 
pouch lavage was performed followed by biopsy collection from the pouch wall including lining. 
Collected viable cells were counted using a hemocytometer with trypan blue exclusion. 
Differential leukocyte count was done in Wright-Giemsa stain of cytospinned lavage aliquots. 
Biopsy samples were kept in 4% formalin until next day when they were transferred in 10% 
sucrose for 3 days. Samples were sectioned using a cryostat (t2) and stained (t3) with either 
hematoxylin & eosin (H&E) for general tissue structure or Masson's trichrome for collagen 
staining (Fig. B.1.2.1.). 
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Figure B.1.2.1. Air Pouch Recruitment- Experiment Design 
Subcutaneous air pouches were raised by injecting sterile air under dorsal skin on days O and 3. 
On day 6 mice received TNF a inside the pouch and 4 hours later the air pouches were sampled 
for leukocyte content and evaluation of air pouch wall microvasculature. Cryostat sections of 
biopsies collected from the pouch wall including were stained with H&E and Masson's 
trichrome ( collagen specific). 
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1.3. Methods 
Air pouch 
Dorsal subcutaneous air pouches were raised as previously described [372]. On day 0, 3 
ml of sterile air were injected under the skin between the scapulas under brief isoflurane 
anesthesia. Injection was repeated on day 3. On day 6 a single dose of 30 ng TNFa in 0.5 ml 
saline (3.5 nM) or saline alone (control) was injected into the pouch using a 1 ml insulin syringe 
with 27 G needle. Four hours later mice were sacrificed with CO2 according to the guidelines of 
IACUC. Air pouch lavage was performed with a 22 G needle attached to a 5 ml syringe. In order 
to avoid further tissue expansion by lavage fluid that may break the fragile inner lining 1-2 ml air 
from the pouch was first suctioned into the syringe. This measure also served as verification of 
correct positioning of the needle tip inside the air pouch. The pouch cavity was flushed 3 times 
with 3 ml ofDPBS per flush. The pouche was rubbed gently to release leukocytes attached to the 
pouch lining. To avoid multiple punctures of the skin that may result in leakage of lavage fluid 
the needle was left in place between flushes. This measure also avoided passing the cells through 
the needle twice during collection from the pouch and while releasing them into the collection 
tube. A two-way pass of cells through the needle may compromise membrane integrity (22 G = 
0.72 mm in diameter). The skin was disinfected with 70% ethanol and hair was gently removed 
with scissors. A skin biopsy of 1 cm2 was collected from each air pouch wall including the 
"outer" lining in 4% formalin (Fig. B.1.3.1.). 
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Figure B.1.3.1. Model of Inflammation - Dorsal Subcutaneous Air Pouch 
A. Dorsal subcutaneous air pouches were used to assess leukocyte recruitment in Akita diabetic 
mice. Topographically the epithelial lining of the air pouch cavity is divided into inner lining 
covering the paravertebral muscles and outer lining situated under dorsal skin. The air pouch 
wall biopsy is collected from dorsal skin including the outer lining. 
B. Representative sections from air pouch wall biopsies in Masson's trichrome and H&E 
stainings. Masson's trichrome: from outside to inside the pouch the wall histological structure 
consists of 1. epidermis (black indicates nuclei of epithelial cells), 2. dermis rich in collagen 
(blue) and blood vessels, 3. muscle layer (red) and 4. pouch lining. The lining consists of a 
connective tissue layer containing collagen (blue) and elongated fibroblasts. In thin sections ( 10 
µm thick) the lining is easily spread during sectioning due to its fragile structure. H&E: 
structural characteristics of air pouch wall. Numerous leukocytes can be identified in the air 
pouch lining 4 hours after pro-inflammatory stimulation (grey arrows). Elongated fibroblasts 
were identified at the separation of pouch lining from the air cavity (black arrows). 
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Leukocyte Counting 
Viable leukocytes recruited inside air pouches were counted using a hemocytometer and 
trypan blue exclusion at a dilution 1: 1. Ten µl from the 1: 1 mixture of lavage fluid and trypan 
blue were loaded on the hemocytometer underneath a glass cover slip and cells were counted in 4 
comer squares (Fig. B.1.3.2). Total number of viable leukocytes per ml was calculated as 
average of the 4 counts multiplied by the dilution factor (x 2) and by 104 (volume corresponding 
to each comer square). Total cell count was obtained from further multiplication by the volume 
n 
of lavage fluid collected: total leukocyte count (TLC)= L i i 4 x 2 x 104 x volume collected; i = 
i=l 
1 to 4 comer counts. Then 50 µl from each lavage fluid was loaded on cytospin glass slides, air-
dried and stained with Wright-Giemsa. Different leukocyte subtypes (PMN, 
monocytes/macrophages, lymphocytes) were counted m 6-9 different fields, usmg x 1000 
magnification (Fig. B.1.3.3.). Assignment to a leukocyte subtype during the differential 
leukocyte count (DLC) was based on cell size, nuclear morphology and nuclear to cytoplasm 
ratio (NCR). PMN have intermediate size (10-12 µm diameter) between lymphocytes (the 
smallest, 7-8 µm) and macrophages (the largest, 15-17 µm). The characteristic multilobed 
nucleus clearly distinguishes them from other leukocytes. Lymphocytes have the highest NCR, 
monocytes generally have a C-shaped nucleus and macrophages have a characteristic bluish 
cytoplasm visible due to a relatively low NCR. Results were expressed as total leukocyte 
count/pouch for TLC and percentage of the TLC for DLC. 
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Total number of circulating leukocytes was measured using a Hemavet® machine that 
was set to perform complete blood counts for mice. For this purpose 20 µl peripheral blood was 
collected by facial vein puncture , centrifuged at 1000 x g for 5 minutes at 4 °C to separate the 
serum and cell pellet was immediately re-suspended in 480 µl of Hemavet solution for complete 
blood count (CBC). 
Air pouch wall biopsies were sectioned in 10 µm and 50 µm thick sections using a 
cryostat. Sectioned samples were stored on superfrost plus glass slides at -20°C and stained on a 
subsequent day with either hematoxylin and eosin or Masson's trichrome (Fig. B.1.3.1.). 
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Figure B.1.3.2. Hemocytometer - Total Cell Count 
Aliquots from air pouch lavage fluid were mixed 1: 1 with trypan blue and loaded on a 
hemocytometer for counting of viable leukocytes under the microscope using x 100 
magnification. Schematic representation of hemocytometer central chamber as seen under the 
microscope in x 2.5 magnification showing the 4 (1-4) comer squares (volume 10-4 ml) where 
viable leukocytes (bright spots) are counted. Dead leukocytes loose their cell membrane integrity 
resulting in uptake of trypan blue (black spots). Average of the 4 counts is multiplied by the 
dilution factor in tripan blue ( x 2), by 104 (volume of each square) and by total volume of lavage 
fluid collected to calculate the total leukocyte count (TLC). 
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Figure B.1.3.3. Wright-Giemsa - Differential Leukocyte Count 
Aliquots of 100 µl lavage fluid collected from air pouches after pro-inflammatory stimulation 
were cytospinned and stained with Wright-Giemsa. Different leukocyte subtypes were counted in 
6 to 9 different fields under the microscope in x 1000 magnification for a total of 200 
cells/sample. PMN, monocyte/macrophages and lymphocytes were expressed as percent of the 
total leukocyte count/sample. 
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1.4. Results 
Complete blood count was performed for Akita and WT mice. Akita mice have higher 
numbers of circulating leukocytes with significantly more PMN compared to WT (total 
leukocytes: WT, 8.28 ± 0.45 x 103/µl; Akita, 8.76 ± 0.39 x 103/µl; PMN: WT, 1.18 ± 0.08 x 
103/µl; Akita, 1.97 ± 0.26 x 103/µl; Fig. B.1.4.1.). Six-day-old dorsal subcutaneous air pouches 
were sampled for leukocyte content in WT and Akita mice 4 hours after TNFa or saline injection 
(Fig. B.1.4.2 A and B, Fig. B.1.4.4.). Following saline injection pouches of Akita mice contained 
more leukocytes than those of WT (WT: 0.88 ± 0.067 x 106 cells/pouch, Akita: 1.56 ± 0.097 x 
106 cells/pouch, n = 4/group). Effects of TNFa administration inside the pouch were visualized 
as shown in Fig. B.1.4.2 C-E. Exogenous TNFa induced markedly lower leukocyte recruitment 
in Akita compared to WT (WT: 3.89 ± 0.42 x 106 cells/pouch, Akita: 2.01 ± 0.27 x 106 
cells/pouch, n = 9/group) as shown in Fig. B.4.1.3-4. Differential leukocyte counting in Wright-
Giemsa showed that upon stimulation the percentage of PMN increased significantly in WT but 
not in Akita. (PMN: WT 64.09%, WT+ TNFa 80.85%, Akita 56.5%, Akita+ TNFa 54.86%, 
Fig. B.1.4. 5.) 
These results led to the conclusion that diabetic mice have higher leukocyte numbers in 
the tissue at baseline and that they recruit fewer neutrophils with pro-inflammatory stimulation. 
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Figure B.1.4.1. Circulating Leukocyte - Differential Count (Hemavet) 
Peripheral blood sampled by facial puncture was run through Hemavet for CBC. Akita have 
overall higher circulating leukocyte numbers although the difference found was not significant. 
Circulating PMN number in Akita was significantly increased. 
*p<0.05, one-way ANOVA, n = 9, mean± SEM 
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Figure B.1.4.2. Leukocyte Transmigration ( x 1000) 
Comparison between two dorsal skin ( air pouch wall) post-capillary venules of equal diameter 
(30 µm) in WT (A) and Akita (B) showed increased venule wall thickness in the latter in vessels 
of Akita (Masson's trichrome stain, x 1000). Intravascular and transmigrating leukocytes in 
dorsal skin microvasculature of Akita 4 h after TNFa injection inside the air pouch were 
visualized in trichrome stain. Collagen fibers are stained in blue and cell nuclei in black ( C and 
D). Trans-sectioned microvessles in air pouch wall visualized in H&E staining show nuclei of 
pericytes (J) and EC (2) having characteristic fusiform shape and multiple nuclei of cells located 
inside the vessel wall ( 3) that may belong to transmigrating leukocytes. The shape of these nuclei 
ranges from round to elongated with the long axis perpendicular to vascular longitudinal axis. 
This latter identification of transmigrating leukocytes would suggest both trans-cellular and para-
cellular transmigration considering the frequency of "leukocytes" inside the vessel wall relative 
to nuclei of EC (E and F). 
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Figure B.1.4.3. Leukocyte Recruitment In Air Pouch- Wright Giemsa 
Left side: representative images of air pouch lavage samples from WT mice that received TNFa 
(top) or vehicle (bottom) 4 h before lavage was performed. TNF a induced significant PMN 
recruitment in WT. Right side: Akita response to acute pro-inflammatory stimulation showing 
impaired leukocyte recruitment (top) and higher mononuclear cells in the absence of stimulation 
(bottom). 
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Figure B.1.4.4. Leukocyte Recruitment In Air Pouch-Total Cell Count 
Akita had higher leukocyte numbers in the air pouch following saline injection compared to WT. 
TLC from air pouch lavage of Akita and WT mice 4 hours after pro-inflammatory stimulation 
showed significant leukocyte recruitment in WT. Leukocyte recruitment was significantly 
reduced compared to WT. 
*p<0.01, one-way ANOVA, n = 9, mean± SEM 
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Figure B.1.4.5. Leukocyte Recruitment In Air Pouch- Differential Cell Count 
Differential leukocyte counting from air pouch lavage fluid collected 4 hours after pro-
inflammatory stimulation showed significant increase m PMN percentage relative to other 
leukocytes in WT compared to vehicle treated mice. The percent of PMN m Akita was 
significantly lower than in WT. 
*p<0.05, one-way ANOVA, n = 9, mean± SEM 
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The second aim was to investigate in vivo the leukocyte-endothelial cell interactions 
under chronic hyperglycemia. Fluorescence methods were used for measurement of 
microvascular permeability and identification of leukocytes, leukocyte subtypes and adhesion 
molecules. Leukocyte-EC interactions were assessed in Akita mice by gingival intravital 
microscopy and surface expression of adhesion molecules by flow cytometry. 
2.1. Materials 
Rhodamine 6G (R6G), fluorescein isothiocyanate-dextran (FITC-D, molecular weight 
[MW] 150 kDa), TNFa (Roche Diagnostics, Indianapolis, IN, USA), sterile saline solution 
(0.9% NaCl), PBS (lnvitrogen, Carlsbad, CA, USA), isoflurane 2%, ketamine, xylazine (Baxter 
Healthcare Corp, Deerfield, IL, USA), 5-0 silk suture (Benco Dental, Marlborough, MA, USA) 
anti-CD45-PE/CY7, anti-LY6G-FITC, anti-CDl la-PE, anti-PSGL-1-PE (BD Biosciences, San 
Jose, CA, USA), FIT<;: and TRITC filter sets (Chroma Technology, Rockingham, VT, USA), 
stereo microscope (Leica Microsystems, Heerbrugg, Switzerland), Zeiss Axiovert 200 inverted 
epifluorescent microscope equipped with a Sony DFW-X700 digital video camera, Sonycap 
(Sony Corporation, Tokyo, Japan) and Olympus MicroSuite software were obtained 
commercially, as indicated (Fig.B.2.3.2.). FACScan flow cytometer with Cellquest™ software 
was used in the Boston University Flow Core Facility. 
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2.2. Design of Experiments 
Gingival Leukocyte-EC Interactions In Vivo 
Gingival intravital microscopy (GIM) was used to assess leukocyte-EC interactions in 
diabetes in vivo. GIM was performed after preparation of mice by inducing tail vein dilation and 
general anesthesia. Intragingival administration of TNFa in WT mice to induce acute 
inflammation was performed 2 hours before microscopic visualization (to) and served as positive 
control for leukocyte-EC interactions in diabetic mice. WT mice with no treatment prior to GIM 
served as negative control. Intravenous bolus administration of labeling (R6G, anti-L Y6G-FITC) 
and tracer (FITC-D 150 kDa) dyes (t1) was followed by microscopic visualization and recording 
of videos of rolling leukocytes within 15-30 minutes from IV injection (t2). Rolling leukocytes 
were counted by video-playback analysis (t3) (Fig. B.2.2.1.). 
Peripheral Blood Immunophenotyping 
Peripheral blood immunophenotyping (PBI) by flow cytometry was used to evaluate 
expression of surface adhesion molecules on circulating leukocytes in diabetic mice. Peripheral 
blood was collected via facial vein puncture in EDT A to prevent coagulation. Sample was 
divident m 2 equal aliquots for CBC and flow cytometric analyses. Data acquisition was 
performed within 2 hours from collection followed by analysis (Fig. B.2.2.2.). 
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Figure B.2.2.1. Gingival Intravital Microscopy- Experiment Design 
R6G and FITC-D or R6G and anti-LY6G-FITC were administered IV for labeling of leukocytes 
(R6G, all leukocytes; L Y6G, PMN) and for assessment of microvascular permeability (FITC-D) 
(t1). To induce acute gingivitis some mice were injected TNFa in labial gingiva between the two 
lower incisors 2 hours before labeling (to). Gingival Intravital microscopy (GIM) was performed 
within 30 minutes after IV administration of fluorescent dyes (t2) and 30 second videos were 
recorded under the TRITC filter. Analysis of leukocyte-EC interactions was performed on a 
subsequent day by video playback analysis to count rolling leukocytes along endothelium (t3). 
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Figure B.2.2.2. Peripheral Blood Immunophenotyping - Experiment Design 
Peripheral blood was collected by facial vein puncture, mixed with EDT A to prevent coagulation 
and half of the volume (20 µl) was incubated with fluorescent-labeled antibodies for leukocyte 
common antigen (CD45), PMN-specific antigen (LY6G) and surface adhesion molecules 
(PSGL-1 or CDl la). The other half (20 µl) was prepared for CBC. FACS acquisition and 
analysis were performed the same day. PMN were selected from CD45+ cells based on positivity 
for L Y6G and subsequently assessed for levels of surface adhesion molecules. 
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2.3. Methods 
Gingival Intravital Microscopy 
Mice were weighed, placed under a heating lamp for 20 minutes to induce tail vein 
vasodilation to facilitate intravenous administration of labeling dyes, and then anesthetized with 
a mixture of Ketamine (100 mg/kg body weight) and Xylazine (10 mg/kg body weight) 
intraperitoneally. Body temperature was monitored with rectal thermal probe. Dyes for 
microvascular visualization, assessment of microvascular permeability (FITC-D) and leukocyte 
labeling (R6G, anti-LY6G-FITC) were administered as intravenous bolus. 
A 5-0 silk suture was placed into the lower lip for retraction during microscopic 
visualization of labial interincisal gingiva and the mouse was transferred on a glass support plate 
and viewed under the inverted microscope. Gingival moisture was maintained with PBS at all 
times during the microscopic analysis (Fig. B.2.3.1-2.). 
Single unbranched postcapillary venules (20-40 µm diameter, > 100 µm length) were 
selected for assessment of microvascular permeability and leukocyte-EC interactions. In the 
selected fields pictures and several 30-second videos were recorded under the TRITC filter using 
x 40 magnification. Rolling and attached leukocytes were counted on the recorded videos. 
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TNFa-induced Gingival Inflammation 
Four to six week old male mice weighing 20-25 g received 10 µl TNFa at different 
concentrations ( 1 or 10 µg/ml) intragingivally on labial side between mandibular incisors, under 
brief isoflurane anesthesia. Anesthetized mouse was rapidly placed in supine position under the 
microscope set on x 2.5 magnification. The lower lip was gently retracted with the 0.5 ml INS 
syringe loaded with the aliquot to be delivered by holding it parallel to lower incisors. TNF a was 
injected into alveolar mucosa on midline. Mouse recovered spontaneously and was returned to 
cage until preparation for microscopic visualization 1.5 h later as described above (Fig.B.2.3.3. ). 
Microvascular Permeability 
Intravenous FITC-D 150 kDa was used as tracer molecule to measure microvascular 
permeability in Akita compared to healthy WT and WT with induced acute gingivitis. The high 
MW (> 2 x albumin) prevents FITC-D to escape from the circulation by extravasation through 
the vessel wall or renal clearance under health conditions (Fig. B.2.3.4.). Microvascular 
permeability was measured using an approach published previously [337, 386] with mmor 
modifications based on the assumption of minimal plasma clearance of tracer molecule in the 
interval between intravenous administration and microscopic assessment. Thus, the initial 
fluorescence of solute filling the vessel lumen and plasma clearance constant for FITC-D (MW 
150 kDa, 6 mg/kg) was not taken into account for calculation of permeability index (PI). 
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We measured the initial change in fluorescence intensity as the solute moved across the 
vessel wall. Permeability was assessed on pictures taken under the FITC filter within 30 min 
after tracer molecule injection by calculating the green fluorescence intensity (GFI) ratio in the 
extravascular (EV) vs. intravascular (IV) compartment. The average GFI of 20 randomly 
selected pixels in the perivascular area within a 100 µm2 area on each side of the vessel wall was 
calculated to determine the EV value. The same rule was applied for the intravascular 
compartment over 100 µm vessel length to determine the IV value. The PI was expressed as a 
ratio: PI = Ev/ Iv, where Ev and Iv represent mean GFI values for each compartment. Ratios 
were normalized to those of WT control animals (Fig.B.2.3.5.). 
Leukocyte In Vivo Labeling 
A 50 µl mixture of FITC-D (6 mg/kg, vasculature visualization) and R6G (0.15 mg/kg, 
leukocyte labeling) in PBS was injected intravenously via one of the two side tail veins once 
appropriate vasodilation was obtained. R6G stains circulating leukocytes by binding mainly to 
mitochondria. Staining with R6G is specific for leukocytes relative to EC, RBC and platelets due 
to the high content of mitochondria in leukocytes (Fig. B.2.3.6-7.). 
After IV injection mouse was transferred on the glass support plate and set on the 
inverted microscope with appropriate body temperature monitoring during the entire experiment. 
Additional light was used for localization of postcapillary venules in visible light. One hundred 
161 
Aim 2: Impact of Chronic Hyperglycemia on Leukocyte-EC Interactions 
µm of vessel length was visualized and cells moving along the vessel wall considered rolling, 
while those that remained stationary for the 30-second observation period were considered 
attached. 
To differentiate rolling and attached PMN from other leukocytes in vivo during 2h 
gingival inflammation, a 50 µ1 mixture ofFITC-LY6G (0.02 mg/kg, for PMN labeling) and R6G 
(0.15 mg/kg, for nonspecific leukocyte labeling) was administered intravenously. The merged 
pictures taken under the red and green filters show attached PMN in yellow and rolling PMN in 
green. The red-labeled cells indicate rolling leukocytes (Fig. B.2.3.8.). 
Peripheral Blood Immunophenotyping 
One sample of 40 µl peripheral blood was collected via facial vein puncture (Fig. 
B.2.3.9.). Each aliquot was quickly mixed with 0.5 M EDTA 1 at pH 8 (1:10) to prevent 
coagulation and then divided into 2 equal samples (20 µ1 each) followed by processing for flow 
cytometric analysis as previously described [ 433]. One sample was used for flow cytometry and 
one for CBC (Hemavet) (Fig. B.2.3.10.A). 
Antibodies for CD45 ( common leukocyte antigen) were used for selection of leukocytes 
during the flow cytometric analysis of the 4% whole blood sample. Anti-LY6G antibodies were 
used for selection of PMN (L Y6Ghigh) from CD45-positive (CD45+) cells. Anti-PSGL-1 and anti-
1 EDT A, Ethylenediaminotetraacetic acid, Caz+ chelator 
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CD 11 a antibodies were used for detection of surface adhesion molecules involved in rolling 
(PSGL-1) and attachment (LFAI) of leukocytes to EC (Fig. B.2.3.10.B). A 0.5 ml mixture of 
antibodies in antibody buffer (1 % BSA and 0.1 % sodium azide in Dulbecco's PBS without 
Ca2+ /Mg2+) was prepared for each adhesion molecule with the following concentrations: anti-
CD45-PE/CY7 1.1 µg/ml, anti-LY6G-FITC 0.55 µg/ml and anti-PSGL-1-PE or anti-CD! la-PE 
0.22 µg/ml. Blood samples were not spun, fixed or processed for lysis of red blood cells (RBC). 
Each 20 µl blood sample was incubated with 30 µl antibody mixture for 1 hour in dark at room 
temperature followed by suspension of the 50 µl incubation volume in 450 µl (1: 10 dilution) 
antibody buffer to stop reaction. Samples were kept on ice until analysis performed the same 
day. 
Flow-cytometric analysis was performed with a F ACScan flow cytometer using Cellquest™ 
software. The flow cytometer was set for triggering on FL-3 channel (PE/CY7) with the 
threshold set at 200. Dot plotting for SSC (side scatter) versus FL-3 was used to select 
leukocytes based on positivity for common leukocyte antigen (CD45+) by gating the distinct 
population (Fig. B.2.3.11.). Selected leukocytes (CD45+) were analyzed on a double parameter 
dot plot with FL-I (FITC) on X-axis and FL-2 (PE) on Y-axis for assessment of PSGL-1 or 
CDI la expression on PMN (LY6Ghigh). Geometric means (GM) of upper right quadrant (Q2) for 
surface expression of the specific adhesion molecule (PSGL-1 high or CDlliigh) on PMN surface 
in each sample were compared between Akita and healthy WT. 
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Similarly, upper left quadrant (Ql) was used to measure the levels of the adhesion molecule on 
surface of mononuclear cells (monocytes and lymphocytes). Sample labeling was normalized to 
unlabeled negative control for each mouse to exclude non-specific cellular autofluorescence in 
all channels used (FLl, FL2 and FL3). One experiment was separately carried with isotype 
control antibodies to exclude non-specific binding (e.g. to FcR). All antibodies demonstrated 
high specificity to antigens tested. Due to limited sample size only unlabeled negative controls 
have been included in each experiment. Backgate analysis of populations selected from the 
parent gate (CD45+) has confirmed their identity with respect to granularity and cytoplasmic 
complexity. PMN are located in the 400-800 arbitrary units range and mononuclear cells in the 
100-500 range on the SSC. PMN have lower CD45 levels compared to mononuclear cells 
(Fig.B.2.3.12). 
164 
Aim 2: Impact of Chronic Hyperglycemia on Leukocyte-EC Interactions 
Figure B.2.3.1. 
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Figure B.2.3.1 Gingival Intravital Microscopy (GIM) 
GIM was performed on mandibular labial gingiva in the incisor region. This region offers the 
advantage of thin soft tissue where microvasculature can be visualized with reduced fluorescent 
background noise when using fluorescence microscopy. Anesthetized mouse that received the 
labeling fluorophores (R6G, FITC-D) or fluorophore-conjugated antibodies (anti-LY6G-FITC) 
IV was placed on a glass support plate with continuous body temperature control and transferred 
on an inverted microscope. Post-capillary venules of 20-40 µm diameter were assessed for 
microvascular permeability and leukocyte-EC interactions. 
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Figure B.2.3.2. 
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Figure B.2.3.2. Gingival Intravital Microscopy- Instruments and Set-up 
5.0 silk suture and instruments (J) were used to place a suture in the lower lip for retraction 
during microscopic visualization of mandibular incisor gingiva; PBS (2) was used to maintain 
gingival moisture during the entire experiment; Ketamine and Xylazine (3) were used to induce 
general anesthesia; Insulin syringe ( 4) was used for IV injection; Labeling dye (FITC-D/ R6G/ 
anti-L Y6G-FITC) (5); Glass plate ( 6) was used to support the mouse in prone position during 
GIM; Heating pad , rectal thermo probe (7) and temperature monitor (8) were used to maintain 
body temperature constant at 37°C by placing the pad under the glass support plate and 
monitoring temperature with thermo probe connected to the temperature monitor; Inverted 
microscope (9) was used to perform GIM; Progressive scan video camera (J 0) connected to the 
microscope was used to record videos under TRITC filter for assessment of leukocyte-EC 
interactions and to capture pictures under the FITC for assessment of microvascular 
permeability ; External light source (11) was used during localization of post-capillary venules; 
Computer monitor ( 12) was used throughout the experiment for visualization of images and 
videos. 
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Figure B.2.3.3. 
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Figure B.2.3.3. Model of Acute Gingival Inflammation - Intragingival TNFa 
Acute gingival inflammation was induced in WT mice by injecting TNFa in mandibular labial 
gingiva 2 hours before performing GIM. Gingival microvasculature was visualized as described 
previously in this chapter for assessment of leukocyte-EC interactions and microvascular 
permeability. 
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Figure B.2.3.4. Gingival Microvascular Permeability- Intravenous FITC-Dextran 
FITC-dextran (FITC-D, MW 150 kDa) was used during GIM for assessment of microvascular 
permeability for macromolecules. Top: FITC has a maximum absorption at 494 run ( dotted line) 
and emission at 521 run wavelength (filled curve). Middle: ball and stick representations of FITC 
and glucose molecules. Dextran with MW of 150 kDa (D 150) contains approximately 833 
molecules of glucose linked through a-1,6 glycosidic bonds in the central skeleton and through 
a-1,3 glycosidic bonds in the side branches. The size of D 150 is much greater than that of 
albumin (69 kDa) making it virtually impossible to cross the vascular walls under health 
conditions or to be cleared by the kidneys. Dextrans may remain in the circulation for weeks 
before they are completely processed by EC to free glucose and water. Large dextrans are used 
in surgical emergencies to replace lost blood through acute isovolemic hemodilution generated 
by their osmotic properties. Hemodilution also improves blood flow in addition to the ability of 
dextrans to bind RBCs, platelets and ECs and reduce RBC aggregation and platelet adhesiveness 
by increasing their surface electronegativity. Bottom: FITC-D 150 kDa was administered IV by 
tail vein injection for visualization of microvasculature and measurement of permeability during 
GIM. 
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20min 
Figure B.2.3.5. 
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Figure B.2.3.5. Gingival Microvascular Permeability- Quantification 
Microvascular permeability was measured in gingiva by comparing intravascular (IV) with 
extravascular (EV) fluorescence intensity on pictures taken under the FITC filter during GIM. 
Permeability index was calculated as follows: 
Permeability Index: PI= Ev/ Iv~ d.11 
Ev - extravascular fluorescence intensity; Iv - intravascular fluorescence intensity 
Derived from: 
Ps= Js/ SAC= 1 / Alo (d.11/ dt)i (D /4) 
Where: Ps - permeability of solute, Js - flux of solute through vessel, ~C - coefficient of 
diffusion across vessel wall, Mo - initial fluorescence intensity of solute filling the vessel, D -
vessel diameter, dt - time interval for assessment of permeability; d.11, variation in fluorescence 
intensity 
Assumptions: 
1. Minimal plasma clearance for dt used (20 min) 
2. Equal vessel diameters among groups (D) 
3. Same time interval ( dt) - normalization to negative control (healthy WT) 
4. Low background fluorescence noise (thin) 
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Figure B.2.3.6. In Vivo Leukocyte Labeling - Intravenous Rhodamine 6G 
Circulating leukcytes were labeled with R6G in vivo. Top: PE has a maximum 
absorption/emission at 566/576 nm wavelengths (dotted line/filled curve). R6G has similar 
properties to PE as fluorophore with a maximum absorption at 521 nm and maximum emission 
at 550 nm. Middle: ball and stick representation of R6G structure. Bottom: R6G was 
administered IV via one side tail vein. R6G is a liposoluble dye that crosses cell membranes and 
is released from the cell by efflux through multi-drug resistance (MDR) pumps of the ABC-type 
transporter family. Inside leukcoytes R6G, which is lipophilic and positively charged at pH <7.4 
quickly binds the abundant mitochrondria. Some of the dye is released through MDR pumps. 
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Figure B.2.3.7. In Vivo Leukocyte Labeling- Blood Smear 
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Figure B.2.3.7. In Vivo Leukocyte Labeling- Blood Smear 
Blood smear from a mouse injected with R6G intravenously (0.15 mg/kg) was visualized by 
light and fluorescence microscopy in phase contrast (top) and under TRITC filter (bottom) 
respectively demonstrating specific staining of leukocytes. 
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Figure B.2.3.8. In Vivo Differential Leukocyte Labeling - Intravenous FITC-LY6G (PMN) and 
R6G (leukocyte) 
WT mice were injecte IV a bolus containing a mixture of R6G and anti-LY6G-FITC and then 
GIM was performed as described. Overlapping images of R6G-positive (red) and LY6G-positive 
(green) cells indicate that the majority of leukocytes 2 h after tumor necrosis factor a (TNFa) 
stimulation is PMNs (yellow). The white arrows indicate intravascular leukocytes as follows: 1, 
rolling leukocyte (red); 2, rolling PMN (green); and 3, attached PMN (yellow). The black arrows 
indicate the outer side of the vessel wall. Original magnification x 400. Note: capture of pictures 
under FITC and TRITC filters was sequential. Only cells that were not moving ( attached 
leukocytes) have been captured in the same position (PMN, yellow). 
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Figure B.2.3.9. Peripheral Blood Immunophenotyping- Facial Vein Puncture 
Mouse was restrained in the left hand with appropriate gentle immobilization of the head and 
extension of facial skin against the mandible. In mice and humans anterior facial vein (FV) joins 
deep FV and then retromadibular vein continuing as common FV to drain directly in the internal 
jugular vein. Puncture of FV was performed between deep facial and retromandibular veins, 
along the mandible and immediately posterior to a visible freckle used as landmark. Blood was 
quickly collected with a 200 pp pipette set on 40 µland mixed vigorously with 4 µl 0.5 M EDTA 
to prevent coagulation. Hemostasis was achieved by compression. Approximately 2.5 µl of the 
blood sample was used to measure BG. The sample was further divided in two equal samples for 
CBC and flow cytometric analysis of leukocyte surface markers. 
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Figure B.2.3.10. Peripheral Blood Immunophenotyping - Sample Preparation 
Fresh peripheral blood was incubated in dark at room temperature for 1 hour with a mixture of 
fluorescent-labeled antibodies against common leukocyte antigen (CD45), PMN-specific antigen 
(LY6G) and leukocyte adhesion molecules (PSGL-1 or CD162 and CDI la). Anti-CD45, anti-
PSGLI and anti-CDlla bind monocytes, lymphocytes and PMN and anti-LY6G binds only 
PMN. No antibody binds RBCs (A). With a maximum absorption/emission at 575/780 nm 
wavelengths PE/CY7 can be used simultaneously with FITC and PE with minimal crossbeam 
compensation (B). 
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Figure B.2.3.11. Peripheral Blood Immunophenotyping - Sample Preparation 
Peripheral blood sample ready for F ACS analysis contained fluorophore-conjugated antibodies 
bound to CD45 (anti-CD45-PE/CY7) on lymphocytes, monocytes and PMN, PMN-specific 
antigen exclusively on PMN (anti-LY6G-FITC), and adhesion molecules PSGL-1 or CDlla 
found at different levels on all leukocytes (anti-PSGL-1-PE or anti-CDl la-PE). No antibodies 
were bound to RBCs. This approach eliminated the need for lysis of RBCs to physically purify 
the sample for leukocyte selection. Due to small sample size (20 µl) RBC lysis and the washing 
steps involved would have considerably reduced the number of leukocytes. 
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Figure B.2.3.12. Peripheral Blood Immunophenotyping - F ACS Analysis Protocol 
Labeled and unlabeled (negative control) samples were analyzed by flow cytometry with 
acquisition triggered on FL3 channel (CD45). The CD45+ cells (leukocytes) were selected by 
gating the distinct cell population on a double-parameter dot plot (FL3 vs SSC) (left). 
Leukocytes were analyzed on a double-parameter dot plot (FL 1 vs FL2) divided in quadrants. 
PMN specific antigen (FITC-conjugated) was analyzed on x-axis and adhesion molecule (PE-
conjugated) on the y-axis (middle). Geometric mean for each quadrant was used in statistical 
analysis. Histograms of each quadrant for FL2 (adhesion molecule) are shown (right). 
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Figure 2.3.13. Peripheral Blood Immunophenotyping- Backgate Analysis 
Backgate analysis of cell populations selected as describe identified leukocyte subpopulations in 
the parent gate (CD45+) in the FL3 vs SSC dot plot. As expected PMN are located further to the 
right on the x-axis (SSC) between 400-800 arbitrary units compared to other mononuclear cells 
located between 200-600 arbitrary units (top: PMN PSGL-1 high, middle: mononuclear cell PSGL-
1 hig\ mononuclear cell PSGL- 110w). This is explained by the PMN high granular content and 
complex nuclear morphology. 
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2.4. Results 
Microvascular Permeability 
Vascular permeability in gingival postcapillary venules was measured using GIM. Wild-
type (WT) and Akita mice were injected with a 50 µl intravenous bolus of FITC-D (MW 150 
kDa; 6 mg/kg), and 30 min later pictures were taken under the FITC filter. Healthy WT served as 
negative controls for microvascular permeability. Acute gingival inflammation was induced in 
some WT mice by injecting TNFa (100 ng) in the gingiva 2 h before the experiment and they 
served as positive controls. Fluorescence signal intensity measurement in IV and EV 
compartments revealed a higher vascular permeability in Akita gingival vessels compared with 
WT. The FITC-D was retained in the gingival vasculature of a healthy WT mouse (Fig. 
B.2.4.1 .A). Increased FITC-D extravasation in Akita gingiva within the same time period was 
observed (Fig. B.2.4.1.A-B). Statistical analysis of 3 groups (WT, Akita , WT + TNFa) x 4 
experiments (1 mouse I experiment/ group) revealed the following PI values: WT , 0.75 ± 0.05 ; 
Akita , 1.1 ± 0.03; p < 0.05. Increased microvascular permeability in Akita was comparable to 
acute gingivitis in WT (PI, 1.17 ± 0.16). Results are expressed as mean± SEM (Fig. B.2.4.1.C) 
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Leukocyte Rolling 
Circulating leukocytes were labeled by injecting intravenously R6G, a fluorescent dye 
that had been shown to specifically stain white blood cells and platelets with no effect on 
leukocyte kinetics [24, 142, 277]. Pictures of selected microvessels for analysis were taken under 
the FITC (green) and TRITC (red) filters and merged to illustrate rolling of leukocytes inside 
gingival post-capillary venules (Fig. 2.4.2.A). Playback of recorded videos was used to count 
rolling cells as described above. The number of rolling leukocytes along the gingival 
endothelium of Akita mice was significantly increased compared with WT (WT, 25 ± 3.7 
cells/min; Akita, 42 ± 8.5 cells/min; n = 4; p < 0.05). Stimulation with 10 ng TNFa in WT 
gingiva 2 h before the experiment resulted in a comparable elevation in leukocyte rolling (Fig. 
2.4.2.B). The number of attached leukocytes, defined as R6G-posit~ve cells that do not move in 
the 30 second observation period , was not significantly different between WT, Akita and WT+ 
TNFa-injected mice (WT, 3.5 ± 5.1 cells/min; Akita, 0.66 ± 0.53 cells/min; WT+ TNFa , 2.9 ± 
0.33 cells/min). Double labeling with FITC-L Y6G/R6G indicated that the majority of attached 
leukocytes under TNFa stimulation are PMN (Fig. B.2.3.6.). 
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Leukocyte Surface Adhesion Molecule Expression 
Peripheral blood immunophenotyping for leukocyte surface adhesion molecules showed 
higher levels of PSGL-1 surface expression by Akita PMN compared to WT (MFI: WT, 1068.48 
± 63.94; Akita, 1342.32 ± 74.79; mean ± SEM, n = 23 WT, n = 11 Akita) (Fig. B.2.4.3.). 
Mononuclear cells expressed PSGL-1 at lower levels compared to PMN in Akita and WT. 
Similar to PMN, mononuclear cells had higher levels of PSGL-1 in Akita compared to WT 
(MFI: WT, 532.35 ± 21.63; Akita, 673.43 ± 52.74; mean± SEM, n = 20 WT, n = 14 Akita) (Fig. 
B.2.4.4.). 
Surface expression of CDlla was similar in Akita and WT PMN (MFI: WT, 602.62 ± 
36.85; Akita, 642.64 ± 25.51; mean± SEM, n = 12 /each group) (Fig.B.2.4.5.). Mononuclear 
cells on the other hand, although had lower CD 11 a levels compared to PMN in both phenotypes, 
they had higher levels in Akita compared to WT (MFI: WT, 217.27 ± 9.04; Akita, 260.63 ± 
14.64; mean± SEM, n = 15 WT, n = 11 Akita) (Fig. B.2.4.6.) 
These results have led us to conclude that: 1. Gingival microvasculature has higher 
permeability for large molecules in diabetic Akita mice compared to healthy WT and similar to 
induced gingival inflammation; 2. Leukocytes of diabetic Akita mice have a higher rolling rate in 
gingival microvasculature compared to WT; 3. PMN and mononuclear cells of Akita express 
more PSGL-1 on their surface compared to WT; 4. PMN of Akita and WT express similar levels 
of CD I la; 5. Mononuclear cells of Akita express more CD I la. 
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Figure B.2.4.1. 
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Figure B.2.4.1. Gingival Microvascular Permeability 
Postcapillary venules of diameters of 20-40 µm were selected to measure microvascular 
permeability. FITC-D is retained inside blood vessels of WT mice as indicated by the high 
intensity of green fluorescence in the IV compared to the EV compartment (A). On the other 
hand, Akita had a lower IV green fluorescence intensity compared to EV compartment within the 
same time interval after tracer molecule administration. Note that the high fluorescence intensity 
of FITC-D inside the vessel expands on approximately IO µm in the EV compartment as 
observed by comparison of the same field in visible light and under the FITC filter. For this 
reason diameter-based selection of vessels assessed was done in visible light. Black arrows 
indicate the outer side of the vessel wall ± IO µm. 
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Figure B.2.4.2. Gingival Microvascular Permeability 
Statistical analysis of three experiments for each treatment group including Akita, healthy WT 
and WT with acute gingivitis (TNFa-induced) showed significant increase in PI in Akita 
compared to healthy WT. PI in Akita was comparable to values measured in WT that received 
intragingival TNFa 2 h before GIM. * p<0.05, one-way ANOVA, n = 3/group, mean± SEM 
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Figure B.2.4.3. 
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Figure B.2.4.3. Leukocyte Rolling in Gingival Microvasculature 
Pictures taken under FITC and TRITC filters during GIM after concurrent IV administration of 
R6G and FITC-D were merged to identify rolling leukocytes (red) on endothelium. 
Representative images for healthy WT and Akita leukocyte-EC interactions show more 
leukocytes rolling in Akita. Leukocytes that remained stationary inside the vessel during the 30-
second observation period there were considered attached. No significant difference was 
observed in attachment in Akita compared to healthy WT. 
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Figure B.2.4.4. Leukocyte Rolling in Gingival Microvasculature 
Average numbers of rolling leukocytes from 4 experiments for each group were compared. Akita 
leukocytes rolled with significantly higher rate that healthy WT. Rolling rate in Akita was 
comparable to low-dose (10 ng) TNFa-induced acute gingivitis in WT. WT that received high 
dose TNFa (100 ng) had significantly higher rolling rates that all other groups. *p<0.05, one-
way ANOVA, n = 4 /group, mean± SEM. 
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Figure B.2.4.5. Peripheral Blood PMN PSGL-1 
F ACS analysis of peripheral blood was used to measure leukocyte surface adhesion molecule 
expression. Mean fluorescence intensity (MFI) for PMN surface PSGL-1 PMN was compared in 
Akita and WT. Levels of PMN PSGL-1 in both Akita and WT have a positive skewed 
distribution (mean: Akita 1500.38 and WT 1132.49; median: Akita 1240.21 and WT 1028.88). 
Akita PMN have higher PSGL-1 levels compared to WT. Minimal PSGL-1 MFI in Akita 
(1092.43) was higher the median MFI in WT (1028.88). * p<0.03, t-test, n = 11 Akita, n = 23 
WT, mean± SEM; values are expressed in arbitrary units 
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Figure B.2.4.6. Peripheral Blood Mononuclear Cell PSGL-1 
MFI for mononuclear cell PSGL-1 was measured in Akita compared to WT. Mononuclear cells 
in Akita had higher levels of PSGL-1 with a positive skewed distribution (mean a.u.: Akita 844 
and WT 519; median a.u.: Akita 654 and WT 517). In approximately 50% of Akita mononuclear 
cells PSGL-1 was higher than the maximum WT MFI (Akita median MFI, 654 and WT 
maximum MFI, 666). * p<0.03, t-test, n = 14 Akita, n = 23 WT, mean ± SEM; values are 
expressed in arbitrary units 
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Figure B.2.4.7. Peripheral Blood PMN CDl la 
Comparison of MFI for PMN CD 11 a in Akita and WT mice showed no significant difference 
between the two groups. PMN CDl la levels had a slightly negative skewed distribution (mean: 
Akita 666.2 a.u.; median: Akita 643.1). On the other hand, PMN CDl la levels in WT had a 
positive skewed distribution (mean: WT 672.62; median: Akita 530.71). t-test, n = 12 /group, 
mean± SEM; values are expressed in arbitrary units. 
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Figure B.2.4.8. Peripheral Mononuclear Cell CD 11 a 
Comparison between MFI for CD 11 a levels on mononuclear cell surface in Akita and WT 
showed increased levels in Akita. Both Akita and WT levels of PSGL-1 had a slightly positive 
skewed distribution (mean: Akita 267.5 and WT 220.5; median: Akita 249 and WT 209). 
P<0.03, t-test, n = 11 Akita, n = 15 WT, mean± SEM; values are expressed in arbitrary units. 
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The third aim of the present study was to investigate the ability of Akita PMN to 
phagocytose and kill pathogens. For assessment of phagocytosis PMN from Akita and WT were 
incubated ex vivo with labeled zymosan and phagocytosis quantified by flow cytometry. For 
assessment of bacterial killing ability viable PMN were incubated with E. coli and killing 
efficiency was measured by counting the surviving colony forming units (CFUs) on LB-agar 
plates after overnight incubation. 
3 .1. Materials 
Zymosan A from Saccharomyces cerevisiae (Sigma-Aldrich, St-Louis, MO, USA), Alexa 
Fluor 488 - zymosan, Hank's Balanced Salt Solution with Ca2+ and Mg2+, R6G, (lnvitrogen, 
Carlsbad, CA, USA), E.coli strain MC1061 (donation from dr. Elena Black), Luria-Bertani (LB) 
broth was prepared from yeast extract, triptone and sodium chloride (Sigma-Aldrich, St-Louis, 
MO, USA), Bacteria Colony Counter 500A (Spiral System Instruments Inc., Gaithersburg, MD, 
USA), SmartSpec TM Spectrophotometer (Bio-Rad Laboratories, Hercules, CA, USA), MaxQ Mini 
4000 incubator, Barnstead Lab-Line, Melrose Park, IL, USA), hemocytometer and trypan blue 
4% solution (see chapter B.1.3). FACS acquisition was performed using a FACSscan machine. 
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3.2. Experiment Design 
Phagocytosis by PMN 
Leukocytes were recruited intraperitoneally (IP) by injecting 1 ml of 0.2 mg/ml zymosan 
A in the lower right quadrant of abdomen. Cells were collected by peritoneal lavage performed 2 
h later and counted using a hemocytometer. PMN were incubated with opsonized Alexa Fluor 
488 labeled zymosan (zymosanAlexaF488) for 30 minutes and then samples were processed for 
F ACS acquisition and fluorescence microscopy that were performed the same day. F ACS 
analysis was performed on a subsequent day (Fig. B.3.2.1.). 
Bacterial Killing by PMN 
E. coli was grown for 18 h the day before the experiment (day 0). On day 1 leukocytes 
were recruited in the peritoneal cavity by zymosan-induced acute peritonitis as described 
previously. Bacteria was opsonized with mouse serum and then incubated with leukocytes at 
different leukocyte to bacteria ratios. The surviving colony forming units (CFU) were plated on 
LB agar plates and incubated overnight. To exclude reversible growth arrest and confirm 
bacterial killing the remaining incubation volume of each sample was kept overnight on the 
bench and aliquots plated the next day (day 2). CFUs were counted after 24 h incubation of 
plated bacteria (Fig. B.3.2.2.). 
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Figure B.3.2.1. Ex Vivo Phagocytosis by PMN - Experiment Design 
Leukocytes were recruited in the peritoneal cavity by injecting zymosan A IP. Peritoneal lavage 
was performed 2.5 hours later and cells counted using a hemocytometer. Blood was collected by 
heart puncture following peritoneal lavage, left to clot and then spun to separate serum. 
ZymosanAiexaF488 was opsonized with 10% serum for 20 min and then incubated 10: 1 with 
leukocytes (>75% PMN) for 30 min. Following incubation the sample was divided in two for 
fluorescence microscopy and F ACS analysis. 
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Figure B.3.2.2. Bacterial Killing by PMN - Experiment Design 
E. coli was grown in LB broth for 18 hours to an OD = 1 representing approximately 109 
bacteria/ml. Leukocytes were recruited in the peritoneal cavity following the protocol used for 
the phagocytosis assay. Approximately 108 bacteria were opsonized with 10% serum and then 
incubated with PMN at different bacteria to PMN ratios for 1 hour. Reaction was stopped by 
dilution in distilled water and serial dilutions performed. Aliquots of surviving CFU were plated 
on LB agar plates and incubated overnight. Part of the samples were kept overnight in the initial 
incubation tube and plated the second day to exclude reversible growth arrest induced by PMN. 
CFU were counted on day 2 and 3. Alternatively cells collected from air pouches 4 hours after 
pro-inflammatory stimulation were used for assessing bacterial killing in the same way. 
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3.3. Methods 
Peritoneal Collection of Leukocytes 
Mice were administered 1 ml of 0.2 mg/ml zymosan A in PBS IP using a 3 ml syringe 
with 25 G short needle and returned to cage. Two hours later mice were euthanized with 
isoflurane overdose and peritoneal lavage performed. Abdominal skin was incised to expose the 
peritoneum without opening the peritoneal cavity. Four ml of filtered PBS were injected into the 
peritoneal cavity using a 5 ml syringe with 22 G needle. Peritoneum was gently rubbed with 
needle in place to prevent leakage. Lavage fluid was collected into a 15 ml tube with needle 
detached to reduce through-needle passes of cells. Viable leukocytes were counted using a 
hemocytometer with trypan blue exclusion as described in chapter B.1.3 and diluted in PBS to a 
concentration of 106 cells/ml. Wrigh-Giemsa staining was performed to confirm that the 
composition of inflammatory exudate predominated by PMN (Fig. B.3 .3.1.). 
Zymosan Opsonization 
Whole blood was collected by heart puncture from mice following peritoneal lavage, kept 
on the bench for several minutes to clot and then spun to separate serum. L yophilized zymosan A 
particles labeled with AlexaFiuor488 were suspended in PBS at 100 µg/ml and number of particles 
per aliquot counted with hemocytometer. Each 100 µg/ml aliquot containing approximately 25 x 
106 labeled zymosan particles was stored at -20°C. For each experiment 15 x 106 zymosan 
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particles were opsonized with 10% serum in 1 ml PBS total volume at 37°C for 20 minutes on a 
shaking platform. 
Phagocytosis Assay 
Opsonized zymosan particles were incubated with peritoneal-recruited PMN at 10 to 1 
ratio in a total volume of 1 ml in dark at 37°C for 30 minutes. Following incubation 0.5 ml of 
each sample was kept on ice in dark until F ACS acquisition and the other 0.5 ml was mixed with 
300 ng R6G for leukocyte labeling (Fig. B.3.3.2. A). A I 00 µl aliquot of each stained sample was 
cytospinned on a superfrost plus slide and visualized under the microscope. Pictures were taken 
in x 1000 magnification under the FITC and TRITC filters, and then merged to identify 
phagocytosed zymosan particles in green inside red-labeled leukocytes (Fig. B.3.3.2. B). 
F ACS Analysis Protocol for Phagocytosis 
Samples of PMN incubated with zymosanAlexaF488 were run through F ACSscan. 
Acquisition was triggered on FSC with threshold set at O to include free zymosan. Different 
leukocyte populations were identified on a SSC vs FSC dot plot. PMNs were analyzed on FLI 
for labeled zymosan phagocytosis. Geometric means were used to compare Akita with WT PMN 
phagocytosis (Fig. B.3.3.3.). Backgate analysis of gated PMN that were highly positive on FLl 
was performed to confirm that green fluorescence measured was derived from zymosanAlexaF4ss. 
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Bacterial Killing Assay 
E. coli was grown on LB broth at 37°C, on a shaking platform, for 18 hours to an OD = 1 
(optical density) at 660 nm wavelength, representing 109 bacteria/ml. PMN were collected by air 
pouch ( described in chapter B .1. 3) or peritoneal lavage 2-4 hours after pro-inflammatory 
stimulation (Fig. B.3.3.4. A). Viable leukocytes were counted using a hemocytometer and trypan 
blue exclusion and re-suspended to a 106 cells/ml. More than 75% of leukocytes were PMN as 
confirmed in Wright-Giemsa staining of samples collected. PMN were incubated with opsonized 
bacteria at different PMN to bacteria ratios: no PMN, 1:1, 1:10, 1:30 and 1:100 for 60 minutes at 
37°C, shaking at 200 rotations per minute, followed by xlO dilution in distilled water to lyse 
PMN. A 30 µl from serial dilutions 1/102, 1/103 and 1/104 was spread on a LB agar plate for 
each PMN : bacteria ratio and incubated overnight at 37°C (Fig. B.3.3.4. B). The rest of each 
sample at dilution 1/103 was kept overnight at room temperature and the next day a 50 µl aliquot 
was spread on a LB agar plate. All plates were incubated overnight at 37°C. This step would 
exclude bacterial reversible growth arrest induced by PMN. Quantification of CFU that grew on 
LB agar plates overnight after the 60 minutes incubation with PMN was performed with a colony 
counter. Error on counting was established at± 3% by comparing different readings of the same 
sample and with counting by eye. 
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Figure B.3.3.1. Peritoneal recruitment of PMN 
PMN were recruited in the peritoneal cavity by zymosan IP injection. Peritoneal lavage was 
performed after 2.5 hours and 100 µl lavage fluid was cytospinned and stained with Wright-
Giemsa. A representative image of stained leukocytes shows that PMN predominated the 
inflammatory exudate. Few PMN and some macrophages have phagocytosed zymosan in vivo 
(arrows). A few lymphocytes and RBC were also present. 
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Figure B.3.3.2. Phagocytosis by PMN Ex Vivo 
Leukocytes that were incubated with labeled zymosan ex vivo were stained with R6G, 
cytospinned and assessed for phagocytosis using fluorescence microscopy. (A) R6G will stain 
leukocytes in red by binding to mitochondria. (B) Pictures were taken under FITC and TRITC 
filters in x 1000 magnifications and then merged. Some of the unlabeled zymosan phagocytosed 
by PMN in the peritoneal cavity could be identified (J). Most PMN have phagocytosed 
AlexaF488 d . . . b . (2) S PMN h h d . . bl zymosan unng ex vzvo mcu ation . ome t at p agocytose m vivo were a e 
to continue phagocytosing ex vivo. Free zymosanAlexaF488 could also be identified (3). 
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Figure B.3.3.3. F ACS Analysis Protocol for Quantification of Phagocytosis 
Phagocytosis of zymosanAiexaF488 by PMN was quantified by flow cytometry. Acquisition was 
triggered on FSC and data was analyzed on a FSC vs SSC dot plot. The PMN population was 
identified by the advanced positioning on the SSC due to internal complexity of PMN. 
Mononuclear cells were identified in a lower position on the SSC with lymphocytes slightly to 
the left of monocytes on the FSC. RBCs were located even further to the left on the FSC due to 
h . 11 . F AlexaF488 "d "fi d . h" 1 . 1 11 d" h t e1r sma size. ree zymosan was i entl ie wit m a re ative y sma area a Jacent to t e 
intersection of FSC and SSC axes. 
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Figure B.3.3.4. Bacterial Killing Assay 
PMN were recruited in the peritoneal cavity or air pouch and incubated with opsonized bacteria 
for 1 h at 3 7° C. Reaction was stopped by dilution 1: 10 in distilled water and surviving CFU 
plated on LB agar plates (A). Serial dilutions of surviving bacteria were used to plate 30-50 µl 
aliquots containing 102 -104 bacteria (B). 
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3.4. Results 
Consistent with previous observations of reduced leukocyte recruitment inside au 
pouches in Akita recruited fewer leukocytes in the peritoneal cavity. Most of the leukocytes 
recruited at 2 h following IP zymosan injection were PMN (Figs. B.3.4.1, B.3.4.4). Flow 
cytometric analysis of phagocytosis showed higher efficiency in Akita compared to WT mice. 
Most PMN have phagocytosed labeled zymosan in both Akita and WT within the 30 minutes 
incubation period (Figs. B.3.4.2, B.3.4.5). Backgate analysis of phagocytosed compared to free 
labeled zymosan showed efficient phagocytosis by Akita and WT PMN (Figs. B.3.4.3, B.3.4.6). 
Following incubation of PMN with bacteria at 1: 1 ratio both Akita and WT have reduced 
significantly the number of CFU although phagocytes of Akita were less efficient in killing (Fig. 
3.4. 7.). Results were expressed as percentage of total CFU (not incubated with PMN). Akita 
PMN have been inefficient in clearing CFU at ratios 1: 10 and 1 :30 PMN to bacteria compared to 
WT (surviving CFU count, percent of total: WT 1:10, 64.27 ± 11.05%, Akita 1:10, 90.03 ± 
9.47%, WT 1:30, 70.44 ± 5%, Akita 1:30, 93.39 ± 13.01%) (Fig. B.3.4.8.). When incubated at 
ratio 1: 100 PMN to bacteria neither WT nor Akita were efficient in reducing CFU (WT 1: 100, 
95.55 ± 7.29%, Akita 1:100, 101.1 ± 13.39%,) (Fig. B.3.4.9.) 
These results have led us to conclude that: 1. Both WT and Akita were efficient in 
phagocytosing zymosan particles; 2. PMN of Akita diabetic mice were inefficient in killing E. 
coli compared to WT mice. 
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Figure B.3.4.1. Peritoneal Recruitment of PMN in WT (2 h) 
Top: Peritoneal lavage fluid collected 2.5 hours after zymosan injection was stained with Wright-
Giemsa. PMN predominate in the exudate. Lymphocytes, monocytes, macrophages and RBCs 
are also distinct. Bottom: Double parameter dot plot FSC vs SSC showing distinct leukocyte 
populations, RBC and other small particles including zymosan. Leukocytes represented 21 % of 
the total 105 events tested that included any particle since threshold had been set at O on FSC. 
PMN to mononuclear cell ratio was 2: 1. 
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Figure B.3.4.2. Phagocytosis by WT PMN Ex Vivo 
Leukocytes that have been incubated with labeled zymosan were then stained with R6G. To 
verify leukocyte labeling an aliquot from the peritoneal lavage fluid was stained with R6G. 
Pictures were taken under FITC and TRITC filters and merged (top row). Similarly, a sample 
containing leukocytes incubated with labeled zymosan but unstained with R6G was analyzed. 
Zymosan particles were identified but association with leukocytes could not be identified (middle 
row). Leukocytes incubated with labeled zymosan and stained with R6G were identified in 
merged pictures under FITC and TRITC filters. Most PMN have phagocytosed up to 6 labeled 
zymosan particles during the 30 minutes incubation (bottom row). 
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Figure B.3.4.3. Backgate Analysis WT PMN Phagocytosis 
The PMN population selected on the FSC/SSC dot plot was evaluated for MFI on FLl to 
1 h . f AlexaF488 C 11 "d d . . C: fl eva uate p agocytos1s o zymosan . e s were cons1 ere positive 1or green uorescence 
by comparison with PMN that were not incubated with labeled zymosan. This latter population 
showed no peak on FLl. Results showed that 86.7% of PMN had phagocytosed zymosanAlexaF488. 
Backgate analysis of this subpopulation confirmed that the green fluorescence measured in PMN 
was generated by zymosanAlexaF488 (top row). Conversely, free zymosanAlexaF488 was gated on the 
FSC vs SSC dot plot and analyzed for green fluorescence showing 85. 7% positivity on FL-1. A 
total of 4270 PMN were analyzed on FLl (MFI 369 a.u.). 
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Figure B.3.4.4. Peritoneal Recruitment of PMN in Akita (2 h) 
Top: Peritoneal lavage fluid collected from an Akita mouse was stained in Wright-Giemsa 
showing lower total leukocyte numbers but a high PMN to mononuclear cell ratio. Bottom: 
Double parameter dot plot FSC vs SSC showing distinct leukocyte populations, RBC and other 
small particles including zymosan. Leukocytes represented 15% of the total 105 events tested that 
included any particle since threshold had been set at O on FSC. PMN to mononuclear cell ratio 
was 3: 1. 
I 
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Figure B.3.4.5. Phagocytosis by Akita PMN Ex Vivo 
L uk ti Ak . · b d · h AlexaF488 ( ) d · h AlexaF488 e ocytes rom ita mcu ate wit out zymosan top row an wit zymosan 
(bottom row) were stained with R6G. One PMN sample that was incubated with zymosanAiexaF488 
was not stained with R6G (middle row). PMN from Akita phagocytosed up to 6 labeled zymosan 
particles. 
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Figure B.3.4.6. Backgate Analysis Akita PMN Phagocytosis 
The PMN population selected on the FSC/SSC dot plot was evaluated for MFI on FLl as 
described in fig. B.3.4.3. Results showed that 94.5% of PMN from Akita had phagocytosed 
zymosanAiexaF488 . Backgate analysis of this subpopulation confirmed that the green fluorescence 
measured in PMN was generated by zymosanAiexaF488 (top row). Conversely, free 
zymosanAiexaF488 was gated on the FSC vs SSC dot plot and analyzed for green fluorescence 
showing 94.7% positivity on FL-1. A total of 4190 PMN were analyzed on FLl (MFI 1163). 
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Figure B.3.4.7. Bacterial Killing at 1 to 1 PMN to Bacteria Ratio 
Leukocytes were incubated with E.coli at ratio 1: 1 for 1 hour and aliquots of surviving CFU 
were plated on LB agar plates and incubated overnight at 37° C. CFU were counted with a 
colony counter. Akita PMN reduced CFU by roughly 30% (675/940 CFU) while WT PMN 
reduced CFU by 50% (505/981 CFU). Left: pictures taken using x 25 magnification show high 
number of round shaped CFU in different sizes. Note: CFU were counted after 24 h incubation of 
plates and pictures were taken at a later time point after plates were stored at 4 ° C where bacteria 
slowly grew on nutrients from the plate. 
/ 
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Figure B.3.4.8. 
/ 
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Figure B.3.4.8. Bacterial Killing by Akita Leukocytes 
CFU from dilutions 102 -104 were incubated overnight after incubation with PMN at 30: 1 ratio. 
Counts from dilution D (30 µ1 from 103) were used for comparison between Akita and WT. WT 
PMN reduced CFU by 30% while Akita reduced counts by 7%. 
/ 
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Figure B.3.4.9. Bacterial Killing by PMN 
Comparison between Akita and WT PMN killing efficiency showed significant reduction in CFU 
counts in WT at PMN to bacteria ratio of 1: 10 and 1 :30. Akita PMN were inefficient in clearing 
CFU compared to WT at ratios 1: 10 and 1 :30. When PMN were incubated with bacteria at 1: 100 
ratio neither WT nor Akita were able to reduce CFU counts. *<0.05, one-way ANOVA, n = 3 
experiments , mean± SEM. 
/ 
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The fourth aim was to investigate in vivo the actions of RvEl on leukocyte recruitment at 
sites of inflammation. For this purpose the dorsal subcutaneous air pouch model of inflammation 
was used in Akita and WT mice. 
4.1. Materials 
Synthetic RvEl was prepared by total organic synthesis as previously described [19]. The 
RvEl stock in ethanol was stored at -80°C free from atmospheric 0 2 by passing a gentle stream 
of nitrogen on top of the vial after each opening and before sealing it for re-storage. The other 
reagents and equipment used in all experiments have been mentioned in chapter 1.1. 
4.2. Experiment Design 
Leukocyte recruitment was assessed using the experiment design described in chapter 1.2 
with modifications for RvEl treatment. RvEl was injected inside the air pouch 15 minutes 
be~ ro-inflammatory stimulation. Air pouch lavage was performed 4 h later. Air pouch wall 
sampling, leukocyte counting and processing of biopsies were performed as described earlier 
(Fig. B.4.1.1.). 
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Figure B.4.1.1. RvEl Actions on Leukocyte Recruitment- Experiment Design 
Dorsal subcutaneous air pouches were raised on days O and 3. On day 6 RvE 1 was injected 
inside the pouches 15 minutes before pro-inflammatory stimulation with TNFa. Air pouch 
lavage was performed 4 hours later and leukocytes were counted using a hemocytometer for total 
count and Wright-Giemsa for differential leukocyte count. 
/ 
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4.3. Methods 
The air pouches were raised on days O and 3 as described. On day 6 of the experiment, 
one dose of 100 ng RvEl in 250 ml saline for each mouse was prepared from the stock. RvEl 
was injected inside the pouch using a 1 ml insulin syringe with 27 G needle under brief 
isoflurane anesthesia. The pouch was gently rubbed and mouse was returned to cage. Fifteen 
minutes later each mouse received 30 ng TNFa in saline (3.5 nM) or saline alone inside the 
pouch under brief isoflurane anesthesia and was returned to cage. Four hours later mouse was 
euthanized with CO2 and air pouch lavage, total and differential count, and cryostat sectioning 
and staining were performed as described in chapter 1.3. 
4.4. Results 
Six-day-old air pouches were sampled for leukocyte content after RvEl or vehicle 
injection inside the pouch prior to pro-inflammatory stimulation. WT mice recruited significantly 
fewer leukocytes in the presence of RvEl compared to vehicle (total leukocytes: WT + saline, 
/ 
0.89 ± 0.06 x 106 cells/pouch; WT+ 0.4% ethanol+ TNFa, 3.89 ± 0.42 x 106 cells/pouch; WT+ 
RvEl + TNFa, 1.98 ± 0.35 x 106 cells/pouch). Akita recruited fewer leukocytes during pro-
inflammatory stimulation with RvEl or vehicle administered inside the pouches with no 
significant difference between the two conditions and compared to saline alone (total leukocytes: 
Akita+ saline, 1.56 ± 0.09 x 106 cells/pouch; Akita+ 0.4% ethanol+ TNFa, 2.14 ± 0.28 x 106 
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cells/pouch; Akita+ RvEl + TNFa, 2.05 ± 0.37 x 106 cells/pouch) (Fig. B.4.4.1.). Differential 
leukocyte counting showed slightly reduced numbers of PMN and higher numbers of monocytes 
in WT treated with RvEl compared to vehicle (PMN: WT + saline, 0.56 ± 0.023 x 106/pouch; 
WT + 0.4% ethanol + TNFa, 2.46 ± 0.088 x 106/pouch; WT + RvEl + TNFa, 1.46 ± 0.068 x 
106/pouch; Monocytes: WT+ saline, 0.19 ± 0.006 x 106/pouch; WT+ 0.4% ethanol+ TNFa, 
1.01 ± 0.033 x 106/pouch; WT + RvEl + TNFa, 0.37 ± 0.001 x 106/pouch). Akita recruited 
slightly higher PMN and fewer monocytes in the presence ofRvEl (PMN: Akita+ saline, 0.88 ± 
0.02 x 106/pouch; Akita + 0.4% ethanol + TNFa, 1.28 ± 0.1 x 106/pouch; Akita + RvEl + 
TNFa, 1.37 ± 0.07 x 106/pouch; Monocytes: Akita+ saline, 0.43 ± 0.005 x 106/pouch; Akita+ 
0.4% ethanol + TNFa, 0.67 ± 0.03 x 106/pouch; Akita + RvEl + TNFa, 0.57 ± 0.02 x 
106/pouch) (Fig. B.4.4.2). 
These results have led us to conclude that: 1. RvEl reduced PMN recruitment in WT in 
acute inflammation; 2. Akita recruited significantly fewer PMN compared to WT during acute 
~mmation; 3. RvEl did not reduce PMN recruitment in Akita 
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Figure B.4.4.1. RvEl Reduces Leukocyte Recruitment 
Total leukocyte counts from Akita and WT air pouches treated with RvEl or vehicle. WT mice 
recruited significantly higher numbers of leukocyte when stimulated with TNFa compared to 
PBS. RvEl reduced the number leukocytes recruited in WT compared to vehicle. Akita recruited 
less leukocytes with or without RvEl during pro-inflammatory stimulation. * p<0.05, one-way 
ANOVA, n = 4 /group, mean± SEM. 
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Figure B.4.4.2. RvEl Action on Recruitment of Different Leukocyte Subsets 
Differential leukocyte counting was performed in Wright-Giemsa stain of air pouch lavage 
samples. Results showed significant PMN infiltration under pro-inflammatory stimulation in 
WT. RvEl reduce significantly PMN and monocyte recruitment inside the pouch. Akita recruited 
fewer PMN and RvEl had no significant impact on leukocyte recruitment compared to vehicle. 
* p<0.05, one-way ANOVA , n = 4 /group, mean± SEM. 
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The fifth aim of the study was to investigate the actions ofRvEl on surface PSGL-1 and 
CD 11 a on circulating PMN in the absence and in the presence of acute inflammation in Akita 
and WT. RvEl was administered IV and adhesion molecule levels were measured by FACS. 
5.1. Materials 
Synthetic RvEl was handled as previously described in chapter 4.1. Disposable no. 11 
blade scalpel, 5 ml syringe with 22 G needle, cell strainer (BD Biosciences, San Jose, CA, USA). 
The other reagents and equipment used in all experiments have been described in chapter 2.1. 
5.2. Experiment Design 
Experiments were carried as described m chapter 2.3 with modifications for RvEl 
administration. A blood sample was collected by facial puncture for baseline levels of adhesion 
molecules tested (to). Vasodilation was induced by placing the mouse under a heating lamp to 
prepare the tail veins for IV administration of RvEl. RvEl or vehicle was delivered IV and 
~oo d samples were collected by facial puncture 1 h and 4 h later respectively (t1 and t2). All 
three samples were prepared for FACS analysis as described in chapter 2.3 (Fig. B.5.1.1.). 
For assessment of R v E 1 action during acute inflammation O .2 mg zymosan A (Z) was 
injected IP to induce peritonitis as described in chapter 3.3. RvEl was administered IV 15 
minutes before Z injection and blood samples were collected before treatment (to), 2 h (t1) and 4 
h (t2) after Z injection (Fig. B.5.1.2.). 
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Figure B.5.2.1. RvEl Actions on Peripheral PMN - Experiment Design 
One blood sample was collected by facial puncture to serve as control for time points following 
treatment (t0). RvEl or vehicle was administered IV via one side tail vein and peripheral blood 
samples were collected 1 h (t 1) and 4 hours (t2) later by facial vein puncture. Samples were 
incubated with a mixture of antibodies for CD45, LY6G and PSGL-1 or CDlla and analyzed by 
F ACS. Results were compared with baseline levels (to) for each mouse. Half of the blood sample 
was analyzed for CBC. 
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Figure B.5.2.2. RvEl Actions on Stimulated Peripheral PMN - Experiment Design 
For assessment of RvEl action on peripheral leukocyte surface adhesion molecules during acute 
inflammation RvEl was administered IV 15 minutes before Z IP injection. Peripheral blood 
samples were collected before teatments (to), 2 hours (t1) and 4 hours (t2) after pro-inflammatory 
stimulation. Samples were analyzed by F ACS and results were compared to baseline levels (t0). 
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5.3. Methods 
Peripheral Blood Immunophenotyping 
Akita and WT mice were placed under a heating lamp for 20 minutes to induce 
vasodilation and 100 ng RvEl or vehicle (2% ethanol) in 50 µl PBS were administered 
systemically via one tail vein in each mouse. Blood samples were collected by facial vein 
puncture 1 hand 4 h after RvEl administration. 
To investigate RvEl actions in vivo on PMN surface adhesion molecules during acute 
inflammation 1 ml of Z in PBS (0.2 mg/ml) was injected IP 15 minutes after RvEl IV 
administration. Blood samples were collected 2 hand 4 h after Z injection. 
Blood samples from all mice were analyzed by flow cytometry as described in chapter 
2.3. Leukocytes were selected based on positivity for CD45 (Fig. B.5.3.1 top). Geometric means 
of upper right quadrant for PMN and upper left quadrant for mononuclear cells in double 
parameter dot plots (LY6G vs PSGL-1 or CDl la) were used for quantification of surface 
adhesion molecules. Results were normalized to baseline levels for each mouse (Fig. B.5.3.1. 
~ 
bottom). 
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Bone Marrow Immunophenotyping 
In order to investigate the presence of antigens tested (CDl la and PSGL-1) on bone 
marrow (BM) PMN aspirates from femur BM of WT C57BL/6 were analyzed by microscopy 
and F ACS. Healthy WT mice were euthanized with CO2, disinfected with 70% ethanol, and both 
femurs collected and processed until free of soft tissues. Epiphyses were removed using an 11-
blade scalpel. To collect BM the femurs were flushed with x 1 PBS using a 22 G needle attached 
to a 5 ml syringe until collection fluid was clear and femur was white. Mouse femurs have thin 
cortical bone that makes BM reddish color visible when it fills the BM cavity (Fig. B.5.3.2). 
BM samples were incubated with antibodies for PSGL-1 and CD 11 a using the protocol 
described in chapter B.2.2. Leukocytes were selected based on positivity for CD45. 
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Figure B.5.3.1. F ACS Protocol - Immunophenotyping of Stimulated Peripheral Leukocytes 
Leukocytes (CD45+) were selected on a FL3 vs SSC dot plot and analyzed for L Y6G and PSGL-
1 or CDl la levels at different time points (A) . Results were normalized to an unlabeled blood 
sample used as negative control for each mouse. Double parameter dot plots FLl (LY6G) vs FL2 
(PSGL-1) at baseline , 2 h and 4 h after pro-inflammatory stimulation show significant increase in 
circulating PMN at 2 h (35% vs 4.04% of CD45+) and in mononuclear cells PSGL-1 high at 4 h 
(49.1% vs 31.8% ofCD45 +) (B). 
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Figure B.5.3.2. Bone Marrow Immunophenotyping 
The femurs from a WT C56BL/6 were flushed with PBS to collect a bone marrow aspirate. 
Cells were strained and analyzed for PMN surface expression of PSGL-1 and CD 11 a. One 
aliquot was stained with Wright-Giemsa for identification of blood cells. 
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5.4. Results 
RvEl Action on Circulating PMN Numbers 
A single bolus of 100 ng RvEl or vehicle (50 µl of 2% ethanol in PBS) was administered 
via one tail vein and CBC done 1 hand 4 h later to investigate the impact of RvEl on circulating 
PMN numbers. RvEl induced no change in numbers of PMN compared to vehicle (PMN 
number: WT + vehicle baseline, 1.58 x 103 ± 0.67 cells/µl; WT + vehicle 1 h, 2.54 x 103 ± 0.19 
cells/µl; WT+ vehicle 4 h, 1.82 x 103 ± 0.16 cells/µl; WT+ RvEl baseline, 1.08 x 103 ± 0.10 
cells/µl; WT+ RvEl 1 h, 2.12 x 103 ± 0.34 cells/µl, WT+ RvEl 4 h, 1.87 x 103 ± 0.28 cells/µl, 
n = 6 Akita) (Fig. B.5.4.1.). 
RvEl Action on BG 
BG levels measured in the absence and presence of acute inflammation showed no 
difference between vehicle of RvEl treated mice either diabetic or healthy (BG: WT baseline, 
171.11 ± 11.68 mg/dl; WT+ TNFa + vehicle 1 h, 160.67 ± 9.91 mg/dl; WT+ TNFa + vehicle 4 
h, 123.67 ± 11.9 mg/dl; WT+ TNFa + RvEl 1 h, 208.17 ± 10.89 mg/dl; WT+ TNFa + RvEl 4 
~ 
h, 205 ± 18.76 mg/dl; WT+ RvEl 1 h, 208.8 ± 8.87 mg/dl; WT+ RvEl 4 h, 157.63 ± 11.23 
mg/dl; Akita baseline, 529.29 ± 13.94 mg/dl; Akita+ TNFa + vehicle 1 h, 543.5 ± 74.21 mg/dl; 
Akita+ TNFa + vehicle 4 h, 518.5 ± 2.93 mg/dl; Akita+ TNFa + RvEl 1 h, 540.8 ± 42.83 
mg/dl; Akita+ TNFa + RvEl 4 h, 554.4 ± 29.75 mg/dl; Akita+ RvEl 1 h, 600 mg/dl; Akita+ 
RvEl 4 h, 592.75 ± 5.79 mg/dl; n = 6 Akita) (Fig. B.5.4.2.). 
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RvEl Action on Leukocyte PSGL-1 and CDlla 
Blood samples collected 1 h and 4 h after RvEl IV administration were analyzed by 
F ACS for surface expression of PSGL-1 and CD 11 a. Results were normalized to baseline levels 
for each mouse and expressed as percent change in MFI. RvEl reduced surface PSGL-1 in Akita 
by approximately 20 % after 4 h from administration bringing PSGL-1 down to levels 
comparable to WT baseline. RvEl had no impact on PSGL-1 in WT (PSGL-1 percent change 
MFI: WT+ RvEl 1 h, 102.54 ± 8.34 %; WT+ RvEl 4 h, 108.13 ± 0.52 %; Akita+ RvEl 1 h, 
88.64 ± 6.3 %; Akita+ RvEl 4 h, 80.34 ± 3.75 %; n = 4/group) (Fig. B.5.4.3.). 
RvEl did not have a prominent impact on circulating mononuclear cell PSGL-1 in Akita 
or WT (PSGL-1 percent change MFI: WT + RvEl 1 h, 105.24 ± 5.97 %; WT + RvEl 4 h, 
125.68 ± 7.53 %; Akita+ RvEl 1 h, 91.14 ± 1.18 %; Akita+ RvEl 4 h, 123.47 ± 10 %; n = 3 
Akita) (Fig. B.5.4.4.). RvEl did not change the expression of CDl la by Akita or WT PMN 
(CDl la percent change MFI: WT+ RvEl 1 h, 95.15 ± 2.72 %; WT+ RvEl 4 h, 114.67 ± 24.88 
~ kita + RvEl 1 h, 90.88 ± 2.56 %; Akita+ RvEl 4 h, 104.47 ± 4.87 %; n = 4/group) (Fig. 
B.5.4.5.) RvEl increased CDlla expression by peripheral mononuclear cells in Akita but not 
WT at 4h (CDl la percent change MFI: WT + RvEl 1 h, 95.15 ± 4.87 %; WT + RvEl 4 h, 
100.05 ± 0.04 %; Akita+ RvEl 1 h, 151.45 ± 37.45 %; Akita+ RvEl 4 h, 145.53 ± 7.98 %; n = 
3 Akita) (Fig. B.5.4 .6.) 
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To investigate the actions of RvEl on PMN PSGL-1 and CDl la BM 
immunophenotyping was performed to confirm the presence of these antigens on BM PMN. BM 
aspirates stained with Wright-Giemsa showed PMN and other myeloid precursors in BM of WT 
C57BL/6 (Fig. B.5.4. 7.). Fluorescence microscopy of BM samples incubated with anti-LY6G-
FITC and anti-PSGL-1-PE or anti-CDlla-PE confirmed the presence of PSGL-1 and CDl la on 
BM PMN (Fig. B.5.4.8-10.). FACS analysis of BM aspirates for PMN adhesion molecules 
showed that 95% of PMN-LY6Ghigh in BM have PSGL-1 on their surface (Fig. B.5.4.11.). 
Peripheral blood collected 2 h and 4 h after pro-inflammatory stimulation with RvEl 
treatment was analyzed by FACS for PSGL-1 and CDl la expression by circulating leukocytes. 
Results were normalized to baseline levels for each mouse. Leukocytes were selected based on 
positivity for CD45 and then analyzed on a double parameter dot plot for LY6G and PSGL-1 or 
CDl la. Backgate analysis of populations selected from the parent gate (CD45+) was performed 
to confirm their identity with respect to granularity and cytoplasmic complexity (Fig. B. 5.4.12. ). 
~ PSGL-1 surface expression by circulating WT PMN during acute inflammation was 
higher than baseline levels 2 h after pro-inflammatory stimulation. On the other hand PSGL-1 
expression by Akita PMN was significantly lower compared to baseline levels 2 h after 
stimulation and continued to decrease within 4h. While >90% of WT PMN have PSGL-1 levels 
greater than 103 arbitrary units at baseline only 50-60% of PMN fall into that range at 4 h. The 
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number of circulating PMN increased 2 h after pro-inflammatory stimulation and decreased by 4 
h. On the other hand, PMN PSGL-1 expression decreased in Akita during acute inflammation 
although higher numbers of PMN are released into the circulation form BM compared to WT. 
The high number of circulating PMN remains relatively constant within 4 h after pro-
inflammatory stimulation (PMN, percent of CD45+: WT baseline, 7.61 %; 2 h, 43.5%; 4 h, 
33.4%; Akita baseline, 13.6%; 2 h, 63.3%; 4 h, 63%) (Fig. B.5.4.13-14.). Statistical analysis 
showed a significant PSGL-1 reduction in Akita peripheral PMN of approximately 20% 2 h 
following ZIP injection (PSGL-1 percent change MFI: Akita+ Z 2 h, 80.34 ± 12.03%; Akita+ 
Z 4 h, 60.19 ± 11.38%; n = 5). An increased expression of PSGL-1 was observed in WT PMN 
after stimulation (PSGL-1 percent change MFI: WT + Z 2 h, 119.03 ± 18.27%; WT+ Z 4 h, 
104.98 ± 12.26%; n = 5). 
The numbers of circulating PMN in WT were significantly increased 2 h after pro-
inflammatory stimulation and decreased by 4 h. In Akita the numbers of circulating PMN were 
higher at baseline, increased significantly by 2 h and slightly decreased by 4 h. (PMN percent of 
~ 
CD45+: WT baseline, 9.73 ± 1.68 %; WT 2 h, 41.25 ± 1.28 %; WT 4 h, 32.29 ± 1.81 %; Akita 
baseline, 21.44 ± 3.04 %, Akita 2 h, 75.04 ± 2.76 %, Akita 4 h, 66.2 ± 3.33 %) (Fig. B.5.4.15). 
RvEl reduced PMN PSGL-1 expression by 28% in WT 2 h after Z injection while no 
difference was observed for Akita compared to vehicle (PSGL-1 percent change MFI: WT + Z + 
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RvEl 2 h, 72.3 ± 2.82%; WT+ Z + RvEl 4 h, 100.87 ± 15.45%; Akita+ Z + RvEl 2 h, 78.41 ± 
2.21 %; Akita+ Z + RvEl 4 h, 80.39 ± 15.57%; n = 5 /group) (Fig. B.5.4.16). 
CD 11 a expression by circulating PMN during acute inflammation has not changed 
significantly in Akita or WT (CDl la percent change MFI: WT+ Z 2 h, 117.78 ± 27.32%; WT+ 
Z 4 h, 121.81 ± 21.97%; Akita+ Z 2 h, 110.23 ± 9.67%; Akita+ Z 4 h, 102.61 ± 15%; n = 5 
/group). RvEl did not influence significantly expression of CDlla by peripheral blood PMN 
(CDl la percent change MFI: WT+ Z + RvEl 2 h, 97.25 ± 3.97%; WT+ Z + RvEl 4 h, 115.4 ± 
13.71 %; Akita+ Z + RvEl 2 h, 93.27 ± 3.77%; Akita+ Z + RvEl 4 h, 91.81 ± 9.84%; n = 
5/group) (Fig. B.5.4.17.). 
These results have led us to conclude that: 1. RvEl does not change the number of 
circulating PMN; 2. RvEl does not change BG levels in Akita or WT mice; 3. In WT mice the 
number of circulating PMN increases within 2 h after pro-inflammatory stimulation and 
decreases by 4 h; 4. Circulating PMN increase expression of surface PSGL-1 during acute 
inflammation in WT; 5. RvEl reduces expression of PSGL-1 by WT PMN; 6. In Akita diabetic 
~ 
mice the number of circulating PMN increases within 2 h after pro-inflammatory stimulation and 
remains high by 4 h; 7. Circulating PMN progressively decrease expression of surface PSGL-1 
during acute inflammation in Akita; 8. RvEl does not change significantly the expression of 
PSGL-1 by circulating PMN in Akita during acute inflammation. 
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Figure B.5.4.1. RvEl Does Not Influence Numbers of Circulating PMN 
One blood sample (20 µl) from each time point (baseline, 1 hand 4 h after RvEl administration) 
was run through Hemavet for CBC. Numbers of peripheral PMN increased 1 h after RvEl or 
vehicle administration and decreased by 4 h. 
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Figure B.5.4.2. RvEl Action on Blood Glucose Levels 
BG levels were measured in WT and Akita before and after RvEl treatment in mice with or 
without pro-inflammatory stimulation (zymosan IP). No significant difference was observed in 
BG levels with RvEl treatment. In acute inflammation BG levels decreased progressively in WT 
and Akita. RvEl increased BG levels in WT though not significantly. One-way ANOVA, n = 6 
Akita/group, n = 8 WT/group, mean± SEM 
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Figure B.5.4.3. RvEl Reduces Peripheral PMN Surface PSGL-1 in Akita 
MFI for peripheral PMN PSGL-1 after RvEl treatment were compared with baseline levels and 
results expressed as percent change. RvEl did not influence WT PMN PSGL-1 levels during the 
observation period. In Akita RvEl reduced progressively PMN PSGL-1 levels to 80 % at 4 h. 
* p<0.05, one-way ANOVA, n = 4 Akita, n = 4 WT, mean± SEM 
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Figure B.5.4.4. RvEl Action on Mononuclear Cell PSGL-1 
MFI for peripheral mononuclear cell PSGL-1 after RvEl treatment were compared with baseline 
levels and results expressed as percent change. RvEl reduced mononuclear cell PSGL-1 levels in 
Akita at 1 h by 10%. RvEl increased PSGL-1 levels in both Akita and WT mononuclear cell 
PSGL-1 at 4 h. One-way ANOVA, n = 4/group, mean± SEM 
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Figure B.5.4.5. RvEl Action on Peripheral PMN Surface CDl la 
MFI for peripheral PMN CDl la after RvEl treatment were compared with baseline levels and 
results expressed as percent change. RvEl slightly reduced WT PMN CDl la at 1 h. No change 
was observed in either WT or Akita at 4 h. One-way ANOVA, n = 4/group, mean± SEM 
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Figure B.5.4.6. RvEl Action on Mononuclear Cell CDl la 
MFI for peripheral mononuclear cell CDlla after RvEl treatment were compared with baseline 
levels and results expressed as percent change. RvEl did not influence CDl la levels in WT 
during the observation period. In Akita RvEl increased progressively CDl la within 4 h after 
administration.* p<0.03, t test, n = 3 Akita, mean± SEM 
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Figure B.5.4.7. Bone Marrow Aspirate - Wright-Giemsa 
Wright-Giemsa stain of BM aspirates from a WT C57BL/6 showing band (1) and mature (2) 
PMN. RB Cs, myeloid and other precursors are also distinct. 
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Figure B.5.4.8. 
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Figure B.5.4.8. PSGL-1 and CD 11 a Expression on Bone Marrow PMN - unlabeled control 
Bone marrow aspirate was incubated with a mixture of antibodies against LY 6G and PSGL-1 or 
CDl la for 1 h at room temperature. One unlabeled sample was used as control for labeling. 
Pictures were taken in x 1000 magnification in phase contrast and under the FITC and TRITC 
filters. Pictures under FITC and TRITC filters were merged. Several cells are visible in phase 
contrast (top left). Minimal cell autofluorescence is seen under both green and red light spectra 
(top right, bottom). 
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Figure B.5.4.9. CDl la Expression on Bone Marrow PMN (C57BL/6) 
Bone marrow aspirate was incubated with a mixture of antibodies against LY 6G and CD 11 a for 
1 h at room temperature. Pictures were taken in x 1000 magnification in phase contrast and 
under the FITC and TRITC filters. Pictures under FITC and TRITC filters were merged. Arrows 
indicate BM cells representative for LY 6Ghigh CD 11 iigh ( ++ ), LY 6G10w CD 11 a10w (-- ), 
LY6Gmedium CDl lamedium (+) and combinations of intermediate positivity for antigens tested. 
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Figure B.5.4.10. 
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Figure B.5.4.10. PSGL-1 Expression on Bone Marrow PMN (C57BL/6) 
Bone marrow aspirate was incubated with a mixture of antibodies against LY 6G and PSGL-1 for 
1 h at room temperature. Pictures were taken in x 1000 magnification in phase contrast and 
under the FITC and TRITC filters. Pictures under FITC and TRITC filters were merged. Arrows 
indicate BM cells representative for L Y6Ghigh PSGL-1 high(++). Other intermediate combinations 
are also distinct. 
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Figure B.5.4.11. PSGL-1 and CDl la Expression on Bone Marrow (BM) PMN - FACS Analysis 
BM aspirate incubated with a mixture of antibodies against CD45, LY6G and PSGL-1 or CDl la 
for 1 h at room temperature. F ACS analysis was performed for evaluation of PMN PSGL-1. 
Leukocytes were selected based on positivity for CD45 and analyzed on a double parameter dot 
plot FLl (LY6G) vs FL2 (PSGL-1 or CDl la). PMN represented 42% of all leukocytes in the 
BM aspirate. From all PMN analyzed 99% had high CD 11 a levels and 95% had high PSGL-1 
levels. 
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Figure B.5.4.12. Backgate Analysis - Circulating PMN 2 h After Pro-Inflammatory Stimulation 
F ACS analysis of peripheral blood was performed to quantify PMN PSGL-1 levels during acute 
inflammation. Backgate analysis of peripheral PMN PSGL-1 high 2 h after pro-inflammatory 
stimulation was compared to baseline levels. Numbers of PMN PSGL-1 high increased 
significantly at 2 h. 
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Figure B.5.4.13. WT Peripheral PMN PSGL-1 in Acute Inflammation 
Backgate analysis of PMN PSGL-1 high at baseline, 2 h and 4 h after pro-inflammatory 
stimulation in WT showed significant increase by 2 h and decrease by 4 h (baseline, PMN 
PSGL-lhigh 7.61% ofCD45\ 2 h PMN PSGL-lhigh 43.5% ofCD45\ 4 h PMN PSGL-lhigh 33.4% 
of CD45+) (top). Representative histogram overlay shows significant increase in PMN PSGL-
1 high numbers at 2 h (blue) in the same fluorescence intensity (FI) range as baseline levels (red). 
By 4h the FI peak shifted to the left (green) indicating reduction in surface PSGL-1. 
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Figure B.5.4.14. Akita Peripheral PMN PSGL-1 in Acute Inflammation 
Backgate analysis of PMN PSGL-1 high at baseline, 2 h and 4 h after pro-inflammatory 
stimulation in Akita showed significant increase in circulating PMN numbers by 2 h that 
remained constant by 4 h (baseline, PMN PSGL-1 high 13.6% of CD45+, 2 h PMN PSGL-1 high 
63.3% of CD45+, 4 h PMN PSGL-1 high 63% of CD45+) (top). Representative histogram overlay 
shows significant increase in PMN PSGL-1 high numbers at 2 h (blue) with a shift to the left in 
fluorescence intensity (FI) peak compared to baseline levels (red). By 4h the FI peak shifted 
further to the left (green) indicating reduction of surface PSGL-1 levels. 
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Figure B.5.4.14. Peripheral Blood PMN in Acute Inflammation 
One blood sample was collected by facial vein puncture for measuring circulating PMN baseline 
levels in WT and Akita. All mice were injected 0.2 mg Z IP to induce acute peritonitis. Two 
blood samples were collected 2 h and 4 h post-stimulation from each mouse to measure the 
numbers of circulating PMN. All three samples were processed for FACS analysis as described. 
Circulating PMNs were measured after selection of LY6Ghigh subpopulation from the CD45+ 
population (all leukocytes) . * p<0.03, one-way ANOVA, mean± SEM, n = 12 WT, n = 7 Akita. 
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Figure B.5.4.16. RvEl Reduces Peripheral PMN Surface PSGL-1 in Acute Inflammation 
MFI for PMN PSGL-1 under RvEl treatment was compared in Akita and WT during acute 
inflammation with baseline levels. Results were expressed as percent change in MFI. PSGL-1 
levels increased in WT at 2 h post-stimulation and remained relatively constant by 4 h. In Akita 
PSGL-1 levels decreased progressively within 4 h with significant decrease at 2 h. RvEl reduced 
significantly PSGL-1 on WT PMN within 2 h. * p<0.05, one-way ANOVA, n = 5 Akita, n = 6 
WT, mean± SEM 
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Figure B.5.4.17. RvEl Action on Peripheral PMN CDl la in Acute Inflammation 
MFI for PMN CDl la under RvEl treatment was compared in Akita and WT during acute 
inflammation with baseline levels. Results were expressed as percent change in MFI. CDl la 
levels remained relatively constant during the observation period in both WT and Akita. One-
way ANOVA, n = 5 Akita, n = 6 WT, mean± SEM 
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In the present study, using a non-obese and non-autoimmune mouse model of DM, the 
Akita mouse, it was found that chronic hyperglycemia induces phenotypic changes in leukocytes 
that impact their adhesive, migratory and pathogen-clearing functions. PMN recruitment at sites 
of acute inflammation and bacterial killing were impaired in Akita mice. Furthermore, 
leukocytes had increased rolling rate along gingival endothelium in Akita without exogenous 
stimulation comparable to low-dose TNFa-induced gingivitis in WT mice. Leukocytes of Akita 
had a 20% increase in surface PSGL-1 and mononuclear cells had 17% increase in surface 
CDl la in the absence of exogenous inflammatory stimuli. RvEl reduced PSGL-1 on circulating 
PMN in Akita. Furthermore, RvEl reduced PMN infiltration in the air pouches and reduced 
PMN PSGL-1 levels in acute inflammation in WT mice. 
In Akita mice circulating PMN reach the sites of acute inflammation in lower numbers 
when compared to euglycemic controls. On the other hand, Akita mice have higher numbers of 
circulating PMN without exogenous inflammatory stimulation compared to WT mice and the 
number of circulating PMN in Akita during acute inflammation is higher than in WT. These 
observations indicate that the reduced leukocyte recruitment in Akita may result from a failure of 
PMN to transmigrate the endothelial wall at sites of inflammation. Akita PMNs fail to reach the 
infection site in a timely manner and in sufficient numbers for an efficient clearance of 
pathogens. This may lead to aberrant degranulation and superoxide release in the intra- and/or 
/ perivascular compartment. Inefficient PMN transmigration through the vessel wall or trapping of 
PMN inside the tissue before reaching the target may explain the reduced leukocyte 
·extravasation in diabetic mice. Leukocyte dysfunction was correlated with microvascular 
changes that occur in diabetes such as basement membrane thickening in certain vascular beds 
including the kidney, retina, skin and gingiva [126, 212, 325]. A recent study showed a 
decreased survival rate of Akita mice under septic conditions without an increase in circulating 
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levels of pro-inflammatory cytokines [287]. Thus, reduced recruitment in Akita may be due to 
impaired cytokine response and adhesion molecule expression leading to reduced recruitment 
[ 13]. On the other hand Akita PMN are primed for an exaggerated inflammatory response by 
increased degranulation and superoxide release [129]. Our observation of high number of PMN 
being released in the circulation during acute inflammation suggests impairment in 
transmigration through the vessel wall at the site of inflammation. In addition, while Akita fails 
to mount a robust innate immune response to acute infection they have higher numbers of 
leukocytes inside the tissue at baseline when compared to WT indicating enhanced interaction 
between leukocytes and EC in the absence of an exogenous inducer. 
The observation of reduced leukocyte recruitment in diabetic mice during acute 
inflammation may partially explain the dysfunctional immune reaction to periodontal pathogens. 
A pro-inflammatory state is a well-established factor in the development of periodontal disease. 
The observation that hyperglycemia by itself, in the absence of additional inflammatory signals, 
promotes a pro-inflammatory environment indicates that diabetes is an independent risk factor 
for the development of periodontal disease [121, 143, 144, 184, 209, 241, 288, 308]. 
To get further insight into the mechanisms by which chronic hyperglycemia impacts the 
periodontal tissues we investigated leukocyte-EC interactions in gingival microcirculation in 
vivo. One of the earliest events in inflammation is progressive vascular permeability for small 
/ molecules and later on for macromolecules leading to osmotic changes and eventually edema. 
We measured vascular permeability changes under pro-inflammatory stimulation and in chronic 
hyperglycemia by comparing the outside-inside distribution of the tracer molecule (FITC-
dextran) in non-treated Akita mice and intragingival TNFa-treated WT mice to healthy WT 
controls. Results indicated a significant increase in gingival microvascular permeability for 
macromolecules under chronic hyperglycemic conditions similar to an acute low-dose TNFa 
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induced gingival inflammation. Another study has reported increased microvascular permeability 
for FITC-dextran in a type II diabetes mouse model. Interestingly, the same study reports 
elevated serum levels of TNF a [7]. Leukocyte-EC interactions have also been correlated with 
microvascular permeability increase indirectly via ICAM-1 upregulation [386] and directly via 
release of lytic factors that damage endothelial cells [50]. Circulating PMNs contributed to 
endotoxins-mediated increase in microvascular permeability for FITC-D 150 in check pouches 
of healthy compared to neutropenic hamsters [230]. A thinning of the endothelial glycocalyx 
(EG) that covers the endothelial surface under normal conditions has recently been reported in 
diabetic patients [272]. EG has several important physiological functions including anchorage of 
anti-coagulation factors like anti-thrombin III (ATIII) in arteries and extracellular superoxide 
dismutase (EC-SOD) in veins to protect endothelium from Oz--induced injury. Furthermore EG 
acts as an anti-adhesive coating preventing leukocyte transmigration in non-inflamed blood 
vessels directly through its thickness ranging from 0.5-4.5 µm that exceeds the length of EC and 
leukocyte adhesion molecules [322]. Nonetheless, heparan sulfates anchored in EG have anti-
adhesive functions (Fig. B. 6.1.). Interestingly, EG was reported to be protective against 
~icrovascular leakage in several studies [160, 301, 425, 458]. Chronic hyperglycemia induces 
low-grade inflammation via AGE-RAGE interactions, which lead to induction of ROS release by 
leukocytes and the upregulation of pro-inflammatory mediators and adhesion molecules [61, 
/ 435, 441]. hnpaired chemotaxis [117, 428] and adherence [12, 115] of PMN and delayed 
apoptosis have been reported in diabetic patients [5, 122]. These complex spatial-temporal 
·correlations still remain to be investigated. 
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Figure B.6.1. Microvascular Changes in Diabetes 
In healthy individuals arterial and venous endothelium is covered by a layer of glycocalyx that 
has important anti-inflammatory and anti-thrombotic functions directly by acting as a physical 
barrier and indirectly by anchoring protective enzymes including ATIII (arteries) and EC-SOD 
(veins). In diabetes the endothelial glycocalyx is thinner that in healthy individuals. This 
reduction in size may explain the shedding of protective enzymes and increased chance of close 
proximity between EC and PMN. The PMN-EC interactions in the absence of inflammatory 
stimuli may lead to activation and ROS release in the vasculature that may further contribute to 
endothelial damage. The changes in endothelial BM changes characteristic to DM combined 
with dysfunctional production and release of MMPs by PMN and EC may partially explain the 
inefficiency in PMN transmigration in DM during acute inflammation. 
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Using an intravital microscopic approach to gingival microvasculature developed in this 
laboratory we were able to show that in mice with TlDM leukocytes exhibit enhanced 
leukocyte-EC interactions in vivo by rolling in higher numbers without exogenous stimulation. 
This may be partially explained by the higher number of circulating PMN seen in Akita at 
baseline. Another explanation may be increased capture by EC over-expressing P-selectin in the 
absence of exogenous pro-inflammatory stimulation [368]. A recent study has shown that acute 
hyperglycemia increases leukocyte-EC interactions in vivo by upregulation of P-selectin and 
ICAM-1 on ECs [44]. Other studies have also found increased leukocyte-EC interaction in 
different vascular beds in DM using STZ-induced TlDM rat models [285] and UCPl/DTA 
T2DM mouse models [342]. Increased leukocyte rolling in Akita comparable to low-dose TNFa-
induced gingivitis suggests that chronic hyperglycemia induces changes in circulating leukocytes 
to a pro-adhesive phenotype characteristic to low-grade inflammation. In TNFa-induced 
inflammation leukocyte LFAl and Macl are unregulated, and LFAl is required for slow rolling 
and attachment [90]. Based on in vitro flow chamber experiments NF-KB and protein kinase C 
have been proposed to mediate leukocyte adhesion induced by hyperglycemia [256]. 
Taking a close look at these specific cell-cell interactions and their outcome in vivo is 
indispensable for validating and interpreting their meaning in the context of chronic diseases. 
The intravital microscopy technique for gingival microvascular visualization can be a useful tool 
/4 r in vivo assessment of leukocyte-EC interactions and early events of the innate immune 
response to periodontal pathogens. Gingival video-microscopy gives further insight into the 
specificity of the inflammatory events in the oral cavity. By combining fluorescent labeling with 
gingival microscopy we could identify the behavior of specific leukocyte subtypes during 
recruitment at sites of inflammation. Based on phenotypic features of different organs, these 
events are highly tissue specific although they are part of the "non-specific" innate immune 
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response [363]. We were able to show that the gingival microvascular environment is changed 
under hyperglycemic conditions favoring a pro-inflammatory state. 
To elucidate the mechanisms associated with the observed dysfunctional leukocyte-EC 
interaction we assessed whether diabetic leukocytes express higher levels of surface adhesion 
molecules PSGL-1 and the ~2 integrin (LFAl) component CDl la. The upregulation of P-
selectin and its ligand PSGL-1 are prerequisites for leukocyte rolling and capture by endothelial 
cells [343]. Peripheral blood immunophenotyping by flow cytometry showed a significant over-
expression of PSGL-1 on Akita leukocytes, particularly the PMN subset, when compared to WT 
controls. Mean CD 11 a levels were also higher in Akita mononuclear leukocytes. Previous work 
by our group has also shown that P-selectin expression in gingival ECs is significantly increased 
in Akita when compared to WT. These observations indicate that hyperglycemia itself activates 
both leukocytes and ECs (Fig.B.6.2.). 
These findings correlate with our observation of increased leukocyte rolling along 
gingival microvessels in Akita suggesting that a mechanism for a hyperglycemia-induced low 
level of gingival inflammation in diabetes may be the up-regulation of adhesion molecules on 
both cell types. Our results indicate increased rolling and elevated CD 11 a surface expression in 
Akita gingival vessels but not increased firm attachment. This apparent discrepancy may be due 
to the fact that CD 11 a mediates firm attachment only when coupled with CD 18, and the resulting 
/2 tegrin molecule LFAI is in high affinity conformation [!]. LFAI interacts with endothelial 
ICAM-1 leading to reorganization of cytoskeleton and endothelial junctions. Thus, leukocyte 
surface over-expression of CDl la may explain in part the increased vascular permeability in 
Akita considering. Upregulation of CDI la alone is not sufficient for higher affinity of LFAl 
since it needs to form a heterodimer with CD 18 and change conformation to mediate leukocyte 
attachment on EC. A recent study on the role of cytoplasmic domain of PSGL-1 in leukocyte 
315 
Discussion 
activation clearly showed that it mediates LF Al activation via outside-in activation thus 
indicating that increased P-selectin-PSGL-1 interaction may influence endothelial cell 
cytoskeleton with direct consequences on vascular permeability [244]. 
Peripheral blood immunophenotyping of Akita and WT with induced acute peritonitis has 
shown progressive reduction in surface PMN PSGL-1 in diabetic mice during the 4 hour-
observation periods. This may partially explain their failure to reach the site of inflammation in 
efficient numbers to clear infectious agents. In support of this observation the percentage of 
circulating PMN following pro-inflammatory stimulation was increased at 2 hours and 
progressively returned to baseline levels in WT while it remained increased in Akita. This also 
suggests that release of PMN from BM is not impaired in Akita but rather the events involved in 
margination and diapedesis. 
P-selecting binding by PSGL-1 not only mediates tethering and rolling of leukocytes on 
ECs favoring capture and exposure to chemokines [223] but also leads to LFAl activation via 
inside-out signaling through the cytoplasmic domain of PSGL-1 preparing them for adhesion 
[58, 244, 422, 429, 453]. Thus PSGL-1 overexpression on leukocytes mediates not only their 
prolonged proximity to the vessel wall favoring aberrant superoxide release but also their 
activation for transmigration. The highly conserved cytoplasmic domain of PSGL-1 interacts 
with actin-linking proteins ezrin and moesin leading to both redistribution of PSGL-1 on 
~ olarized surfaces to enhance intercellular interactions and signaling through different pathways 
of which Syk seems to be central [58, 145, 392, 412]. 
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Figure B.6.2. Diabetic Microvascular Changes in Gingiva 
In physiological conditions, circulating PMN are constantly passing through narrow capillaries 
with smaller diameters than their own, resulting in direct contact with EC. This results in 
temporary rolling along the inner vessel wall via P-selectin-PSGL-1 interactions. In the 
postcapillary segment, they detach and continue circulating (left). High BG levels and the AGEs 
lead to both priming of PMN and EC changes which favor longer interaction between the two. 
We showed here that P-selectin on endothelial cells and its ligand PSGL-1 on leukocytes are 
overexpressed, which may in part explain the observed high rolling rate in vivo. Prolonged 
PMN-EC interaction may also promote release of ROS by PMN directly against the vessel wall 
by favoring both proximity and cell activation. Furthermore, changes in EC phenotype and the 
BM structure may explain the increased permeability for large molecules (right). 
/ 
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PSGL-1 binding to P-selectin has also been shown to generate circulating microparticles, 
mostly of leukocyte origin, containing tissue factor but also platelet and EC-derived particles that 
promote a pro-coagulant state in vivo [3, 66, 392]. Another recent study has reported a role of 
PSGL-1 in stimulation of angiogenesis of in direct relevance to the development of diabetic 
microangiopathy [ 107]. Furthermore P-selectin binding to its ligand activates EC to a pro-
inflammatory state. In fact there is growing evidence that PSGL-1 is physiologically 
downregulated upon cell stimulation and its enzymatic shedding has been correlated to apoptosis 
ofleukocytes [58, 155, 381] although this it is still controversial [8]. A recent study has reported 
reduced PMN surface PSGL-1 expression in patients with diabetes who suffered ischemic 
strokes with subsequent neurological deterioration , on day 1 following the ischemic episode as 
opposed to those who fully recovered [409]. Depletion of PSGL-1 surface expression on 
apoptotic leukocytes may prevent ectopic extravasation in peripheral vasculature and thus reduce 
local inflammatory and proliferative responses involved in diabetic complications. 
To further investigate leukocyte dysfunction induced by chronic hyperglycemia we 
assessed bacterial killing efficiency of PMN from Akita. Bacterial killing by PMN was impaired 
in Akita although phagocytosis was not reduced when compared to WT mice. Reduced killing 
efficiency was evident at all leukocyte-to-bacteria ratios but it became significant at higher 
bacterial load. Another study has shown that Oz- -dependent bacterial killing by PMN from 
~ ents with T2DM is impaired although the ability to phagocytose pathogens was found normal 
[442]. Other studies have reported impaired phagocytosis by PMN in diabetes [228, 229, 361]. 
Correlation of leukocyte dysfunction with the level of hyperglycemia may explain the 
controversial findings on phagocytic ability of PMN [234]. Furthermore, the ability diabetic 
PMN to phagocytose and kill depends on species of pathogens tested. One study has shown that 
PMN from diabetic patients phagocytose and kill Staphylococcus aureus less efficiently than 
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those from healthy controls. On the other this difference was not observed for Staphylococcus 
epidermidis [262]. Nonetheless, variability in virulence influences phagocytosis by PMN as 
demonstrated for different Porphyromonas gingivalis strains [72]. Impaired bacterial killing has 
been reported in both humans with DM and animal models for DM [79, 152, 324]. The inability 
of PMN to clear pathogens explains in part the higher incidence and increased severity of 
infections in patients with DM. These observations may also explain the higher incidence and 
severity of PD in DM. 
The switch from a pro-inflammatory state mediated by TNFa to resolution of 
inflammation is essential for restoration of tissue homeostasis and prevention of chronic 
inflammation. There is growing evidence that periodontal disease involves an inefficient 
clearance of pathogens and a failure of resolution mechanisms to restore homeostasis [ 415]. In 
order to control the level of inflammation and promote resolution, we need to identify the 
molecular mechanisms that trigger the inflammatory response. In recent years, extensive 
research has been conducted to understand the sequence of events and the connection between 
DM and inflammation [200, 313, 340, 380]. Most studies have addressed T2DM. Hypertension 
and T2DM correlate in a systemic context marked by increased IR and elevated levels of hsCRP, 
which predict development of the metabolic syndrome. A recent study has reported significant 
microvascular alterations and increased leukocyte-EC interactions in UCPI/DTA pre-diabetic 
~ - This suggests phenotypic changes in leukocytes and EC early in the development of 
T2DM in the context of impaired glucose tolerance, obesity and dyslipidemia [342]. 
Taken together the present study brings evidence that in TlDM leukocytes undergo 
phenotypic changes favoring a systemic low-level inflammatory state similar to T2DM 
suggesting that chronic hyperglycemia impacts innate immune cells altering their functions. This 
homeostatic shift favors enhanced leukocyte-EC interactions that may lead to local activation 
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and microvascular damage mediated by PMN-derived factors contributing to progressive 
angiopathy that underlies all diabetic complications. We demonstrated that chronic 
hyperglycemia creates a microvascular environment in the gingiva that is in many aspects 
comparable to acute inflammation, including increased vascular permeability, increased 
leukocyte adhesion molecule expression and enhanced leukocyte rolling. Impaired PMN 
recruitment may result in dysfunctional inflammatory response to periodontal pathogens in 
patients with DM. This explains in part, the increased rate and severity of PD in people with DM. 
We next assessed whether RvEl can reduce surface PSGL-1 on Akita PMN. RvEl 
reduced PMN infiltration in several disease models and induced a pro-resolution state [347, 359]. 
PSGL-1 levels on circulating diabetic PMN were reduced by 20% within 4 hours after 
intravenous administration of RvEl while no change was observed in WT mice. This action led 
to a reduction of PSGL-1 over-expression by Akita PMN to levels comparable to those expressed 
by WT PMN. By reversing PSGL-1 over-expression RvEl may act to prevent enhanced 
leukocyte-EC interactions and migration of leukocytes cells into the tissue in the absence of 
exogenous stimuli. A recent study has shown a reduction of leukocyte rolling in cremaster 
muscle microvasculature with RvEl treatment [87]. Furthermore, RvEl reduced surface PSGL-1 
by 40% on stimulated peripheral PMN in healthy WT mice within 2 h post-stimulation. 
Interestingly, stimulated PMN of diabetic mice progressively decreased surface PSGL-1 and 
/4wed no response to RvEl during acute inflammation. These observations suggest an anti-
adhesive and pro-resolution action of RvEl in vivo that may prevent development of diabetic 
microangiopathy (Fig. B.6.3.). RvEl ability to reduce PMN recruitment in acute inflammation 
may be partially explained by the shedding of PSGL-1 probably through release of ADAM-
family or other MMPs [58, 348]. Further studies are necessary to elucidate the exact mechanisms 
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through which RvEl leads to shedding of leukocyte adhesion molecules. It is noteworthy that 
RvEl did not influence glucose levels either in the presence of absence of acute inflammation. 
PSGL-1 shedding may induce a pro-apoptotic phenotype in peripheral PMN leading to 
their local and splenic clearance to restore homeostasis. RvEl is partial agonist of BL Tl receptor 
on leukocytes, particularly PMN, partially explaining its anti-inflammatory action. There is 
growing evidence that the new classes of .Q-3-derived lipid mediators have potent anti-
inflammatory actions in different disease models [164, 221, 350, 355]. New drugs to stop cell 
migration are promising in clinical trials and animal models of inflammatory diseases with 
impact not only on migration of leukocytes to a tissue but also on other processes such as 
mediator release and agiogenesis [224]. 
/ 
322 
(Q) . 
0 
O 0 
I 
Figure B.6.3. 
RBC 
6, PMN 
~ Monocyte 
~ EC 
Discussion 
ll P-selectin 
fi PSGL-1 
~ CXCR 
l CXCL 
o ROS 
u RvE1 
© 
323 
Discussion 
Figure B.6.3. RvEl Action on Leukocyte Adhesion Molecules 
In TlDM , leukocytes and EC undergo phenotypic changes that result in over-expression of 
adhesion molecules on their surface leading to enhanced interactions between the two cell types. 
Activated EC may further activate PMN to a pro-inflammatory state by presenting chemokines 
such as IL-8 on their surface. This results in ROS release in the microvasculature , leukocyte 
accumulation in the tissue and neovascularization that contribute to development of diabetic 
microangiopathy (left). RvEl reduced surface over-expression of PSGL-1 by leukocytes during 
acute inflammation and prevented leukocyte extravasation at sites of inflammation. Furthermore 
it lowered PSGL-1 over-expression by PMN of mice with TlDM suggesting a potential action of 
RvEl in prevention of diabetic angiopathy (right). 
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The present study shows that there is dysregulation of the acute and chronic 
inflammatory response in TIDM. Our observations bring further evidence that chronic 
hyperglycemia induces leukocyte phenotypic changes that alter their adhesive, migratory and 
pathogen-clearing functions. Leukocytes in the Akita mouse TIDM model are inefficient in 
migrating at sites of acute inflammation although they are primed to a pro-adhesive phenotype. 
Nevertheless, mononuclear leukocytes accumulate in the extravascular compartment in the 
absence of exogenous pro-inflammatory stimulation. 
RvEl reduced PMN infiltration in the tissue and reversed over-expression of adhesion 
molecule PSGL-1 by leukocytes of healthy mice during acute inflammation. On the other hand, 
in diabetic mice, RvEl did not reduce recruitment of PMN in acute inflammation and had no 
impact on PSGL-1 expression with pro-inflammatory stimulation . However, RvEl reduced 
PSGL-1 elevated expression by unstimulated circulating leukocytes of diabetic mice. The 
evidence described herein demonstrates that RvEl has potent anti-inflammatory actions in vivo. 
The growing evidence that chronic conditions such as DM, Alzheimer's and coronary 
heart disease are characterized by a failure to resolve inflammation imposes development of new 
terapies that can act to promote the resolution of low-grade inflammation. By reversing the eukocyte pro-adhesive phenotype RvEl may prevent dysfunctional leukocyte-EC interactions 
and microvascular changes induced by chronic hyperglycemia. 
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